I’ll start with the obvious: we shouldn’t exist. But we do. Nothingness is the more plausible outcome — in nearly every case, it is easier for there to be nothing than something. And yet here is a universe instead: infinite, incomprehensible, inexhaustible. It is here. We can’t leave it, not even in death.

These may sound like philosophical abstractions — and they are, if you haven’t lived the awe personally. So let me start instead with something real, and specific, that also shouldn’t be here, and certainly not in the most impossibly gorgeous form I know: the peacock. It is a key. Turn it, and it unlocks the doors of perception at every scale at once.

The colors are not in the feather

Start with the secret almost no one who gasps at a peacock ever learns.

Grind a peacock’s train to powder and you get brown. Drab, dead-leaf brown. There is no blue pigment in the bird. No green. No gold. Chemically, the feather holds exactly one colorant: melanin — the same dark molecule that colors your skin and hair, and the darkest pigment in the living world.

So where does the fire come from?

Not from a substance. From a structure. The blue, the green, the copper-gold are not painted onto the feather. They are built out of its architecture — and the architecture is built out of the dark.

Here is the cleanest way to hold it. A pigment makes color by swallowing most of the light that hits it and letting one color bounce back; the color is a property of the stuff. The peacock does something else entirely. It has almost no colored stuff. Instead it grows a shape so precise that when ordinary white sunlight falls on it, the shape sends one color back to your eye and quietly disposes of the rest. Take the bird into the dark and the color vanishes — not dimmed, gone — because there was never any color in the feather to begin with. There was only a structure waiting for light to arrive so it could do its arithmetic again.

This is called structural color, and once you understand it, you cannot un-see it. It means the peacock’s blue is not a thing the bird has. It is a thing the bird does — computed fresh, every instant, out of whatever light is falling.

The crystal inside the barbule

Take one of the tiny branchlets of a peacock feather — a barbule, thinner than a hair. Slice it open, put it under an electron microscope, and you find something that has no business being inside a bird.

A crystal.

Not a gem — a photonic crystal: a precise, repeating lattice of melanin rods stacked in orderly rows inside clear keratin, with tiny channels of air running between them. A grid. A grating. An array as regular as something etched in a chip factory — grown by a bird, in the dark, out of pigment and air.

And the spacing of that grid is the whole secret. In a landmark 2003 study in the Proceedings of the National Academy of Sciences, the physicist Jian Zi and his colleagues measured the lattice spacing under each color of barbule. The numbers are absurdly small, and absurdly close together:

• Blue barbules: rods spaced about 140 nanometers apart

• Green barbules: about 150

• Yellow barbules: about 165

A nanometer is a billionth of a meter. The entire difference between the blue of the neck and the gold of the train is a change in spacing of about twenty-five billionths of a meter — smaller than a biological nanoparticle, e.g. exosome or virus. The bird tunes its color not with different pigments, but by adjusting the gap between rods by a few dozen atoms’ width.

It would be easy — and the temptation is everywhere — to make the miracle precision: the bird as an impossibly exact machinist, hitting a tolerance our own factories struggle to match. But the real measurements tell a stranger and better story, and it is worth getting right, because the truth here is more astonishing than the legend.

The lattice is not perfect. When researchers looked closely (Freyer, Wilts and Stavenga, 2018), the rows of rods were visibly irregular — sizes wandering, spacing drifting, the grid nothing like the flawless diagram. So they ran the obvious experiment in simulation: they deliberately broke the crystal, letting the rod and channel sizes vary randomly by as much as 30 percent, and recalculated the color.

The color barely moved. A third of the structure thrown into disorder, and the brilliance dropped by less than a tenth.

Sit with that, because it overturns the easy version of the marvel. The peacock does not need nanometer perfection. It can be sloppy — a third of its dimensions can wander — and the blue holds. Think of a single guitar string: tighten it a hair and the note shifts, because everything rides on that one piece. Now think of a great choir: a few singers drift sharp, a few drift flat, and the chord still lands true, because the note is something the crowd makes together, not any one voice. The peacock’s color is choir-like. No single rod matters. The color is an agreement among thousands of them, and an agreement that large does not break when a few members stray.

That is the deeper engineering, and it is the opposite of fragile precision. Evolution did not solve color by achieving an impossible tolerance. It found a structure where the color is a stable, emergent property — something that survives the noise and slop of being grown inside a living cell, by a body with no eyes inside its feathers and no ruler. Not a watchmaker’s miracle. Something better: a design so robust it can afford to be imperfect and shine anyway.

Hold that against your own life. The color does not depend on any single rod being perfect; it emerges from the whole, flaws and all. We are built the same way. The best version of a person is not the flawless one — it is the one who has owned every fragment, the light and the dark together, and learned to shine as a whole rather than in spite of the parts. Perfected imperfection. Not the absence of the flaw, but the brilliance that the flaws, gathered up and owned, turn out to make possible.

The rainbow is born from the black

Now the part I can’t get past.

That melanin — the brown, the darkest thing in the bird — is not the enemy of the rainbow. It is its source. And it works two jobs at once, both of which the color depends on.

First, melanin bends light hard. Physicists measure this with a number called the refractive index — how much a material slows and turns a light wave passing through it. Melanin’s is about 1.8, higher than the keratin around it (about 1.54), higher than window glass. And the contrast between the dark rods and the clear keratin is exactly what a structural-color grid needs: the sharper the difference in how two materials bend light, the more cleanly the lattice can sort one color out of the white and send it back. The darkest pigment in the body turns out to be a superb material for making color. The dark is not a compromise. It is the right tool.

Second — and this is the part that turns physics into something close to prayer — melanin swallows light. It is one of the broadest absorbers in nature, drinking up wavelengths across the whole ultraviolet-and-visible range. In the peacock’s barbules the absorption is near-total: measurements show that across the blue-green band, less than about one percent of the light that enters comes back out the other side. Shine a light through a barbule and it looks almost black — a deep red-brown — even as its surface flames blue.

Here is why that matters. Behind and around the color-making lattice, the melanin eats the stray, scattered, leftover light — every photon that isn’t the one pure color the structure is sending to your eye. Without that darkness, all that random light would leak back out as a pale gray wash and dilute the color into a chalky shimmer. The melanin devours the noise. And against a background that dark, the surviving color reads as more vivid than it has any right to be — the way a single candle is overwhelming in a black room and invisible at noon.

Read that again, because it is the center of the whole thing. The fire is vivid precisely because the darkness behind it has devoured everything else.

The same molecule is both the architecture and the void that frames it. The rainbow is born from the black. The lotus from the mud. The brightest thing in the bird is built, literally and optically, out of the darkest — and could not shine without it. Beauty here does not arrive despite the darkness. It comes from it, and needs it to be seen at all.

(Nature knows how far this can be pushed. Some birds-of-paradise grow feathers whose microscopic structures trap light in tiny chambers, bouncing it until almost none escapes — absorbing up to 99.95 percent of the light that lands on them. Super-black, blacker than fresh asphalt or charcoal. And those birds grow the super-black right beside their brightest color patches, because against that much dark the eye reads the color as more brilliant than the light alone can explain. The darkness is not the absence of the display. It is part of the display.)

The bird grew an interferometer

Stop and name what the peacock has actually built, because it has a name, and the name is worth earning.

Go back to the stack of layers — melanin, air, melanin, air — and follow a wave of light as it enters. It doesn’t simply bounce off the front. It reflects a little at everylayer it crosses, and all those small reflections travel back out and overlap. Now, light is a wave, with crests and troughs. When two waves meet crest-to-crest, they add and brighten — physicists call this constructive interference. When they meet crest-to-trough, they cancel and go dark — destructive interference.

[A glorious “peacock opal,” as jewelers name them]

The spacing of the lattice decides which color does which. At 140-nanometer spacing, all the little reflections of blue light come back lined up crest-to-crest. They reinforce. Blue floods back to your eye, bright. Every other color comes back out of step — crest landing on trough — and erases itself. The blue you see is not light the feather added. It is the one wavelength that survived an enormous, exact cancellation, while every other color was made to annihilate itself into darkness.

A device that splits light into many paths and recombines them so they interfere, letting one result live and cancelling the rest, has a name. It is an interferometer. We build them to detect gravitational waves rippling in from colliding black holes, to measure distances to a fraction of an atom’s width, to tune our most precise lasers. They are among the most exact instruments humanity has ever made — and the peacock’s own scientists named the effect plainly: in the 2003 measurements, the spectra carry the fingerprint of Fabry–Pérot interference, the same physics as a laboratory optical cavity.

The peacock grew one. In the dark. Out of pigment and air. With no eye inside its feather and no instrument but its own growing body. Each barbule is a tiny biological interferometer, and the train is a field of thousands of them, each one keeping a single color alive by making all the others cancel.

And here is the thought I want to leave you holding. The cancellation is not loss. It is creation. The peacock’s color is made of destructive interference — made of what was removed. The fire is what remains after a vast and precise erasure. Glory by subtraction. It is the same gesture as the darkness that frames it: the beauty is what is left when the structure has taken almost everything away.

The peacock is not alone

If the peacock were the only place in nature that built color this way, you could call it a fluke. It isn’t. The same trick — color from structure, not from pigment — has been discovered, independently, over and over, across creatures that share no recent ancestor and no common chemistry. Once you know what the lattice does, you start seeing it everywhere.

The blue of a Morpho butterfly is not blue paint; it is ridged scales, layered at the scale of a light wave, throwing back blue the same way the peacock does. The metallic flash of a jewel beetle or weevil is a three-dimensional lattice inside its shell. And — the one I find most quietly astonishing — the fire inside an opal is the same physics in a mineral: precious opal is built of tiny silica spheres, packed in a regular array, with the spacing tuned to the wavelength of visible light. The gem has no pigment either. Its greens and blues and reds are a photonic crystal made of glass beads and the gaps between them, sorting white light into color exactly as the feather sorts it.

That kinship is worth dwelling on, because it tells you the peacock’s beauty is not a biological accident — it is a physical law that life and geology both stumbled into. A bird grows melanin rods in a two-dimensional grid; a gemstone settles silica spheres into a three-dimensional one; a butterfly stacks ridges in a single dimension. Different builders, different materials, different worlds — and the same answer, because there is only one way for a periodic structure to turn white light into a pure, angle-shifting color, and everything that found beauty found that same way.

Figure. Structural color across the living and mineral worlds. (a) the blue Morpho butterfly, with an electron micrograph of its layered wing-scale ridges. (b) a peacock eyespot, with a micrograph of the melanin-rod lattice in its barbules — the 2D photonic crystal this essay has been describing (scale bar 400 nm). (c) a precious opal, with a micrograph of its packed silica spheres — a 3D photonic crystal (scale bar 500 nm). (d)an iridescent weevil and the lattice inside its scales (scale bar 5 µm). (e) the underlying scheme: photonic crystals come in one, two, and three dimensions, depending on how many directions the structure repeats in. The peacock is the 2D case; the opal, the 3D. Different kingdoms of nature, one law of light.

The peacock, then, is not a miracle that happened once. It is the most extravagant member of a family — the place where a law that also lit the opal and the butterfly was pushed furthest, by a creature with energy to burn and a mate worth dazzling.

The eye it is made for

A peacock’s color would be half-wasted on us. It was not built for human eyes.

We are trichromats — we have three kinds of color cone, peaking roughly at 424, 530, and 560 nanometers. The peahen the peacock is actually addressing is a tetrachromat. She has four kinds of cone, peaking near 370, 445, 508, and 565 nm — including one tuned into the ultraviolet, a whole band of the spectrum we cannot see at all.

So the peacock’s display reaches into colors we have no name for and no organ to perceive. The blue she sees is not quite the blue we see; it is richer, with a dimension folded into it that our eyes simply drop. When we admire the train, we are seeing a translation — the legible fraction of a far richer signal pitched to an eye more capable than ours. The full glory is addressed to someone else. We are reading a love letter over the peahen’s shoulder, in a language we only partly speak.

It is not only seen. It is felt.

Here the science turns genuinely strange, and genuinely beautiful.

When a peacock displays, he does not hold the train still. He rattles it — vibrating the great fan rapidly, a behavior called train-rattling. Suzanne Amador Kane, Roslyn Dakin and colleagues measured it (PLoS One, 2018). The train-rattle runs at about 25 to 28 cycles per second — a mean near 25.6 Hz.

Then they measured the little crest of feathers on the peahen’s head — the small fan of filaments crowning her. They mounted crests on a mechanical shaker and swept through frequencies to find where they resonated. The crest’s natural resonant frequency: about 28 Hz in females, 26 Hz in males.

The two numbers match.

The frequency at which the male shakes his train is tuned to the frequency at which the female’s crown naturally vibrates. When he rattles, the air carries that pulse across the space between them, and her crest — sitting on mechanosensory nerve endings at its base — begins to resonate, like a struck tuning fork. She does not merely see his display. She feels it, on her head, at her body’s own resonant pitch. And the researchers confirmed: this match does not appear in the peacock’s other feathers, nor in the crests of four other bird species they tested. It is specific. It is tuned.

He is not performing at her. He is vibrating with her, across the air, at a frequency her body was built to answer. The display is a duet between his motion and her crown — a coupling we could not see at all until we measured it.

[You are looking at the Met’s “Peacocks and Dragons” material, e.g. a 19th‑century robe where the peacock’s ‘hundred eyes’ and royal aura are stylized into pattern, the lush green hewn from peacock feathers interwoven with silk.]

The hundred eyes

Step back and take in the whole train, and you are not looking at a fan. You are being looked at.

A hundred or more ocelli — the eyespots — turn toward you at once. Each is a target of structured fire: a core of blue-green ringed in bronze and gold, every band a different lattice spacing, every color computed from the same dark pigment tuned to a different gap.

The Romans made a myth of it. When the hundred-eyed giant Argus was slain, they said, the goddess Juno set his eyes into the tail of her sacred bird, so the watchfulness of the world would never close.

To stand before it is to be regarded by a multitude — by a hundred eyes made of geometry, gazing back in colors the bird does not contain.

9. Where the surplus came from

One question remains, underneath all the others. Why? Why would life build something this extravagant — meters of iridescent burden that cannot help the bird fly or hide, that costs enormously to grow and drag and flaunt?

To answer it, go back two billion years.

Once, one cell swallowed another and did not digest it. The captive became the mitochondrion — the power plant. And that single merger, the origin of all complex life, bought the swallower an absurd surplus of energy: far more than mere survival required. Survival was already solved. As the biologist Nick Lane argues, internalizing power this way unlocked an energy budget thousands of times richer per gene than any simpler cell could muster.

So life spent the excess on something other than survival. On complexity. On nervous systems. On vision. And on a crystal lattice in a feather that bends sunlight into colors it does not own, for no reason mere survival could demand.

Beauty is what the surplus was spent on. Not the opposite of thrift — what thrift looks like when there is that much to give.

When I first saw this in flowers, I called it a benevolent superfluity — the universe overshooting bare function and landing in beauty for no reason survival can account for. The peacock is that same superfluity made feather and fire

And none of us arranged the merger. Every one of us is spending an inheritance we did not earn — wearing colors struck from a gift two billion years older than our names. The peacock does not know it is beautiful. That not-knowing is the holiness in it. The splendor that does not preen is the only splendor worth the word.

The myths were right

For three thousand years, before anyone could slice a barbule or measure a lattice, people looked at this bird and knew things about it. They wrote those knowings as myth. And the strange thing — the thing this whole essay has been circling — is that the science, when it finally arrived, did not overturn the myths. It rhymed with them.

The hundred eyes. We met that myth already — Argus’s eyes, set by Juno into the bird’s tail. A pretty story. But then we learned that the peacock’s display is, in fact, addressed to an eye — to the four-color vision of the peahen, richer than our own three, reaching into ultraviolet we cannot see. The bird that is covered in images of eyes turns out to be speaking, in colors, to an eye. The myth pointed at the truth before the truth could be measured.

[Hera and Argus – Peter Paul Rubens Public Domain via Wikimedia Commons]

The incorruptible. Early Christians made the peacock a symbol of resurrection and eternal life, on the strength of an old belief — Augustine repeats it — that the peacock’s flesh does not rot. The flesh does rot; they were wrong about the substance. But they were right about the thing. Because something in the peacock genuinely outlasts the body: the color. Structural color does not fade the way pigment does — pigment browns and dulls over the centuries, but the peacock’s blue is not pigment, it is structure, and as long as that structure holds, the fire remains. The blue in a museum drawer burns as bright a hundred years on as the day the bird wore it. The ancients attached the permanence to the wrong layer — the flesh instead of the lattice — but they correctly sensed that here, in this creature, was something that outlasts the body that carries it. The incorruptible was real. It was just made of order, not meat.

The transmutation of poison. This is the one that stops me. In Buddhist tradition the peacock is the great transmuter — the bird that eats what is poisonous and is not harmed, the emblem of taking in toxin and converting it to beauty, darkness converted to radiance. The Peacock Wisdom King, Mahamayuri, is poison swallowed and made into light.

[The Peacock King Mahamayuri Vidyarajni Bodhisattva is a Bodhisattva (an “enlightened” being of compassion) and female Wisdom King in Mahayana and Vajrayana Buddhism.]

And what did we find, when we looked closely? That the peacock builds its entire glory out of melanin — the dark pigment, the dead-leaf brown, the blackest material in the body — and out of cancellation, the destructive interference that annihilates every wavelength but the one it allows to live. The bird makes its beauty by swallowing the dark and erasing nearly everything. The fire is what survives the erasure. The blue is what the darkness did not keep.

The Buddhists had no electron microscope. They looked at the surface and intuited something the depths would later confirm: that here was a creature whose radiance comes out of its darkness, not in spite of it. They could not have known the mechanism — melanin, interference, the cancelled wavelengths — and they did not need to. They sensed the shape of the truth from the outside, and the measurement, when it came, rhymed.

[Kartikeya (Murugan) rides his peacock mount, Paravani, the serpent clutched in its claws.]

The crown. In India, Krishna wears the peacock feather at the crown of his head — the feather at the highest point, the seat of grace. And the science of the display turns on exactly that: the organ that receives the peacock’s courtship is the small crest at the crown of the peahen’s head, the cluster of feathers tuned to resonate at the male’s frequency, the antenna of the crown by which she feels him across the air. The tradition placed the sacred feather at the crown. The biology placed the organ of reception at the crown. Same place. Different millennia.

Each time, the pattern repeats: the myth saw something true on the surface, and the science found it again in the structure. This is what I mean when I say the metaphor came first and was not wrong. The poets and the priests were reading the same bird the physicists would later read — only they read it whole, before we could read it small.

The one myth that got it wrong — and why

There is one tradition that read the peacock differently. In modern Western folklore the bird became the emblem of vanity — “proud as a peacock.” Its feather, brought indoors, became bad luck; its hundred eyes became the evil eye, an omen. The glory was reread as arrogance, the watchfulness as malice.

Notice what happens in that reading. Nearly every culture that held the peacock sacred saw the gift in it — the immortal, the all-seeing, the transmuter, the crown. The reading that calls it vain belongs to an eye that has, somewhere along the way, half-forgotten how to receive a gift at all: an eye trained to see the world as mere mechanism, surface without depth, display without a giver. And to an eye that no longer expects a gift, glory can only look like showing off. The peacock did not change. The seeing did.

[“The Preening Peacock” by Jehan-Georges Vibert (c. 1880s). Location: Musée d’Orsay, Paris, France]

Here is the irony the science resolves. We have learned that the peacock does not know it is beautiful. It grows its lattice with no eye inside its feathers, tunes its color with no ruler, pays for its splendor out of an inheritance two billion years old that it did not arrange and cannot perceive. There is no vanity anywhere in it. The pride was never in the bird. It was a projection — the inability to receive a gift, accusing the gift of arrogance to excuse itself.

The peacock is the cure for exactly that. To stand before it and feel the old, sacred readings rise again — the eyes, the incorruptible, the transmuted poison, the crown — is to have the forgetting lifted for a moment, and to see what every older culture saw: not a vain bird, but a gift that asks nothing, given by something that did not need to give it.

What it asks of you

So gather the facts and hold them all at once.

A bird grows a crystal in the dark, out of the blackest pigment in nature. It does not paint a color; it builds a shape, and lets the shape compute a color out of raw sunlight, fresh, every instant the light arrives. It does this without eyes inside its feathers and without a ruler — and it does not even need to be precise, because the structure is so robust that a third of it can wander out of place and the blue still holds. It makes the color clean by letting the darkness behind it devour every stray ray that would dull it. The blue you finally see is not light the feather kept. It is the one wavelength left standing after the structure has cancelled all the rest into the dark.

None of it is necessary for staying alive — for eating, for flying, for not being eaten. All of it is real. Every number in this essay is measured, published, and repeatable. And this is the thing I most want you to take: knowing exactly how it works does not shrink the wonder. It is the wonder. Followed all the way down to the lattice, the mechanism does not explain the beauty away — it turns out to bethe beauty, read at the scale where it can no longer hide. The miracle was never in our ignorance of how the trick is done. It was in the trick itself, and it only deepens as you learn it.

This is not only intelligent design — that argument was always too small, a god reduced to an engineer filling gaps. What the peacock shows is something else: artistic design. The lawfulness is real, the evolution-over-time is real, and still the result overflows every requirement of survival into sheer, gratuitous beauty. That overflow is the signature. Not a maker who had to build it, but one who did not have to — and made it gorgeous anyway.

You are not a machine either. You were not assembled toward a use. Whatever has tried to price your worth by your function has mistaken what you are. You, too, are an inheritance spent as beauty. You were divinely inspired and loved into this world, as the peacock was. You, too, wear colors you do not contain — struck into fire each time the light finds you, and, like the peacock’s, built to outlast the body that bore them.

When I tried to follow that obligation all the way into a human life (Gaudi, architect of the Sagrada Familia in Barcelona) — what it means to let beauty, not utility, teach you how to live — I called it the cathedral in the body: the sense that your own being is meant as a place where that surplus beauty becomes action, an onto‑ethics written into flesh.

[The Sagrada Familia, Gaudi’s temple of light]

Structural color does not fade the way pigment does. Nor do your acts of selfless kindness and true love. I believe they are carried, timelessly, by everyone you have touched — whether they know it or not. The bird in a museum drawer still burns, a century on. So does a life spent in creative, joyous, selfless acts.

I have tried, this whole way, to show you what I saw. I will end where I might have begun, with the only words that ever quite held it:

God made a rainbow flesh in a bird.

Look. Keep looking. The peacock is only the door. Open it, and everything beyond it glows with the same impossible fact — of being here at all, when there should have been nothing.

Further doorways

If the peacock showed you that beauty is a gift that doesn’t ask for use, the natural next question is how to live inside a world like that. I tried to sketch an onto‑ethics — how love and sovereignty might look in a universe built this way — in The Fold: A Valentine.

If the geometry of the peacock’s lattice — two fields meeting, cancelling, and creating a third thing in the overlap — moved something in you, I tried to follow that same figure into the space between human hands here: Prayer Hands Decoded: The Science Behind Humanity’s Most Sacred Gesture.

If the role of melanin here moved something in you — not just as pigment but as an active, light‑shaping material — I tried to follow that thread into human biology in: The Ultimate Human Superpower You Never Knew You Had: Melanin — The Hidden Solar Panel in Human Biology.

Subscribe now

Share

Notes & Sources

Every number in this essay is measured and published. Each source below is paired with the claim it supports.

1. The single pigment (melanin), the photonic-crystal mechanism, and the lattice spacings (~140 nm blue, ~150 nm green, ~165 nm yellow): Zi, J., Yu, X., Li, Y., Hu, X., Xu, C., Wang, X., Liu, X. & Fu, R. “Coloration strategies in peacock feathers.” Proceedings of the National Academy of Sciences 100(22): 12576–12578 (2003).

2. The robustness to disorder (≤10% change in color with up to 30% size variation), and the finding that a simple layered model reproduces the spectra: Freyer, P., Wilts, B.D. & Stavenga, D.G. “Reflections on iridescent neck and breast feathers of the peacock, Pavo cristatus.” Interface Focus 9: 20180043 (2018).

3. Melanin’s refractive index (~1.8, versus ~1.54 for keratin) and its broadband absorption: Jeon, D-J., Paik, S., Ji, S. & Yeo, J-S. “Melanin-based structural coloration of birds and its biomimetic applications.” Applied Microscopy 51:14 (2021).

4. The near-total absorption inside the barbule (under ~1% transmitted across the blue-green band): measured absorbance values reported in Freyer, Wilts & Stavenga (2018), above.

5. Super-black feathers absorbing up to 99.95% of incident light, grown beside bright color patches: McCoy, D.E., Feo, T., Harvey, T.A. & Prum, R.O. “Structural absorption by barbule microstructures of super black bird of paradise feathers.” Nature Communications 9 (2018).

6. Fabry–Pérot interference as the named optical effect in the barbule:reported in Zi et al. (2003), above.

In April 2026, a Dutch randomized trial reported that women with low-risk “Stage 0 breast cancer” who skipped surgery did no worse than women who had it. I have been making this argument since 2008. Here is the evidence — including the one statistic that quietly dismantles the case for cutting.

Four decades of screening generated an archive of diagnoses — and, the evidence now suggests, more than two million overdiagnoses.

In April 2026, at the European Breast Cancer Conference in Barcelona, Jelle Wesseling of the Netherlands Cancer Institute stood up and said, in the careful language of a man who knows exactly how much weight his words carry, that the early results were “reassuring.”

He was presenting the LORD trial — 1,423 women with low-risk ductal carcinoma in situ, the diagnosis the medical system calls “Stage 0 breast cancer.” Some had immediate surgery. Most chose active surveillance: regular imaging, and surgery only if something changed. After about two years, the women who were simply watched developed invasive cancer at a rate of roughly 6% — lower than the 9% rate in the women who went straight to the operating table.(1)

“For decades,” Wesseling said, “DCIS was framed as ‘early-stage breast cancer.’ As a result, it has almost always been treated in the same way as breast cancer. But if most DCIS will never become dangerous, an important question arises: are some women receiving more treatment than they need?”(1)

I have been asking that exact question in print since 2008, the year I first put my research online with the founding of GreenMedInfo.com. This is not a victory lap. It is something more important: a moment to lay out, in full, the evidence that the most common “cancer” diagnosis surge of the mammography era may have been, in a large fraction of cases, not cancer at all — and to confront the single objection that the entire surgical paradigm rests on, an objection that turns out to be, on close inspection, partly an illusion of arithmetic.

And to count the cost. Because if the science is only now catching up, then the bill for the delay has been paid — is still being paid, this year — by women. Below, I put a number on it.

I. A Twenty-Year Position, Briefly Stated

Since GreenMedInfo’s inception in 2008, I have argued that ductal carcinoma in situ — abnormal cells confined within the milk duct, by definition not invasive, by definition not spread — was misclassified the moment the word “carcinoma” was attached to it.

The dated record:

• 2011–2012: I wrote that DCIS was “a form of breast cancer that a growing body of research indicates may not be cancer at all,” and that the lifetime risk of a given DCIS lesion progressing to invasive disease was “perhaps as low as 2–4%.”(2) The 10-year survival of treated DCIS — 96% to 98% — said everything about how non-lethal the underlying condition was.

• 2012: Building on Bleyer and Welch’s landmark analysis in the New England Journal of Medicine — published 14 years ago next month — I documented that three decades of mammographic screening had generated an estimated 1.3 million American women overdiagnosed and overtreated for breast cancer, many of them for DCIS. That paper is now old enough to drive. The overdiagnosis it described did not stop in 2012; it has compounded every year since. (See Section II-B below for what the number looks like today.)(3)

• 2024: When the COMET trial reported that active monitoring produced no greater two-year risk of invasive cancer than surgery, I wrote that it “marks a pivotal moment in redefining DCIS.”(4) (See: Reclassifying DCIS: A Groundbreaking Shift in Breast Cancer Diagnosis After Over a Decade of Advocacy.)

• 2025–2026: I situated DCIS at the center of the larger mammography overdiagnosis crisis. (See: The Mammography Deception: Why RFK Jr. Is Right for the Wrong Reasons and “We Gave Chemotherapy to 90 Women to Benefit 10.”)

LORD, in 2026, is the second randomized controlled trial — after COMET — to validate the direction of that twenty-year argument. The position is no longer fringe. It is being tested in the most rigorous instrument medicine possesses, and it is holding.

II. What DCIS Actually Is

DCIS by definition: abnormal cells confined within the duct, the basement membrane intact and unbreached. “In situ” means in its original place — not invasive, not spread.

Ductal carcinoma in situ describes a proliferation of abnormal cells within a milk duct. The cells have not crossed the basement membrane. They have not invaded surrounding tissue. They have not spread. In situ means, literally, “in its original place.”

Before mammography, DCIS was almost unknown — it produces no lump, no symptom, no sign. It became visible only when high-resolution X-ray screening began finding microcalcifications in the 1980s. Today it accounts for roughly 20% of all breast cancer diagnoses, more than 50,000 women a year in the United States.(5) A condition that was clinically invisible for the entire history of medicine is now the fourth most common cancer diagnosis in American women — not because women’s bodies changed, but because the detection technology did.

And a 2025 Dutch micro-simulation study published in The Breast put a number on the consequence: in biennial screening, about 1 in 5 DCIS diagnoses is overdiagnosed — detected in a woman who would never have suffered from it. Notably, that overdiagnosis rate was nearly the same across all grades — 24% for grade 1, 20% for grade 2, 18% for grade 3 — and because, as the authors note, “DCIS is always treated when diagnosed,” every one of those overdiagnoses becomes an overtreatment.(6)

II-B. The Fourteen-Year Bill: How Many Women, By This Year?

In November 2012, Bleyer and Welch wrote a sentence in the New England Journal of Medicine that should have changed American medicine. They estimated that over three decades of screening mammography — 1982 to 2011 — breast cancer had been overdiagnosed in 1.3 million U.S. women. In 2008 alone, they wrote, it was overdiagnosed in more than 70,000 women — 31% of all breast cancers diagnosed that year. And of the 122 additional early-stage cancers detected per 100,000 women by screening, only 8 were expected to ever progress to advanced disease.(3)

That paper is now fourteen years old. The screening did not stop. The overdiagnosis did not stop. So the honest question — the one a reader recently put to me — is: if it was 1.3 million women then, what is it now?

Let me show the arithmetic in the open, because a number this large should never be asserted without its scaffolding.

The all-breast-cancer figure. Bleyer and Welch’s 1.3 million covered 1982–2011. From 2012 through this year, 2026, is fifteen more years. If we simply hold the rate at the 2008 steady-state of ~70,000 overdiagnoses a year — assuming, charitably, no growth at all despite rising diagnosis counts — that adds roughly 1.05 million more women. The cumulative total of American women overdiagnosed with breast cancer since screening began now stands at approximately 2.35 million. Hold it instead at a deliberately conservative 60,000/year and the total is still about 2.2 million. Either way: we have crossed two million.

The DCIS-specific figure. Narrow to “Stage 0” alone. The American Cancer Society projects 60,730 new DCIS diagnoses in 2026 — up from 56,500 in 2024 and 59,080 in 2025.(5) Summing the annual DCIS counts from 2012 through 2026 yields roughly 810,000 women diagnosed with DCIS in those fifteen years. Apply Poelhekken’s overdiagnosis rate of about 1 in 5 — and recall that, because DCIS is always treated when found, every overdiagnosis is an overtreatment — and you get an estimated 160,000 to 200,000 American women subjected to surgery, radiation, and/or anti-estrogen therapy in the last fifteen years for a “cancer” that would never have harmed them.(6) At the current rate, that is on the order of 12,000 women every single year — this year — losing breast tissue, enduring radiation, or taking tamoxifen for a lesion their own bodies would have contained.

These are estimates, and I label them as such. They rest on published incidence counts and published overdiagnosis fractions, and they make conservative assumptions at every turn. The precise figure is unknowable; the order of magnitude is not. The cost of the fourteen-year delay between the evidence and the practice is measured in the hundreds of thousands of women.

And here is the finding that should haunt every defender of the status quo. In September 2025, researchers at the American Cancer Society itself — Hyuna Sung, Ahmedin Jemal, and colleagues — published the first long-term analysis of DCIS death rates in Breast Cancer Research. Their conclusion: “the death rate from DCIS in the United States has not decreased from 2000 to 2021.“ Twenty-one years. Hundreds of thousands of surgeries and radiation courses. And the death rate did not move. The authors state it plainly: “advancements in DCIS treatment have not been sufficient to reduce mortality,” and “evidence [is] lacking demonstrating its impact on reducing breast cancer-specific mortality.”(11) We have been treating harder, not living longer.

III. The Objection That Holds Up the Entire Surgical Paradigm

Here is the strongest argument against my position, and I want to state it as fairly as its proponents would.

The observational data appear to show that surgery works. A 2024 systematic review and meta-analysis of nearly 48,000 women found that the 10-year rate of invasive cancer in the same breast was 6.4% in women who had surgery versus 22.7% in women who did not.(7) On its face, that looks devastating: surgery cuts invasive recurrence by more than two-thirds. Case closed.

Except — look closely at what is being counted. The endpoint is “invasive ipsilateral breast tumor event“: invasive cancer detected in the same breast.

Now ask the obvious question. If you have removed the breast tissue — the duct system in a lumpectomy, the entire organ in a mastectomy — where, exactly, is the “ipsilateral recurrence” supposed to appear?

You cannot detect cancer in tissue that is no longer in the body. A meaningful portion of that headline “reduction” is not a biological triumph over disease. It is arithmetic. It is the mechanical consequence of having removed the place where the event was defined to occur. The surgery doesn’t just treat the disease; it deletes the denominator. You have not necessarily made the woman safer — you have made the recurrence unmeasurable.

This is the missing-tissue artifact, and once you see it, you cannot unsee it. The observational literature that “proves” surgery works is, in large part, measuring its own definition.

The missing-tissue artifact: a recurrence can only be counted where the tissue still exists. Remove the breast, and you do not necessarily remove the danger — you remove the place we look for it.

IV. The One Number That Survives the Artifact

There is, however, an endpoint that the missing-tissue artifact cannot touch: death.

A woman can die of metastatic breast cancer whether or not her breast was removed. Mortality doesn’t care where the tissue is. So if surgery and radiation genuinely defeat the danger of DCIS — rather than merely erasing the place we look for it — then more aggressive local treatment should produce lower mortality.

In 2015, Steven Narod and colleagues tested exactly this, using the SEER database — 108,196 women followed for up to 20 years. The findings should have ended the debate:(8)

• Twenty-year breast-cancer mortality after a DCIS diagnosis was 3.3% — already extraordinarily low, in the range of the background population.

• Radiotherapy after lumpectomy cut the rate of invasive in-breast recurrence nearly in half (4.9% to 2.5%) — and yet had no measurable effect on breast-cancer mortality whatsoever (0.9% vs 0.8%; hazard ratio 0.86, not statistically significant).

• Most damning of all: 517 women died of breast cancer without ever having an invasive recurrence in the breast first.

Sit with that last finding. More than five hundred women whose lethal disease appeared despite — or entirely apart from — any local recurrence. Their cancer was already systemic, already capable of killing, at the moment of the DCIS diagnosis. No mastectomy could have removed what had already left the breast. And conversely: preventing local recurrence, the thing surgery and radiation are so good at, did not save lives.

If cutting out the breast removed the danger, treating the breast more aggressively would lower mortality. It does not. That single fact — artifact-proof, drawn from the largest dataset we have — is the quiet demolition of the claim that DCIS surgery is saving large numbers of lives. It is preventing a recurrence statistic. It is not, for the overwhelming majority of women, preventing a death.

And it does not stand alone. The 2025 American Cancer Society mortality-trend analysis is the population-level confirmation of Narod’s patient-level finding: across an entire nation, across two decades, as treatment intensified, DCIS death rates held flat.(11) Two independent lines of evidence — one from the largest patient cohort, one from the longest national trend — converge on the same artifact-proof conclusion. The breast was removed. The radiation was delivered. Death did not retreat.

V. The Honest Caveat — Because This Argument Has to Be Bulletproof

I am not going to overstate this, because the strongest version of an argument is the one that has already absorbed its best counter.

There is one thing surgery does that watchful waiting cannot: it sometimes finds occult invasive cancer that was already present but missed on the needle biopsy. In COMET, roughly 14% of women sent to surgery turned out to harbor invasive disease; in LORD, 29 of 363 surgical patients had invasive cancer detected at the start.(1,9) A computational model by Ryser found that the single most important variable determining whether active surveillance is safe is precisely this “probability of understaging.”(10)

But notice: this is a detection benefit, not a tissue-removal artifact, and it argues for better biopsy and better imaging and careful patient selection — not for the reflexive removal of breasts from 50,000 women a year. It tells us which women need intervention. It does not justify treating an entire category of finding as if it were lethal.

This is why the defensible claim is precise: low-risk DCIS is frequently indolent, systematically over-treated, and — for carefully selected women — safely managed by active surveillance. That is now supported by two randomized trials and the largest mortality dataset in existence. It is no longer a contrarian opinion. It is, increasingly, where the evidence points.

VI. Why This Tragedy Keeps Happening

If the evidence has pointed this way for years, why does a woman still walk out of a clinic this week, this year, with a breast scheduled for removal over a lesion that may never have hurt her? The answer is not a single villain. It is a system with four interlocking failures, and I have spent two decades documenting each one.

First, the naming error. The deepest mistake in the DCIS story was never surgical. It was linguistic. The word “carcinoma” turned a tissue-level finding into a death sentence in the patient’s mind, and the system responded to the word, not the biology. In situ means “in its original place” — contained, not invasive, not spread. But you cannot hear the word “carcinoma” across an exam table and weigh probabilities. You hear cancer, and you consent to almost anything. Women lost breasts to a noun. A growing chorus of clinicians now argues openly that we should “take carcinoma out of DCIS” and stop calling it cancer at all — the precise reclassification I called for more than a decade ago.

Second, the financial cascade. A diagnosis is the entry point to a revenue pipeline: the biopsy, the surgery, the radiation suite, the pathology, the anti-estrogen prescription, the years of follow-up imaging. An entire ecosystem is funded by finding more, not by finding less. As I wrote years ago, the apparatus is capable of “driving billions of dollars of revenue by producing more of what it claims to be fighting.” Nobody bills for reassurance. There is no procedure code for “we watched, and nothing happened.” The incentives run in exactly one direction, and it is not toward restraint.

Third — and this is the part that reaches past breast cancer into the whole of modern medicine — the doctrine of genetic determinism. We were taught that our DNA is destiny, that a “cancer gene” is a loaded fate, and that the rational response to risk is to cut. This is the logic that put a scalpel in the hand and a target on healthy tissue. But it is biologically wrong. As I argue in my forthcoming book Regenerate, the old gene-disease narrative has been supplanted by epigenetics — the science of the factors above the genes that determine which are switched on and which are silenced. Diet, toxic exposures, inflammation, the microbiome, stress, sleep, the “exposome” of our cumulative lifetime insults: these, far more than any inherited sequence, govern whether disease is expressed. Genes load the gun, but environment pulls the trigger.

Nowhere is the determinist error more visible than in the mythology around BRCA1 and BRCA2. We have been sold the idea that these genes are “harbingers of inevitable breast cancer” — the logic that led to prophylactic removal of healthy breasts and ovaries. Yet the medical literature is deeply equivocal: some BRCA polymorphisms are inversely related to breast cancer risk, and women with BRCA mutations who develop breast cancer often have higher survival than those without. The terrain — nutrition, chemical exposure, emotional state — can switch the cancer-protective function of these genes on or off regardless of which version you inherited. To surgically remove organs to prevent lesions from forming, I have written, “makes just about as much sense as decapitation to prevent a headache.” It is the quick-fix, symptom-suppressive reflex of a paradigm with tunnel vision on the tumor — one that misses the forest for the trees and never asks what gave rise to the cancer in the first place.

Fourth, the manufactured fear that makes patients complicit in their own overtreatment. Cancer-phobia, stoked by pink-ribbon marketing and the language of “early detection saves lives,” pours gasoline on the flames. A frightened patient does not negotiate. And here is the cruel biology of it: that very fear produces a flood of stress hormones that, as the research shows, can itself magnify risk — a vicious cycle in which the dread of the disease becomes a driver of it.

Four failures, one outcome: a containment process the body was managing gets reclassified as a catastrophe, monetized as a pipeline, justified by a discredited theory of inevitability, and sold to a terrified patient. The COMET and LORD trials are now dismantling that machinery with randomization and institutional caution — doing, at last, what the evidence supported when I first wrote about it.

VII. The Toll We Do Not Count

The toll begins the moment the word is spoken. Studies find the psychological wound of a breast-cancer diagnosis persists for years — even when the lesion was never a threat.

When we tally the cost of overtreatment, we count surgeries and dollars. We rarely count what the diagnosis itself does to a woman — and that omission is its own injustice.

The psychological wound arrives the instant the word is spoken, and it does not heal cleanly even when the lesion is benign. A study in the Annals of Family Medicine found that women given a false-positive breast cancer diagnosis still reported greater harm across all twelve measured psychosocial domains — dejection, anxiety, sleep, sexuality, sense of attractiveness, inner calm, existential values — fully three years after being declared cancer-free. Six months after the all-clear, their losses of “inner calmness and existential values” were “as great as those reported by women with a diagnosis of breast cancer.” Being cleared left scars equivalent to having had the disease. And the cumulative probability of a false-positive recall or biopsy recommendation after a decade of screening is at least 50%.(12) The risk of suicide in the week after a cancer diagnosis has been measured at up to 16 times higher, and cardiac death up to 26.9 times higher, than after an all-clear.(12) Fear, it turns out, is not metaphorically lethal. It is measurably so.

The biological toll is just as real, and crueler still, because some of it is inflicted by the treatment meant to help. Mammography’s low-energy X-rays are, by radiobiological measure, roughly four to six times more effective at causing mutational damage than the high-energy radiation our risk estimates are based on — meaning the very screening that finds DCIS carries an under-counted potential to cause breast cancer.(12) And the treatments themselves are not benign: research from the UCLA Jonsson Comprehensive Cancer Center found that radiation, even while killing half a tumor’s cells, can leave the survivors — induced breast cancer stem cells — up to 30 times more likely to form new tumors. The therapy shrinks the visible mass, creating the appearance of success, while enriching the population of the most malignant cells.(12) We have, in too many cases, frightened healthy women, irradiated them, and called it care.

This is the human ledger behind the statistics in Section II-B. Behind every number is a woman who carried anxiety for years, or lost a breast she did not need to lose, or was exposed to radiation and cellular harm in the name of a “cancer” that was never going to take her life. That is the tragedy — not an abstraction, but a toll paid in sleep, in intimacy, in inner calm, and sometimes in life itself.

The science is catching up. It took twenty years. The women treated in the interval — the two-million-plus overdiagnosed, the hundreds of thousands overtreated for “Stage 0” alone — deserve to know that the question was being asked all along, and that the answer was, increasingly, on their side.

Dive Deeper

For more information on breast cancer, consult the GreenMedInfo.com database on the subject, and consult my book REGENERATE, whose most comprehensive chapter are on the topic on both the causes and natural and integrative approaches to both diagnosis and treatment.

Share

Subscribe now

References

[1] ASCO Post. “Early Results From a Trial of Active Surveillance for Low-Risk DCIS Are ‘Reassuring,’ Say Researchers.” April 1, 2026. LORD trial (NCT02492607), presented at EBCC15, Barcelona, by J. Wesseling. https://ascopost.com/news/april-2026/early-results-from-a-trial-of-active-surveillance-for-low-risk-dcis-are-reassuring-say-researchers/

[2] Ji, S. “Mammograms Linked To An Epidemic of Misdiagnosed Cancers.” GreenMedInfo, 2012. https://greenmedinfo.com/blog/mammograms-linked-epidemic-misdiagnosed-cancers — “Breast Screenings Creating An Epidemic of Over-Diagnosis.” GreenMedInfo, Feb 27, 2012. https://greenmedinfo.com/blog/breast-screenings-creating-epidemic-over-diagnosis

[3] Ji, S. “30 Years of Breast Screening: 1.3 Million Wrongly Treated.” GreenMedInfo, 2012. https://greenmedinfo.com/blog/30-years-breast-screening-13-million-wrongly-treated — Bleyer A, Welch HG. “Effect of three decades of screening mammography on breast-cancer incidence.” N Engl J Med. 2012;367(21):1998–2005.

[4] Hwang ES, et al. “Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.” JAMA. 2025;333(11):972–980. PMID 39665585. https://pubmed.ncbi.nlm.nih.gov/39665585/

[5] American Cancer Society, Breast Cancer Facts & Figures (DCIS ≈ 20% of new breast cancer diagnoses).

[6] Poelhekken K, et al. “Overdiagnosis of ductal carcinoma in situ by grade and definition in population-based screening: A modeling study.” The Breast. 2025. PMID 41082841. https://pmc.ncbi.nlm.nih.gov/articles/PMC12547802/

[7] Chen Q, Campbell I, Elwood M. “Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis.” Breast Cancer Res Treat. 2024. PMID 39180592. https://pubmed.ncbi.nlm.nih.gov/39180592/

[8] Narod SA, Iqbal J, Giannakeas V, et al. “Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.” JAMA Oncol. 2015;1(7):888–896. PMID 26291673. https://pubmed.ncbi.nlm.nih.gov/26291673/

[9] Surgical upstaging literature: PMIDs 28700803, 34091677, 28795370, 35278202.

[10] Ryser MD, et al. “Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis.” J Natl Cancer Inst. 2016. PMID 26683405. https://pubmed.ncbi.nlm.nih.gov/26683405/

[11] Sung H, Jiang C, Jatoi I, Jemal A. “Trends in breast cancer death rates from ductal carcinoma in situ in the United States.” Breast Cancer Res. 2025 Sep 26;27:164. doi:10.1186/s13058-025-02068-9. PMID 41013593. https://pmc.ncbi.nlm.nih.gov/articles/PMC12465744/ — death rate from DCIS “has not decreased from 2000 to 2021.”

[12] Ji, S. “’Hidden Dangers’ of Mammograms Every Woman Should Know About.” GreenMedInfo. https://greenmedinfo.com/blog/hidden-dangers-mammograms-every-woman-should-know-about — synthesizing: Brodersen J, Siersma VD. “Long-term psychosocial consequences of false-positive screening mammography.” Ann Fam Med. 2013;11(2):106–15 (PMID 23508596); Hubbard RA, et al. “Cumulative probability of false-positive recall after 10 years of screening mammography.” Ann Intern Med. 2011;155(8):481–92 (PMID 22007042); and UCLA Jonsson Cancer Center radiation-induced breast cancer stem cell findings (Cancer, 2012).

[13] Ji, S. Regenerate: Unlocking Your Body’s Radical Resilience through the New Biology — on epigenetics, the exposome, BRCA mythology, and “genes load the gun, but environment pulls the trigger.”

There’s a particular kind of tiredness that caffeine doesn’t fix.

You know the one. It sits underneath the coffee — which, as I've written about, acts on the same brain receptors as opioids — the fatigue the third cup only papers over, the afternoon wall, the wired-but-exhausted feeling that more stimulant somehow makes worse — and the sleepless night that sends you back to the pot the next morning.

We’ve built an entire economy around papering over it: caffeine, energy drinks, nicotine pouches now dressed up as “nootropics,” synthetic B-vitamin megadoses. Each one promises energy. Each one, really, just lends it to you — and the interest is brutal.

Because here’s what almost no one selling those products will tell you: you were never meant to borrow your energy. You make immense amounts of it. Right now, in quantities that are genuinely hard to believe.

I find this one of the most moving facts in all of biology. Inside every cell in your body, an electric field runs across a membrane only five nanometers thick — on the order of 30 million volts per meter. That’s not a figure of speech; it’s published, peer-reviewed measurement, and it puts the field inside your mitochondria in the same intensity range as a lightning bolt. You carry something like ten quadrillion of these tiny charged membranes, all running at once, as you read this. Your body mints and recycles its own weight in cellular energy every single day.

So the real question was never how do I get more energy from outside?

It was: why has the engine inside gone quiet — and what does it actually need?

To answer that, you have to go back about two billion years.

Your mitochondria — the structures inside your cells that produce that energy — aren’t originally human. In the deepest sense, they’re cyanobacteria. Roughly two billion years ago, an ancient cell engulfed one of these light-harvesting microbes and, instead of digesting it, struck a bargain: you handle the energy, I’ll handle shelter. That single partnership became the eukaryotic cell — the lineage that produced every plant, every animal, you. You are its descendant, in every cell, right now.

That ancestry has a consequence almost no one has thought through. The blue pigment in spirulina — phycocyanin — is a light-harvesting molecule built around the same ancient chemistry your own mitochondria descend from. When you take it in, you’re not introducing something foreign your body has to brace against. You’re reintroducing a molecule your cells have been reading, in one form or another, for two billion years. The same is true of chlorophyll, whose metabolites actually concentrate inside your mitochondria when you eat your greens. We are, quietly, beings of light — fed by it, and built to generate it.

You can learn about phycocyanin's remarkable two-billion-year prehistory — and why a growing body of research keeps circling back to this single blue molecule — in my latest research article below.

But here's the part I keep coming back to. The modern energy economy is built on force — push the nervous system, spike it, crash, repeat. But the body doesn't run on force. It runs on substrate and signal (I wrote an entire book on the topic called REGENERATE) — the raw materials and the ancient molecular language its energy machinery evolved alongside, and which the industrial diet quietly stripped out.

That idea — that the answer to the energy crisis is deeper nourishment at the cellular level, not stimulation — is the whole reason I built my second product in the Regenerate line. (view my first product, CardioNK here, if you missed it!)

Hippocrates told physicians to leave their drugs in the chemist’s pot when the patient could be healed with food. That has been my mission for over two decades, through everything I’ve done at GreenMedInfo. MethylateBLUE™ is that conviction in a capsule: phycocyanin from organic spirulina, paired with chlorophyll, the four methylated B-vitamins, fermented nicotinamide, and minerals bound to spirulina peptides — the cofactors your cells actually recognize and use. No stimulant. No nicotine. No synthetic dye. It doesn’t whip the engine. It feeds it — giving your cells the raw materials they need to do what they've always done: harvest light and transform it into cellular energy.

Phycocyanin and chlorophyll don’t just rival methylene blue’s light absorption — together they cover more of the spectrum.

I traced the whole history of this molecule — where it came from and what the research actually shows — in The Methylene Blue Mistake.

If the wonder here pulls at you the way it pulls at me, I wrote the full story of this two-billion-year partnership — the chemistry, the ancestry, why this molecule seems to know us — in a companion piece: We Are, In Part, Cyanobacteria. That’s where the science goes deep.

And if you’d rather just begin, the full formula, the research behind every ingredient, and how to start are all on the product page.

→ See MethylateBLUE™ at Regenerate — Subscribe & Save 25% during initial launch.

With gratitude, Sayer

Reset Your Energy with Methylate Blue

What’s Inside MethylateBLUE™

Every ingredient was chosen for a clear role your cells already recognize — not to pad the label.†

Organic Blue Spirulina Extract (phycocyanin), 500 mg — the cornerstone pigment; supports the body’s own antioxidant response and helps protect mitochondrial function.†

Chlorophyll from spirulina — partners with phycocyanin to support clean cellular electron flow and the conversion of light into energy.†

Methylated B-Vitamins (B2, B6, Folate, B12) — the active, body-ready forms (R-5-Phosphate, P-5-Phosphate, L-5-MTHF, and cyanide-free methylcobalamin), so the methylation cycle runs without a conversion bottleneck.†

Fermented Nicotinamide — a food-form precursor your cells use in the NAD⁺ pathway that powers cellular energy production.†

Peptide-Powered Minerals™ (VerdeMins™) — nine essential minerals (iron, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum) bound to spirulina peptides for intracellular delivery.†

Vegan capsule. No artificial fillers, colors, soy, gluten, or nuts.

→ See the full label and begin at Regenerate — Subscribe & Save 25% during initial launch.

Founder, Regenerate™ & GreenMedInfo™

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Share

Phycocyanin — the blue pigment that gives spirulina its color — shares a two-billion-year history with your own cells. What the science keeps pointing toward isn't a drug mechanism. It's an ancestral one.

What if the reason this cyanobacterial pigment shows such broad biological activity across the research is not that it is a remarkable drug — but that your cells are, in part, descended from the organism that makes it?

This is the part of the work I love most. Not the cataloguing of studies — though there is something quietly thrilling about watching 107 abstracts resolve into a coherent portrait of a molecule the medical establishment has largely ignored. What I love is the moment when the pattern becomes visible. When the data stops being a list of therapeutic actions and starts being a story about who we are.

Modern science has a particular limitation that almost never gets named. It is not a limitation of intelligence or effort. It is a limitation of funding. What gets studied is, in large part, what can be patented. What can be patented is what can be isolated, synthesized, and sold. A pigment protein derived from a cyanobacterium that has been consumed by human ancestors for as long as there have been human ancestors — that is, by definition, unpatentable. Which means it falls outside the zone of serious pharmaceutical interest. Which means the literature that does exist represents a fraction of what would exist if the economics were different.

That is not a conspiracy. It is a structural reality. And it does not mean the science is absent. It means we have to be pioneers to find it.

The Ancestral Relationship: We Are, In Part, Cyanobacteria

The mitochondrion and the cyanobacterium — not analogy, but ancestry. Every human cell carries the descendant of this ancient partnership.

Start here, because everything else follows from it. Your mitochondria — the organelles inside every cell of your body that produce ATP, the currency of biological energy — are not originally human. They are, in the deepest sense, cyanobacteria.

Roughly 1.5 to 2 billion years ago, an ancient archaeal cell engulfed a cyanobacterium. Instead of digesting it, the two organisms struck an arrangement that would eventually produce every complex life form on Earth: the cyanobacterium traded its energy-production capacity for shelter and nutrition. That partnership became the eukaryotic cell. You are its descendant.

“Your mitochondria and spirulina’s phycocyanin-producing apparatus share a common ancestor. They are not strangers to each other. They are, in the most literal biological sense, relatives.”

This is not metaphor. It is the established scientific consensus on eukaryotic evolution. And its implications for how we understand phycocyanin’s activity in human tissue have been almost entirely unexplored.

Phycocyanin — specifically C-phycocyanin (C-PC), the dominant blue pigment protein of Spirulina — is a light-harvesting molecule. Its biological function in cyanobacteria is to capture photons and channel their energy into the electron transport chain. The electron transport chain that exists in your mitochondria. The same chain, evolutionarily continuous, now running on oxygen rather than light — but descended from the same ancient apparatus.

When you consume phycocyanin, you are not introducing a foreign pharmacological agent into your biology. You are reintroducing a molecule whose chemical language your cells have been reading — in one form or another — for two billion years.

The Chromophore: Where the Chemistry Becomes Unmistakable

The active chromophore inside phycocyanin is phycocyanobilin — a tetrapyrrole ring structure. Look at that structure carefully, and then look at biliverdin, the heme breakdown product your own liver produces. They are near-identical. Biliverdin is your body’s precursor to bilirubin — the endogenous antioxidant that circulates in your blood and protects LDL from oxidation.

The tetrapyrrole ring is one of the most ancient and conserved molecular structures in all of biology. It is the core of chlorophyll. It is the core of heme. It is the structure your body produces, with extraordinary metabolic effort, to manage oxidative stress. And it is the structure at the heart of the pigment that gives spirulina its blue color.

This structural kinship explains something the literature documents but rarely accounts for: phycocyanin activates Nrf2, the master transcription factor that governs the body’s own antioxidant and cytoprotective response. Bilirubin — your own tetrapyrrole — is a natural Nrf2 activator. When phycocyanobilin enters the cell, the body may be reading it as a recognized signal. Not a drug. Not a supplement. A molecular communication it already knows how to receive.

What 107 Studies Reveal: A Literature Review

The GreenMedInfo database currently indexes 107 abstracts on phycocyanin and 58 documented pharmacological actions, yielding a Cumulative Knowledge Score of 173 and an overall research rating of Good.

The two highest-scoring pharmacological actions in the database are anti-inflammatory activity (40 abstracts, Cumulative Knowledge 64) and antioxidant activity (41 abstracts, CK 62). These are not niche findings. Inflammation and oxidation are two of the master regulatory processes in human physiology. What distinguishes phycocyanin is not the presence of these effects — it is the remarkable precision and multiplicity of the mechanisms through which they are achieved.

ANTI-INFLAMMATORY MECHANISMS

COX-2 inhibition (10 abstracts), NF-κB suppression (8 abstracts), TNF-alpha inhibition (13 abstracts), IL-6 downregulation (7 abstracts), IL-1β reduction, PGE2 suppression, IL-10 upregulation, and Nrf2/HO-1 pathway activation. A multi-target profile no single pharmaceutical can replicate.

A NOTE ON THE BREADTH OF THE LITERATURE

What’s striking about the phycocyanin research isn’t any single finding — it’s the range of fields engaged with it. The published literature spans neuroscience, oncology, cardiometabolic science, hepatic and renal physiology, immunology, and more, with most of the activity converging on two underlying mechanisms: the modulation of inflammatory signaling and the support of antioxidant defense.

I’m not going to summarize those clinical literatures here, for two reasons. First, this is an article about why a molecule might show such range — the ancestral argument — not a medical review. Second, the appropriate home for that body of research is the open database itself, where each abstract can be read in its original context. The full catalog of indexed studies — across every field of investigation — lives at GreenMedInfo’s phycocyanin entry, and I’d encourage anyone who wants the specifics to read the primary sources there rather than take my framing for it.

What matters for the argument I'm making is simpler: a single molecule has drawn serious scientific attention across an unusually wide range of human biology. The question this article asks is why — and the answer, I'll argue, is older than any of the individual studies.

The Co-Evolutionary Explanation: Why This Molecule Knows Us

The breadth of phycocyanin’s activity across 82 disease conditions is, on the surface, implausible. No single molecule should address cancer and Alzheimer’s and kidney disease and radiation damage and infertility and colitis. Unless the explanation is not that the molecule targets 82 conditions — but that it restores the regulatory conditions in which the body’s own intelligence can address them.

Consider the evolutionary timeline. Cyanobacteria oxygenated the atmosphere — a transformation that took hundreds of millions of years and made complex aerobic life possible. Vertebrate animals evolved in aquatic and semi-aquatic environments where cyanobacteria were at the base of the food web. The relationship between cyanobacterial molecular chemistry and animal physiology is not supplementary. It is foundational.

It is plausible that the inflammatory and antioxidant signaling systems of animals co-evolved in the presence of cyanobacterial chemistry. That NF-κB, Nrf2, and the cytokine networks were calibrated, over hundreds of millions of years of evolutionary pressure, in an environment where cyanobacterial pigment proteins were a regular feature of the biochemical landscape. That the absence of these molecules from the modern diet is not neutral — it is a deficit. And that the 82-condition footprint of phycocyanin in the literature is not a pharmacological curiosity but a biological signal: the body recognizing, and responding to, a chemistry it was shaped to expect.

“We are not consuming something alien. We are, in a sense, reintroducing a molecular conversation that industrial food systems interrupted.”

This is what it means to draw from ancient intelligence using modern science. The studies are necessary — they give us the precision, the mechanisms, the language of causality that the modern mind requires. But the deeper question the studies are answering was never a pharmacological one. It was an evolutionary one. Why does the blue pigment of a cyanobacterium restore order in human cells? Because human cells are, in part, cyanobacterial. Because the molecule is not foreign medicine. It is ancestral chemistry, finally coming home.

How Do You Take It?

Phycocyanin is one of those compounds where sourcing and form matter enormously. The difference between a meaningful dose and an inert one comes down to three things: purity grade, extraction method, and stability preservation. Here is what to look for, and how to think about incorporating it.

Purity Grade

Phycocyanin is graded by “color value” — a measure of absorbance at 618nm that reflects the concentration of active pigment. The most common commercial forms of blue-green algae typically run between 1–3% of dry weight. For encapsulated forms taken with in doses of physiological relevance, look for 25% concentrations or above. A dedicated phycocyanin extract delivers meaningfully more active compound per gram, and is more likely to be taken daily than the powder form.

Extraction and Stability

Phycocyanin is a protein, and proteins degrade. Heat, light, and prolonged exposure to water all compromise its activity. Freeze-drying (lyophilization) is the gold standard preservation method — it retains a substantially higher concentration of functional molecules than heat-based drying. When evaluating any phycocyanin product, look for cold-processed or freeze-dried on the label. Avoid products that have been sitting in clear containers exposed to light, or formulations that use heat-intensive manufacturing processes.

Dosing: What the Research Suggests

Most of the research on phycocyanin uses doses in the range of 100–300mg of purified C-phycocyanin per day for systemic anti-inflammatory and antioxidant effects. Some human studies — including the ACE human trial cited in this review — used formulations delivering phycocyanin as part of a broader spirulina-derived complex. As with most whole-food-derived compounds, consistency over weeks rather than single large doses appears to be the pattern the research supports. On an empty stomach first thing in the morning is generally considered optimal for absorption.

Sources Worth Knowing

The market for phycocyanin ranges from high-integrity to inert. A few benchmarks worth knowing when evaluating sources:

• Whole spirulina powder (organic, cold-processed) — the most accessible entry point. Look for USDA Organic certified, Arthrospira platensis, with no fillers or flow agents. Provides phycocyanin alongside the full complement of co-factors including chlorophyll, phycoerythrin, and accessory pigments. Dose: 3–5g daily. Add to water, smoothies, or juice. The flavor is mild when the quality is high.

• Blue spirulina extract (phycocyanin isolate) — the concentrated form, stripped of chlorophyll and most of the green pigment, leaving a vivid cobalt-blue powder. Delivers more phycocyanin per gram than whole spirulina. Look for freeze-dried, no fillers, purity-graded. Works well dissolved in cold water or added to light-colored drinks where you want the blue without the green. Dose: 0.5–1g daily.

• Encapsulated phycocyanin complexes — when phycocyanin is formulated with complementary compounds that stabilize the protein and enhance bioavailability, including lipid carriers or co-factors that support the electron transport activity the molecule is known for. This is where formulation intelligence matters most.

A NOTE ON STIMULANT-FREE ENERGY

Most energy products work by stimulating the adrenal-sympathetic axis — caffeine, guarana, B-vitamin megadoses, adaptogens that push cortisol. The come-up is real. So is the crash, and the cumulative load on the nervous system over months and years of use. Phycocyanin’s energy-supporting mechanism is categorically different. It works at the level of the electron transport chain — the same chain your mitochondria use to generate ATP. Rather than borrowing energy from tomorrow, it supports the conditions under which your cells generate energy today. No stimulant effect. No adrenal load. No crash.

This distinction matters most for people who are already running on reserves — those managing chronic inflammation, post-viral fatigue, or the accumulated oxidative load of a high-demand life. For these individuals, the last thing the system needs is another stimulant. What it needs is substrate: the molecular raw material for the electron transport chain to do its work properly. That is precisely what phycocyanin provides.

A Formulation I Built Around This

The research on phycocyanin is what led me to formulate with it. I wanted a version that respected what makes the molecule worth taking in the first place — so MethylateBLUE™ is organically produced, freeze-dried to protect the fragile pigment, and concentrated to roughly 50% phycocyanin.

It isn’t an energy drink and it isn’t an adaptogen stack. I paired the phycocyanin with co-factors I chose to support the body’s own cellular energy machinery — including fermented nicotinamide, a precursor your cells use in the NAD⁺ pathway. The idea was simple: work with the chemistry described above rather than around it.

If the science here interests you the way it does me, you can see the full formula and the thinking behind it on the product page.

→ See MethylateBLUE™ at Regenerate

References

1. Nova M, Citterio S, Martegani E, Colombo S. Unraveling the Anti-Aging Properties of Phycocyanin from the Cyanobacterium Spirulina (Arthrospira platensis). Int J Mol Sci. 2024 Apr 11;25(8):4215. doi: 10.3390/ijms25084215. PMID: 38673801.

2. C-Phycocyanin from Spirul

ina Inhibits α-Synuclein and Amyloid-β Fibril Formation. J Nat Prod. 2019. doi: 10.1021/acs.jnatprod.8b00610. PMID: 30571090.

3. C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy. Sci Rep. 2019 Dec 16;9(1):19161. doi: 10.1038/s41598-019-55606-x. PMID: 31844085.

4. Bioactive C-phycocyanin exerts immunomodulatory and antitumor activity in mice with induced melanoma. Toxicol Appl Pharmacol. 2024 Mar;484:116874. PMID: 38428464.

5. Castro-Gerónimo VD et al. C-Phycocyanin: A Phycobiliprotein from Spirulina with Metabolic Syndrome and Oxidative Stress Effects. J Med Food. 2024 Sep;27(9):807–813. doi: 10.1089/jmf.2022.0113. PMID: 37668603.

6. Biomimetic phycocyanin lipid-based nanoparticles ameliorate placental dysfunction and restore angiogenic balance in a pre-eclampsia model. J Nanobiotechnology. 2026 May 7. PMID: 42098767.

7. Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Pharmacol Res. 1999 Jan;39(1):55–59. PMID: 10366332.

8. C-phycocyanin alleviated cisplatin-induced oxidative stress and inflammation via gut microbiota-metabolites axis in mice. Front Nutr. 2022;9:996614. PMID: 36225866.

9. Fernandes R et al. Exploring the Benefits of Phycocyanin: From Spirulina Cultivation to Its Widespread Applications. Pharmaceuticals. 2023;16(4):592. doi: 10.3390/ph16040592. PMC: 10144176.

10. Andonova V et al. Spectral Characteristics, In Silico Perspectives, DFT, and Therapeutic Potential of Green-Extracted Phycocyanin from Spirulina. Int J Mol Sci. 2024;25(17):9170. doi: 10.3390/ijms25179170. PMC: 11394851.

11. Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res. 1998 Jan;47(1):36–41. PMID: 9495584.

12. Spirulina phycocyanin extract and its active components suppress epithelial-mesenchymal transition process in endometrial cancer. Biomed Pharmacother. 2022 Aug;152:113219. PMID: 35691155.

Full citation database available at GreenMedInfo.com/substance/phycocyanin (107 abstracts indexed). This article is for educational purposes and does not constitute medical advice.

A turtle survives six months without oxygen. A dark pigment may be why. I asked three of the world’s most advanced AI systems to hunt the answer — independently, adversarially, across all the science on Earth. Here is what they found, and the two experiments that would finally settle it.

This is part of my ongoing series on Sacred Technology. It is also, I'll admit, the most rigorously self-critical thing I've published on melanin — because I deliberately set out to prove myself wrong, and then to prove the skeptics wrong too. What survived that crossfire is the most honest account I can give you of where this extraordinary question actually stands. If you haven't read it yet, the bold case this essay puts on trial is The Ultimate Human Superpower You Never Knew You Had.

A turtle that should be dead

Start with an animal that breaks a rule you were taught was unbreakable.

Every autumn, in the ice-locked ponds of the northern United States and Canada, the western painted turtle sinks to the bottom and stops breathing. Not for minutes. Not for hours. For up to 170 days — nearly six months — buried in near-freezing, oxygen-free mud, its heart barely beating, its brain dark and still (the Warren Lab; Odegard et al. & Ultsch and Jackson, J. Exp. Biol.2025). It is, by a wide margin, the most anoxia-tolerant four-limbed animal known to science. Put a rat, a rabbit — or you — in those conditions for four minutes and the brain begins to die. The painted turtle does it for half a year and swims away in spring, its neurons intact.

How? The textbook answer is real, and it is genuinely brilliant: the turtle performs a near-total metabolic shutdown, dropping its energy demand by as much as 700-fold, buffering the acid of anaerobic metabolism in its own shell, and somehow preventing the burst of cell-killing free radicals that should ravage its brain when oxygen returns (Bundgaard et al., Acta Physiologica2022). Spend an afternoon in that literature and you will come away dazzled by how the turtle manages to spend almost nothing.

But sit with it a moment longer and a quieter question surfaces — the kind that, in my experience, is usually where the real story hides. Almost nothing is not nothing. Over six months, in the cold and the dark, the turtle’s brain still has to keep the lights on — maintain ion gradients, hold its membranes together, stay alive enough to wake up. Anaerobic metabolism yields less than a tenth of the energy that breathing does (J. Exp. Biol. 2025). The accounting is tight. And there is one molecule packed into that turtle — into the dark dorsal shell that faces the light, into its skin, into its very brain — that almost every one of those metabolic studies declines to mention. Hold that thought. We will come back to the turtle, because it may be the most important witness in this entire story.

Read more

The same group cast as an AI-safety watchdog in Florida’s blockbuster case against OpenAI was privately discussing how to “Kill Musk’s Twitter,” trigger regulation across the U.K., EU, and U.S., jailbreak AI tools, and weaponize synthetic media for policy and press advantage.

Share the X thread dedicated to this article.

Story at a glance

• Florida’s complaint against OpenAI leans on CCDH’s research to portray the group as a credible authority on AI harms, especially harms to minors.

• CCDH’s own internal planning memo shows a recurring strategic objective to “Kill Musk’s Twitter,” alongside plans to “Trigger EU & UK regulatory action” and drive “Progress towards change in USA and support for STAR.”

• The same memo shows CCDH planning AI voice-clone and AI-image campaigns aimed at policymakers, broadcasters, and major newspapers.

• CCDH explicitly discussed jailbreaking AI tools to generate political images and then using those outputs as evidence that AI companies had failed to install proper guardrails.

• Internal discussions framed election-disinformation and child-safety content not just as public-interest work, but also as vehicles for “planting a flag,” driving profile growth, increasing SEO traffic, and supporting fundraising.

• The resulting picture is not of a neutral watchdog, but of a sophisticated political-pressure operation whose private methods appear to run directly against its public posture.

A massive lawsuit filed by the State of Florida against OpenAI and Sam Altman is being presented as a landmark case about the harms of artificial intelligence: manipulated minors, addictive chatbot design, unsafe medical advice, and the commercial deployment of a system the state says was marketed as safe and trustworthy when it was not. That story alone is explosive.

But buried inside the same legal and documentary universe is a second story that may prove just as important: one of the lawsuit’s most useful outside validators, the Center for Countering Digital Hate (CCDH), whose antics I have been reporting on for the past 5 years, appears in its own internal planning documents as something very different from the sober, neutral, public-interest watchdog it presents to the world.

Florida’s complaint relies in part on CCDH’s research to support the claim that ChatGPT can encourage self-harm, provide dangerous guidance to teens, and operate without meaningful guardrails. In the complaint, CCDH is treated as a credible authority on what unsafe AI looks like and why inadequate controls matter.

Yet CCDH’s own internal “Portfolio Planning Monthly Meeting” memo reveals a private operating posture that is not merely activist, but overtly strategic, adversarial, and at points startlingly deceptive in relation to its public face. Over and over, across multiple 2024 entries, CCDH lists as a standing priority: “Kill Musk’s Twitter.” In the same recurring priority blocks, it lists “Advertising focus,” “Trigger EU & UK regulatory action,” and “Progress towards change in USA and support for STAR.”

That language matters because it strips away the polished rhetoric of public safety and reveals an organization openly pursuing pressure campaigns against named targets while simultaneously seeking the authority of a neutral nonprofit expert. A group whose recurring internal goal is to “Kill Musk’s Twitter” is not simply studying platform harms from a distance.

The memo says the quiet part out loud

The internal memo does not read like the notes of an independent research charity cautiously documenting online harms. It reads like the playbook of a coordinated influence operation measuring success in press hits, policy hits, legal leverage, donor cultivation, and regulatory outcomes.

One passage calls for reports on “metrics to do with press coverage and policy hits from recent reports.” Another describes a “big data point” in an antisemitism report “to drive profile growth.” Elsewhere, election-disinformation content is discussed as a way to “plant a flag,” while AI-related content is described as useful for “SEO - increasing traffic to CCDH” and “fundraising too.”

That is not ordinary mission language. It is campaign language.

Synthetic media for pressure politics

The sharpest contradiction emerges in CCDH’s AI planning. Publicly, CCDH presents itself as warning that AI systems are dangerous because they produce convincing synthetic content, lack guardrails, and can be weaponized against vulnerable people and democratic systems. Privately, the memo shows CCDH planning to do precisely that for strategic effect.

In the May 23, 2024 entry, CCDH lays out an “AI voice launch” titled Attack of the Voice Clones. The plan includes U.S. outreach to Senator Amy Klobuchar’s team for a quote or endorsement, U.K. outreach through the Cabinet Office, and EU/DSA outreach to the European Commission. It also includes specific discussion of how to use AI-cloned political voices with broadcasters, including the idea of a fake Sunak voice saying: “bad actors can get me to say anything, there are no safeguards.”

The memo states that CCDH had such recordings “ready to use for each of the eight main voices,” while also noting: “We can’t put out the dangerous ones.” It then adds: “We should make the point that the quotes are very convincing – and that is what makes the lack of safety and guardrails so dangerous.”

In plain English, CCDH was privately generating highly convincing AI political voice clones, deciding which ones were too dangerous to release, and using the rest to push lawmakers, regulators, and media outlets toward a preferred policy conclusion. This is not merely analysis of synthetic-media risk. It is active production and deployment of synthetic-media risk for advocacy purposes.

The jailbreak admission

Then comes one of the most revealing lines in the entire memo. In the same May 23 section, discussing “AI images for EU and UK politicians,” CCDH notes that the images had already been created for an NBC request and could be repurposed for broader media use. The memo continues: “The tools may have improved slightly on safety but will be jailbreaking so not 100% sure, but could be evidence that our interventions have helped.”

That line should stop readers cold.

CCDH is publicly positioned as an organization warning that AI companies have failed to install adequate guardrails. Yet internally, it is explicitly discussing how it will jailbreak those tools, circumvent safety features, and then use the resulting outputs as “evidence” in a press campaign claiming the companies have not kept their promises on guardrails.

The memo even sketches the release strategy: an “EU/UK press only hit” on June 5, framed as a warning to voters that major AI platforms had not put in the promised protections. So the same organization criticizing the availability of dangerous outputs was deliberately provoking those outputs to generate a media-ready case for regulation.

Testing political smears with AI

The election-disinformation planning is equally revealing. On January 8, 2024, CCDH discusses how to “intervene in a year of big elections,” including AI’s role in disrupting elections and the press appeal of AI-related case studies. One particularly blunt line reads: “funders and journalists love it. I would probably get names of candidates (Trump/Biden), and test willingness of different AI tools to generate, e.g. Trump meeting KKK, Biden meeting terrorists.”

That is not passive monitoring. It is internal discussion of using AI systems to generate extreme political imagery involving named U.S. candidates in order to prove a point about what those systems allow.

Another participant explains the strategic advantage clearly: “next time there is a popular deep fake video, we can refer back to the fact we had pointed out that these deep fake sites were not ready and we had said so… this would be a good thing to have in our back pocket.” The point was not only to observe a problem, but to pre-position a narrative asset for future crises.

Child safety, list building, and lobbying lines

The memo also sheds light on how CCDH discussed parent-focused and child-safety content. Publicly, CCDH has built much of its authority on claims that it protects children from platform harms, self-harm content, and manipulative digital systems. Internally, the memo shows that a “Parents’ Guide” they were co-developing with Prince Harry’s Archewell Foundation was also valued as a conversion tool.

One line states that downloadable PDFs are “very useful for generating leads.” Another says the guide needs to be “behind an email sign up.” A further remark notes a “66% conversion rate at moment for the guide.” In the same discussion, the memo raises the need to check lobbying limits and, “if necessary register a c4 ASAP.”

None of this proves the child-safety concerns are insincere. What it does show is that material publicly framed as a moral response to harms facing children was also being assessed internally through the lenses of audience capture, conversion, and lobbying exposure.

This is where the child-safety framing collides with one of the most revealing episodes of the entire saga: the Kids Online Safety Act (KOSA). CCDH publicly endorsed KOSA, with CEO Imran Ahmed praising the bill for forcing platforms to be “safe by design” and touting its “duty of care” obligations to protect children. On its face, that is exactly the posture you would expect from a children’s-safety organization.

But the same internal documents that exposed CCDH’s lead-generation calculus also surfaced under a far more damning banner: the leaked “Kill Musk’s Twitter” strategy memo, in which CCDH discussed how to trigger regulatory action against X and degrade the platform’s viability. CCDH has been implicated in aggressive campaigns to deplatform dissenting voices, including Elon Musk himself — the very platform owner whose company would later line up behind a CCDH-backed bill.

And that is the extraordinary irony. As I documented in my earlier alert, “Elon Musk’s X Corp, under his leadership and that of CEO Linda Yaccarino, recently endorsed the Kids Online Safety Act (KOSA)” — the same legislative vehicle championed by an organization that had internally strategized to kill his platform. A self-described “free speech absolutist” and his CEO ended up endorsing a bill backed by the group most aggressively working to regulate, defund, and deplatform X. Whether through goodwill, political pressure, or simply not connecting the dots, Musk and Yaccarino risked empowering the very censorship architecture CCDH had been building — using the moral shield of child safety as the entry point.

The lesson of this section is not that protecting children is a pretext. It is that “child safety” can function simultaneously as a sincere cause, a lead-generation engine, and a regulatory wedge — and that even sophisticated operators like Musk and Yaccarino can be maneuvered into endorsing a framework that cuts directly against their own stated principles.

A campaign operation, not a neutral referee

The broader memo reinforces this pattern. There are references to lobbying in DC with “60 meetings on the Hill,” meetings with 16 congressional offices to discuss the Elon lawsuit and tech policy priorities, active monitoring of lobbying tracking, and briefing preparation for use “in Hollywood.” Celebrity networks such as CAA and UTA appear in the planning, along with discussions of endorsements, PSA circulation, and partner lists. Indeed, in 2024 CCDH hosted a DC event with government officials, NGOs, and even a British embassy official, the details of which are below.

At one point, CCDH even contemplates how to “attach our name” to Canada’s Online Safety Bill despite having “no actual staff in Canada.” At another, internal discussions emphasize how the “State of STAR” conference can showcase that multiple countries now have aligned legislation and that “showing a global movement will be powerful.”

This is the language of a transnational pressure network building legal, media, donor, and regulatory momentum in tandem. It is not the language of a detached umpire simply calling balls and strikes on digital harm.

Why this contradiction matters now

Florida’s lawsuit against OpenAI is likely to draw national attention because it merges AI safety, child harm, consumer deception, and public nuisance into one sweeping state action. If CCDH is going to be treated in that context as a trustworthy outside authority on AI ethics and guardrails, then its own internal approach to AI should matter too.

And what the memo shows is a profound contradiction. CCDH publicly condemns realistic synthetic media, weak AI safeguards, manipulative digital design, and dangerous outputs. Privately, it discusses creating convincing voice clones, generating political AI images, jailbreaking tools to bypass safety systems, and packaging those outputs for lawmakers, broadcasters, major newspapers, donor audiences, and election-cycle narrative advantage.

That does not look like a neutral guardian standing above the fray. It looks like a highly professionalized pressure operation, operating in effect as a foreign influence campaign, that wraps itself in the language of “safety” while using tactics that closely resemble the conduct it accuses others of. That, in turn, runs in parallel with Ahmed’s case in Ahmed v. Rubio, where he argues that U.S. officials are unconstitutionally punishing him—by revoking his visa—for the very advocacy and research that pressure governments and platforms to police speech. A stinging irony I have documented in detail below.

The real issue is not whether AI risks are real; they are. The issue is whether the organizations claiming the moral authority to police those risks are themselves operating honestly. In CCDH’s case, the gap between the public brand and the private memo is not small. It is the story.

If you want to learn more my own federal civil rights lawsuit against CCDH/Imran Ahmed, watch our recent live discussion below with our lawyer, Jeff Childers, who is also has the immensely popular Substack series:

Subscribe now

Share

Leave a comment

Share the X thread dedicated to this article.

Endnotes

1. Complaint, Office of the Attorney General, State of Florida v. OpenAI Global, LLC et al., attached PDF: openai-filed-stamped-complaint.pdf. Used here for the complaint’s reliance on CCDH’s AI-harm research and its framing of ChatGPT as dangerous, deceptive, and unsafe for minors.

2. Portfolio Planning Monthly Meeting memo, attached PDF: portfolio-planning-monthly-meeting-notes-4.pdf. Used here for CCDH’s internal planning language, including “Kill Musk’s Twitter,” “Trigger EU & UK regulatory action,” AI voice-clone planning, AI-image jailbreaking, election-disinformation strategy, lead generation, and lobbying-related discussions.

An evidence review on banana peel’s neuroactive compounds, its emerging role in depression and anxiety research, and what wild animals can teach us about the part we throw away.

Share

The part we discard may be the part that heals

Most of the world treats the banana peel as garbage. Yet a converging body of food-science, plant-physiology, and neuroscience research suggests the peel — not the pulp — concentrates many of the banana’s most biologically active compounds, including dopamine, its precursor L-DOPA, serotonin precursors, and a dense matrix of antioxidant polyphenols. This review traces that evidence, with particular attention to the peel’s emerging role in depression, anxiety, and neurocognitive research, and closes with a revealing observation from the animal kingdom: the creatures that co-evolved with wild bananas never throw the peel away.

This builds on more than a decade of cataloguing the banana’s “secret second life” at GreenMedInfo, where the fruit has been documented “slyly practicing medicine without a license.”

The peel’s brown “sugar spots” are melanin — the end product of the same dopamine pathway explored below (see Section 2 on why a “bad” banana is really making melanin).

1. The banana is a catecholamine factory

The foundational discovery is now a quarter-century old. In 2000, Kanazawa and Sakakibara identified dopamine — a catecholamine best known as a brain neurotransmitter — as a strong, water-soluble antioxidant present at striking levels in the common Cavendish banana (Kanazawa & Sakakibara, J Agric Food Chem).

TissueDopamine contentPeel80–560 mg per 100 gPulp (edible part)2.5–10 mg per 100 g

These levels persist even in ripe, ready-to-eat fruit. Critically, dopamine’s antioxidant potency exceeded that of glutathione, BHA, BHT, luteolin, quercetin, and catechin, and rivaled vitamin C and gallocatechin gallate (Kanazawa & Sakakibara). The authors concluded simply: “Banana is thus one of the antioxidative foods.”

A 2026 electrochemical study confirmed the peel/pulp gradient with a purpose-built dopamine sensor, finding peel dopamine roughly 50% higher than pulp and dropping sharply once the fruit rots — and concluded the peel is “a promising source of dopamine for the production of pharmaceutical formulations” (Elugoke et al., Chemistry Europe).

Bananas are not the only catecholamine-bearing part. As documented in the GreenMedInfo review, the banana plant deploys the catecholamine biosynthetic pathway as a defense mechanism against crown-rot disease (Lassois et al., PMID 22702179), some cultivars excrete serotonin in their sap (Pothavorn et al., PMID 20681667), and noradrenaline and 5-hydroxytryptamine were identified in plantain as far back as 1960 (Foy & Parratt, PMID 13824274).

The ripening pathway: L-DOPA → dopamine → melanin

A 2025 mass-spectrometry imaging study mapped the catecholamine pathway spatially during ripening: L-DOPA declines as the fruit ripens, dopamine rises as the brown “sugar spots” form and then falls, and both localize in the peel — the tyrosine → L-DOPA → dopamine → dopaquinone → melanin cascade that darkens the skin (Shinoda et al., J Agric Food Chem). Earlier work confirmed dopamine is the single highest-concentration polyphenol in the peel throughout development (Hubert et al., J Zhejiang Univ Sci B). Content also varies by cultivar — Robusta tested highest among eight Kerala varieties at 13.3 mg/100 g (Siji & Nandini, IJAERS).

2. When the banana “goes bad,” it is making melanin

Here is the part almost everyone gets backward. When a banana darkens, spots, and finally blackens, we read it as decay — the fruit “going bad.” Biochemically, the opposite is closer to the truth: the browning is the visible end-product of the very catecholamine pathway described above. Those black “sugar spots” are melanin, polymerized from the banana’s own dopamine.

The mechanism is now mapped in detail. As the peel ripens, the enzyme polyphenol oxidase (PPO) oxidizes the peel’s phenolic compounds — with dopamine as its primary substrate — into reactive quinones (dopaquinone), which then polymerize into melanin, the same dark pigment that colors human skin, hair, and eyes (Scientific American; PlantsRule). A 2025 mass-spectrometry-imaging study localized dopamine and dopaquinone inside the forming sugar spots, confirming that L-DOPA → dopamine → dopaquinone → melanin is the chemistry of the brown spots themselves (Shinoda et al., J Agric Food Chem). Classic banana physiology confirmed the same: dopamine is the major PPO substrate, and senescent spotting tracks the conversion of dopamine into brown pigment (Food Preservation Science, Japan).

This reframes the spotted banana entirely. Far from “going off,” the browning fruit is converting a neurotransmitter into a high-value pigment — and the nutritional data follow: antioxidant capacity in bananas peaks at the brown-spotted, overripe stage, even as fiber falls and sugars rise (Verywell Health; Office Fruit). As one explainer puts it, bananas don’t really “go bad” — they evolve.

Why the melanin itself may be a benefit

The pigment forming in that blackening peel is not inert waste. Across biology, melanin is a remarkably active molecule — a stable free-radical scavenger and broad-spectrum energy-handling polymer. I have argued at length that melanin may function as a kind of biological “solar panel” and bioenergetic engine, far more than a passive sunscreen (Sayer Ji, The Ultimate Human Superpower You Never Knew You Had: Melanin). The same pigment chemistry is unfolding on the surface of an over-ripe banana.

The parallel runs deep into our own neurobiology. In the human brain, dopamine spontaneously polymerizes into neuromelanin under oxidative stress — the identical dopamine→melanin reaction — and that neuromelanin then acts as an antioxidant, quenching radicals and binding redox-active iron to protect the cell (Sun et al., Antioxidants). In other words, the banana peel is running, on its skin, a pigment-forming reaction closely analogous to the one our own dopamine neurons run inside the substantia nigra.

The practical upshot is liberating: a spotted or even blackened peel has not lost its value — it has transformeddopamine into melanin and reached its antioxidant peak. When you blend a brown-spotted whole banana (Section 9), you are not salvaging garbage; you are capturing a fruit at the height of its pigment-and-antioxidant chemistry.

3. Is the peel safe to eat?

Yes. Banana peels are not poisonous and are eaten routinely across many cultures. They are a notable source of fiber, potassium, magnesium, vitamins B6 and B12, and antioxidants — and the peel contains more fiber than the fruit, roughly 3–7 g per 100 g (Verywell Health, WebMD).

Three practical caveats matter:

1. Pesticide/fungicide residues concentrate on the outer skin. Wash thoroughly and favor organic. Washing removes surface (non-systemic) residues by roughly 10–82%, but systemic residues that penetrate the tissue cannot be washed off (Lily Nichols RDN, citing Food & Chem Toxicology; NPIC, Oregon State).

2. Texture and bitterness make raw peel tough to digest — cultures that eat peel almost always cook it (curries, “pulled-pork” substitutes, smoothies, banana bread) (Healthline).

3. Insoluble fiber load can cause bloating if introduced too quickly; treat the peel like a vegetable. Ripe peels are thinner, sweeter, and easier to digest than green ones (food-science explainer).

4. Mood and mind: the depression, anxiety, and cognition research

This is the most active and surprising frontier — and again, the peel leads. Multiple independent laboratories have tested banana fruit and peel as antidepressants and anxiolytics, with consistent, mechanistically coherent results (predominantly preclinical).

Antidepressant effects

• The foundational 2011 study: Green and yellow Cavendish peel extract (200–400 mg/kg) significantly reduced immobility in forced-swim and tail-suspension tests in mice. At 400 mg/kg the effect (43–44% reduction) was comparable to Prozac/fluoxetine (45%) (Tee & Hassan, Am J Sci Res).

• Pulp and peel + memory (2017): Both banana pulp (600 mg/kg) and peel (400 mg/kg) produced antidepressant and anxiolytic effects and improved spatial memory in the Morris water maze, alongside elevated brain catalase, SOD, and glutathione (Samad et al., Pak J Pharm Sci).

• BDNF restoration (2025): Unripe Ambon banana peel under chronic mild stress cut immobility ~94% (matching sertraline) and restored hippocampal BDNF — a neuroplasticity marker that conventional antidepressants also upregulate (Suhendi et al., Int J Appl Pharm).

Figure 3. The proposed antidepressant cascade and how peel-extract potency compares with standard drugs in rodent models. Original figure; data from Tee & Hassan 2011, Suhendi et al. 2025, and Hanna et al. 2026.

Read more

An ancient fermented food rivals — and in key respects outperforms — the pharmaceutical drugs sold for bone loss, and a growing body of human clinical evidence now backs up what the original animal data suggested.

Read and share the X thread dedicated to this article here.

Story at a Glance

• A naturally occurring compound in fermented foods, genistein, has shown the ability to improve bone density and strength, matching or surpassing leading osteoporosis drugs in multiple studies.

• Human clinical trials and a 2024 meta-analysis found that genistein significantly improves bone health in postmenopausal women, particularly at doses of 50 mg/day or higher.

• Genistein supports bone formation while reducing bone breakdown, offering a mechanism distinct from many conventional osteoporosis treatments.

• Unlike drugs such as Fosamax, Evista, and hormone replacement therapy—which carry risks including fractures, jaw necrosis, blood clots, stroke, and cancer—genistein has demonstrated a favorable safety profile in long-term studies.

• The evidence suggests that a traditional food-derived compound may provide a safer, effective alternative for supporting bone health, despite receiving far less attention than patented pharmaceutical therapies.

When I first wrote about this subject 14 years ago on GreenMedInfo, the headline finding came from a single, striking animal study. A decade of additional research has only strengthened the thesis. What began as a provocative laboratory result in rats has matured into a credible, human-tested case that a soy-derived nutrient called genistein belongs in the conversation about bone health — not as a fringe alternative, but as an evidence-backed agent that, dose for dose, holds its own against the multi-billion-dollar osteoporosis drug franchise.

This is the expanded, more fully documented version of that argument.

The Study That Started It

The foundational finding was published in the British Journal of Pharmacology in 2008 by Bitto and colleagues. In an animal model of established postmenopausal osteoporosis — not merely prevention, but treatment of bone that had already deteriorated — researchers took 96 ovariectomized rats, waited six full months for osteoporosis to set in, and then randomized them across eight groups to receive genistein aglycone, alendronate (Fosamax), raloxifene (Evista), or ethinyl-estradiol, each at two dose levels, for 12 weeks (Bitto et al., Br J Pharmacol 2008).

The results were remarkable. Genistein at 10 mg/kg produced a greater increase in both bone mineral density (BMD) and bone mineral content than every one of the three drugs. Beyond density — the crude measure of how much bone is present — genistein also outperformed the drugs on the measures that actually matter for fracture prevention: it significantly increased breaking strength and bone quality, raised the bone-formation marker bone-alkaline phosphatase (b-ALP) and the protective protein osteoprotegerin (OPG), and reduced the resorption marker collagen C-telopeptide (CTX) and the bone-degrading signal sRANKL, all “compared with the other treatments at all dose levels” (Bitto et al., Br J Pharmacol 2008).

The authors’ conclusion was unambiguous: “The results strongly suggest that the genistein aglycone might be a new therapy for the management of postmenopausal osteoporosis in humans” (PubMed 18695641).

What makes this groundbreaking is the nature of the comparison. Genistein is a food derivative — a phytoestrogen found in fermented soy, red clover, kudzu, fava beans, and even coffee. The three drug classes it bested are evolutionarily novel chemicals (xenobiotics) carrying well-documented adverse effects. A nutrient your ancestors ate beat the patented molecules at their own game.

This Is No Longer Just a Rat Study — The Human Evidence Has Arrived

The most common — and fair — criticism of the original article was that its centerpiece was an animal study. That objection no longer holds. In the years since, genistein has been tested in humans in long-term, randomized, double-blind, placebo-controlled trials, the gold standard of clinical evidence.

The 24-month Marini trial. Researchers at three Italian university medical centers randomized 389 osteopenic postmenopausal women to either 54 mg/day of genistein aglycone or placebo (both arms received calcium and vitamin D) for two years. At 24 months, BMD had increased in the genistein group and decreased in the placebo group at both the lumbar spine and femoral neck. Genistein also lowered urinary markers of bone breakdown, raised bone-formation markers, and — critically — did not thicken the endometrium (Marini et al., Ann Intern Med 2007).

A three-year safety and efficacy follow-up. When the cohort was followed to 36 months, the BMD gains at the femoral neck and lumbar spine were even larger than at two years. Just as importantly for a compound with estrogen-like activity, genistein “did not significantly change mammographic breast density or endometrial thickness,” preserved BRCA1 and BRCA2 expression, and actually reduced sister chromatid exchange (a marker of genetic damage) versus placebo. The authors described “a promising safety profile with positive effects on bone formation” (Marini et al., J Clin Endocrinol Metab 2008).

Head-to-head against hormone replacement therapy. An earlier randomized, double-blind trial pitted genistein (54 mg/day) directly against conventional HRT (17β-estradiol plus norethisterone) in early postmenopausal women. Both genistein and HRT significantly increased BMD in the femur and lumbar spine versus placebo. But the two diverged on bone-formation markers: genistein raisedbone-specific alkaline phosphatase and osteocalcin (signs of new bone being built), whereas HRT lowered them (Morabito et al., J Bone Miner Res 2002). Genistein matched HRT’s density benefit while behaving more like a true bone-builder.

A post-hoc analysis in frank osteoporosis. Reanalyzing the Marini cohort, investigators isolated the 121 women who were genuinely osteoporotic (not just osteopenic) at baseline. In the genistein group, femoral-neck BMD climbed from 0.62 to 0.70 g/cm² over two years; in placebo it fell from 0.61 to 0.57. By the end, the prevalence of osteoporosis in the genistein group had dropped to 12%, while it was unchanged in placebo (Lasco/Marini et al., Nutrients 2017).

The meta-analytic verdict. A 2024 systematic review and meta-analysis of randomized controlled trials, published in Osteoporosis International, found that isoflavone interventions significantly improved BMD at the lumbar spine, femoral neck, and distal radius in postmenopausal women. Crucially, the benefit was strongest when the intervention lasted at least 12 months and contained at least 50 mg/day of genistein — almost exactly the dose used in the successful Italian trials (Zhang et al., Osteoporos Int 2024).

Genistein’s reach extends beyond the skeleton. In the same 389-woman cohort, two years of genistein improved glycemic control and several cardiovascular risk markers, lowering fibrinogen and showing “favorable effects” the authors believed “might play a preventive role in the development of coronary artery disease” (Squadrito et al., J Clin Endocrinol Metab 2007). Compare that to the cardiovascular harms documented for the drugs below.

Why It Works: Selective Estrogen Receptor Modulation, by a Food

Genistein structurally resembles 17β-estradiol, but it is no blunt hormonal hammer. It functions as a selective estrogen receptor modulator (SERM) — the same principle that the drug raloxifene was engineered to mimic, except genistein arrives pre-packaged in food.

The key is receptor selectivity. Genistein binds preferentially to estrogen receptor beta (ERβ), which is strongly expressed in bone — particularly trabecular bone — rather than to ERα, which dominates in breast and uterine tissue (Akhtar et al., J Clin Aesthet Dermatol review 2024). This lets genistein stimulate bone-building estrogen signaling while leaving — or even down-regulating — the proliferative estrogen signaling in breast tissue. Although its estrogenic activity is far weaker than estradiol’s, genistein binds the receptor for a longer duration, allowing meaningful benefit when the body’s own estrogen has fallen short. Paradoxically, this enables a plant estrogen to blunt the proliferative activity of excess estradiol and xenoestrogen exposures — the same protective logic seen with the lignans in flaxseed.

Mechanistically, genistein works on both sides of the bone-remodeling equation. It promotes osteoblast (bone-building) activity and inhibits osteoclast (bone-degrading) activity, shifting the critical RANKL/OPG ratio toward bone preservation — exactly what the Bitto study measured, and what the human follow-up confirmed when genistein lowered sRANKL and raised OPG in women (Marini et al., J Clin Endocrinol Metab 2008). Animal work has also tied genistein’s effect to restoration of parathyroid-hormone signaling (PTH/PTHR1), suggesting a mechanism that reaches beyond simple estrogen mimicry (Miao et al., Int J Mol Sci 2011).

A note on sourcing: non-fermented soy contains genistin, the inactive glycoside. Friendly gut bacteria — or the fermentation in cultured foods such as miso, tempeh, and natto — biotransform it into the active genistein. This is precisely why traditional Asian diets have long treated fermented soy as both food and medicine.

For Those Wary of Soy: The Chickpea Alternative

None of this requires anyone to embrace soy. Soy carries genuine, defensible concerns — it is one of the U.S. “Top 9” allergens, and it delivers one of the highest dietary isoflavone loads of any common food, on the order of 100–200 mg per 100 g in soy flour per the USDA Isoflavone Database. For a person eating fermented soy occasionally, that load is a feature. But for someone taking a daily product over years, a high, fixed phytoestrogen dose is a design choice with real consequences worth weighing.

This is precisely the reasoning behind why we built our CardioNK fermented natto on chickpeas rather than soy, as I detailed in Why We Built Our Fermented Natto on Chickpeas and Not Soy. The substrate is not a side note — it is the architecture of the product. Chickpea fermentation produces highernattokinase activity than soy under matched conditions (~356 FU/g, roughly 22% above cracked soybean), supports robust vitamin K2 (MK-7) biosynthesis, and generates about 72% less of the sticky γ-PGA byproducttied to natto’s allergenicity and purification headaches — all while sitting outside soy’s allergen class entirely.

Crucially for the bone story told here, choosing chickpea does not mean abandoning the genistein pathway. Chickpea’s isoflavone profile is dominated by biochanin A and formononetin rather than free genistein — and biochanin A is the direct metabolic precursor the body demethylates into genistein. So chickpea delivers genistein’s benefits along a gentler, more gradual route, at a substantially lower total phytoestrogen load than soy. Biochanin A is no bystander, either: in the same ovariectomized-rat model used throughout this article, biochanin A prevented bone loss as effectively as 17β-estradiol — increasing osteoblast activity, suppressing osteoclasts, and lowering the RANKL/OPG ratio — but without the uterine stimulation estradiol caused (Su et al., Evid Based Complement Alternat Med 2013).

The takeaway is liberating rather than restrictive: the bone-protective phytoestrogen pathway is not soy-exclusive. Fermented chickpea offers a lower-allergen, lower-isoflavone-load way to feed the same biochanin-A-to-genistein machinery — which is why we made it the foundation of CardioNK.

Now Look at the Drugs

The true value of the comparison becomes clear when the drugs are examined honestly.

Alendronate (Fosamax) and the bisphosphonates

Alendronate is the franchise leader, and its mechanism is to poison osteoclasts so that old bone is no longer cleared. Over years, this can leave bone denser on a scan but more brittle in reality. The most alarming consequence is atypical femoral fracture — the thigh bone snapping under ordinary load. The risk rises with duration of use, climbing to roughly 100 per 100,000 patient-years after five to eight years of continuous therapy (Cureus 2025 review; Cleveland Clinic J Med 2018). A drug sold to prevent fractures can, with long use, cause a particularly devastating kind of fracture.

Bisphosphonates are also linked to osteonecrosis of the jaw — literally dying, exposed jawbone — a complication serious enough that the FDA-approved Fosamax label and Medication Guide warn of “severe jaw bone problems (osteonecrosis)” and “unusual thigh bone fractures” (FDA Fosamax Medication Guide; FDA Fosamax label). The risk of jaw osteonecrosis rises substantially after three years of oral use (Junquera et al., Med Oral Patol Oral Cir Bucal 2013). Add to this the drug’s notorious capacity to ulcerate the esophagus and stomach — the reason patients are instructed to swallow it with water and remain upright for half an hour — and the risk-benefit math looks very different than the marketing suggests.

Raloxifene (Evista)

Raloxifene is a synthetic SERM — a laboratory attempt to do what genistein does naturally. Its track record includes serious vascular harms. In the large RUTH trial of over 10,000 women, raloxifene significantly increased both venous thromboembolism (blood clots) and fatal strokecompared with placebo (American College of Cardiology, RUTH summary). A pooled analysis of the MORE and RUTH trials confirmed a higher incidence of fatal strokes and venous thromboembolic events on raloxifene, with the excess fatal-stroke risk emerging after three years (Barrett-Connor et al., Stroke 2009). The drug’s own risk profile concentrates the danger in women already at elevated stroke risk (Framingham-based analysis, 2009).

Estradiol and conventional HRT

Pharmaceutical hormone replacement carries the most famous cautionary tale in modern medicine. The Women’s Health Initiative estrogen-plus-progestin trial was halted early when investigators found that long-term use raised the risk of breast cancer by 26%, stroke by 41%, and heart attacks by 29%, and doubled the rate of venous thromboembolism (CMAJ 2002; WHI long-term review, Semin Reprod Med 2014). Estradiol is produced naturally in the body, but at the supraphysiologic, unopposed, or poorly metabolized levels created by pharmaceutical HRT, it can become cardiotoxic and carcinogenic.

Learn more about the under-reported dangers of common osteoporosis drugs on the GreenMedInfo database.

In the Interest of Honesty: The Mixed Evidence

A strengthened thesis is one that confronts its weak points rather than hiding them. The genistein-and-bone literature is not unanimous, and readers deserve the full picture.

Not every soy-isoflavone trial succeeded. Of the long-duration human studies, the Italian genistein trials by Marini and colleagues showed dramatic bone benefits, but three other multi-year trials — the U.S. studies by Levis and Alekel and the Taiwanese study by Tai — found little skeletal benefit from soy isoflavones (reviewed in Lappe et al., Eur J Nutr 2013). A handful of animal studies likewise reported genistein performing worse than estradiol or raloxifene on certain bone-strength measures (Filipović et al., Acta Biochim Pol 2009).

Several factors explain the divergence — and most of them actually sharpen the case for genistein done right:

• Dose matters. The 2024 meta-analysis found benefit specifically when interventions delivered at least 50 mg/day of genistein (Osteoporos Int 2024). The successful Italian trials used 54 mg/day of purifiedgenistein aglycone; the null trials often used lower doses or mixed soy-isoflavone extracts.

• Form matters. Genistein follows a biphasic, dose-dependent curve in animal studies — low-to-moderate doses build bone while excessive doses can blunt the effect — and the active aglycone differs from the inactive glycoside found in unfermented soy (Yang et al., Acta Pharmacol Sin 2011).

• Duration matters. Benefit consistently required 12 months or more of supplementation (Osteoporos Int 2024).

In short, the failures tend to cluster around the wrong dose, the wrong form, or too little time — not around a fundamental failure of the molecule. When genistein aglycone is given at an effective dose for long enough, the human BMD signal is consistent and statistically robust.

The Osteoporosis Myth: When Denser Bones Aren’t Better Bones

There is another layer to this story that is rarely discussed: the assumption that increasing bone mineral density (BMD) necessarily translates into healthier, more fracture-resistant bones.

This assumption underlies much of modern osteoporosis treatment, yet it is increasingly difficult to defend scientifically.

Bone is not concrete. It is living tissue. Its strength depends not only on mineral content, but also on architecture, elasticity, collagen integrity, microvascular supply, and continuous remodeling. A bone can become denser while simultaneously becoming more brittle.

This distinction helps explain one of the most troubling paradoxes in osteoporosis medicine: drugs such as bisphosphonates can increase BMD on a DEXA scan while also increasing the risk of atypical femoral fractures after long-term use. By suppressing osteoclast activity, these drugs reduce the natural turnover process through which old, damaged bone is removed and replaced. The result can be a skeleton that appears stronger on paper while becoming less resilient in reality.

In other words, a denser bone is not necessarily a better bone.

I explored this issue extensively in a previous investigation, The Osteoporosis Myth: The Dangers of High Bone Mineral Density, where I reviewed evidence showing that excessively mineralized bone may lose flexibility and become more susceptible to fracture under certain conditions. This helps explain why some individuals with relatively modest BMD experience few fractures, while others with apparently normal or elevated BMD suffer catastrophic skeletal injuries.

Viewed through this lens, the findings on genistein become even more intriguing. Unlike therapies that primarily suppress bone turnover, genistein appears to support a healthier balance between bone formation and bone resorption, improving not merely density but multiple markers associated with bone quality and structural integrity. The distinction is critical. The ultimate goal is not to produce denser bones. It is to produce stronger, more resilient bones capable of adapting to the stresses of life.

The question we should be asking is not simply, “Does this increase bone density?” but rather, “Does this improve the quality of bone itself?”

The Bigger Picture

Two truths sit at the heart of this story.

First, foods and food extracts cannot be patented. A 54 mg/day dose of a soy nutrient that matches or beats blockbuster drugs threatens a lucrative franchise, which is precisely why genistein has never received the hundreds of millions of dollars in funding that a definitive, fracture-endpoint, head-to-head human trial would require. The researchers behind the most encouraging studies say so plainly, calling for “a large, well designed, and appropriately focused randomized clinical trial” (Nutrients 2017) — a trial that the economics of drug development make unlikely to ever materialize.

Second, age-related bone loss has been aggressively over-medicalized. The reflexive prescription of bisphosphonates for “osteopenia” — a statistical category, not a disease — exposes millions of women to atypical fractures and jaw necrosis in pursuit of a denser scan that does not always mean a stronger bone.

The evidence assembled here does not claim genistein is a miracle, but given its extensively researched profile, it should be considered more seriously for nutritional support. [view the over 250 conditions researchers have been exploring].

This article makes a narrower, sturdier claim: a humble, ancient, fermentable food extract has, in rigorous laboratory and human studies, demonstrated bone benefits that rival the pharmaceutical standard of care — without the strokes, the clots, the cancers, the jaw necrosis, or the brittle thigh bones. That a nutrient eaten for thousands of years can do this should not be surprising. It should be the starting point.

For hundreds of studies on natural approaches to osteoporosis, view the GreenMedInfo.com database on the subject.

Concerned about Soy? Fermented Chickpea is the Alternative

While much of the research on bone-supportive phytoestrogens focuses on soy-derived genistein, soy isn’t the only path. For those seeking a lower-allergen, regenerative-food alternative, fermented chickpea natto offers a compelling solution.

In the article below, I explore why we chose organically grown chickpeas from a regenerative farm using traditional cultivation methods as the foundation for our natto. Beyond providing vitamin K2 and high-potency nattokinase, fermented chickpeas contain biochanin A—a natural precursor to genistein—offering many of the same benefits through a gentler nutritional pathway.

Discover the remarkable nutritional, agricultural, and scientific rationale behind this next-generation fermented food:

Share the X thread dedicated to this post below:

Share

Leave a comment

Subscribe now

Key References

• Bitto A, et al. “Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.” Br J Pharmacol. 2008;155(6):896-905. PubMed 18695641

• Marini H, et al. “Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial.” Ann Intern Med. 2007;146(12):839-47. PubMed 17577003

• Marini H, et al. “Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study.” J Clin Endocrinol Metab.2008;93(12):4787-96. OUP / PubMed 18796517

• Morabito N, et al. “Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women.” J Bone Miner Res.2002;17(10):1904-12. PubMed 12369794

• Lasco A, Marini H, et al. “Antiosteoporotic activity of genistein aglycone in postmenopausal women: a post-hoc analysis.” Nutrients. 2017;9(2):179. PubMed 28241420

• Systematic review/meta-analysis. “Isoflavone intervention and its impact on bone mineral density in postmenopausal women.” Osteoporos Int.2024;35(3):413-430. PubMed 37875614

• Squadrito F, et al. “Effects of genistein on predictors of cardiovascular risk in osteopenic postmenopausal women.” J Clin Endocrinol Metab. 2007;92(8):3068. OUP

• Atypical femoral fracture risk: Cureus 2025; Cleveland Clinic J Med 2018

• FDA Fosamax (alendronate) label & Medication Guide: Label; Medication Guide

• Raloxifene RUTH/MORE: ACC RUTH summary; Stroke 2009

• Women’s Health Initiative: CMAJ 2002; Semin Reprod Med 2014

• Mechanism / SERM / ERβ review: J Clin Aesthet Dermatol 2024; Int J Mol Sci 2011

• Mixed/contradictory evidence: Eur J Nutr 2013; Acta Biochim Pol 2009; Acta Pharmacol Sin 2011

• Biochanin A and bone: Su SJ, et al. “The preventive effect of biochanin A on bone loss in ovariectomized rats.” Evid Based Complement Alternat Med. 2013. PubMed 23533501

• CardioNK substrate rationale: Ji S. “Why We Built Our Fermented Natto on Chickpeas and Not Soy.” Substack, 2026

For fifteen years, Bill Gates bought the most expensive silence in the history of philanthropy. In 2026, a subpoena did what $319 million couldn’t stop.

There is a custom-sized mannequin somewhere in the Gates communications apparatus. Its job was to wear Bill Gates’s clothes before he did — to let a styling team test which neutral crew-neck sweater, which pair of off-brand “Carbon” glasses from a boutique optician, would best project the image of a harmless, brilliant, world-saving nerd. Three outfits, presented to senior staff for approval, for each public appearance. The goal, according to current and former employees who spoke to The Wall Street Journal, was to make a man worth a hundred billion dollars look “reminiscent of Mister Rogers.”

That detail is genuinely revealing, and it is everywhere this week. But it is not the story.

The story is that the mannequin worked — for fifteen years. The story is how it worked, what it cost, and the precise moment this spring when it stopped working. Because the wardrobe was the smallest, cheapest part of a reputation-management operation that ran into the hundreds of millions of dollars and reached into the budgets of the very newsrooms we rely on to hold the powerful accountable. And what finally cracked it was not better journalism. It was a congressional subpoena — the one instrument Bill Gates could not write a check to redirect.

The machine

Start with the number, because the number is the story: at least $319 million.

That is the documented sum the Bill & Melinda Gates Foundation has channeled into news outlets, journalism-training programs, investigative centers, and press associations — a figure assembled by journalist Alan MacLeod, who reviewed more than 30,000 individual Gates Foundation grants for MintPress News. It is not a fringe finding. The Columbia Journalism Review reached the same conclusion a decade earlier, and Gates’s own hometown paper, the Seattle Times, reported back in 2011 that the foundation had devoted roughly $1 billion to “policy and advocacy” — about a tenth of its annual spending — much of which the paper described bluntly as “essentially public relations.”

Look at who took the money. NPR: $24.6 million. The Guardian: $12.9 million. The BBC: $3.6 million directly, plus nearly $53 million to its charitable arm, BBC Media Action. NBC, CNN, Le Monde, Der Spiegel, El País, Al Jazeera, The Atlantic. The investigative outfits we hold up as watchdogs — ProPublica, the Pulitzer Center, the Bureau of Investigative Journalism — each took Gates money too. So did The Lancet, the medical journal whose findings become tomorrow’s health headlines: at least $13.6 million for content.

Here is what that architecture purchased. Not flattery — absence. As CJR documented, Gates funding “appears to have altered the Guardian’s coverage” and “closed off large expanses of storyline,” specifically the storyline that mattered most: critical scrutiny of the Gates Foundation itself. When a single donor underwrites the global-health desk, the development desk, the journalist-training pipeline, and the press association your editor belongs to, you do not need to be told what not to write. The incentive structure tells you. MacLeod put it precisely: the institutions “we rely on to hold accountable one of the richest and most powerful men in the planet’s history are quietly being funded by him.”

For fifteen years, that was the deal. And it is why, in a 2019 YouGov poll, Bill Gates was ranked the single most admired man on Earth — ahead of the Dalai Lama, ahead of the Pope.

The crack

A reputation built on purchased silence has one fatal vulnerability: it depends on the story originating inside a newsroom. Control the newsrooms, control the story.

But you cannot buy a subpoena.

In late 2025, the House Oversight Committee subpoenaed Jeffrey Epstein’s estate. In January 2026, the Justice Department — acting under the Epstein Files Transparency Act — released roughly 3.5 million pages of documents, emails, flight logs, and images. None of it ran through a Gates-funded editor. None of it could be softened by a grant relationship. For the first time in fifteen years, the most consequential story about Bill Gates was being written by a branch of government that he does not fund.

The effect was immediate and visible — and the most telling evidence comes from the outlets he paid. Consider NPR, recipient of $24.6 million in Gates money. In February, on NPR's Wild Card with Rachel Martin, the host sat across from Melinda French Gates and said, on the air: "I have to acknowledge the elephant in the room at this moment. Your ex-husband, Bill, is named in the newest tranche of Epstein files. And there are new alleged details about his past behavior." The funded outlet, naming him, to his former wife's face.

It did not stop there. The Wall Street Journal ran the image-machine exposé that launched this week’s cycle. And Fortune documented something far harder than any wardrobe anecdote: that Jeffrey Epstein personally emailed the wiring instructions for a $5 million Gates Foundation grant to the International Peace Institute, a U.N.-affiliated think tank, in 2013 — part of more than $8.5 million the foundation sent that institution between 2013 and 2020, with Epstein acting as a conduit.

June 10

Which brings us to the date that matters.

On June 10, 2026, Bill Gates is scheduled to sit for a transcribed interview before the House Oversight Committee. He is slotted into a bipartisan investigation between Epstein’s former assistant Lesley Groff and the private-equity billionaire Leon Black. Chairman James Comer has confirmed the schedule publicly; the transcripts will be released; and as Comer has repeatedly noted, lying to Congress is a felony. (I’m tracking each development in The Epstein Files Investigation.)

This is a venue with no firewall. There is no editorial-independence clause to invoke, no grant to renew, no spokesperson to stand between Gates and the question. The same machine that for fifteen years guaranteed “only good press for Bill” has no jurisdiction in a congressional interview room.

Gates’s team has a defense ready, and it is worth naming so it can be dismissed. They will argue that any reduction in the foundation’s media and advocacy spending reflects the planned 2045 sunset — the spend-down of the endowment, not a loss of grip on the narrative. But the break was never about dollars. The break is qualitative, and it is undeniable: the outlets he funded are now running the story he paid them to avoid, and his own foundation has commissioned an external review of his “engagement with Epstein.” Institutions do not audit their own founder when image control is working.

What changed

For fifteen years, the most admired man on Earth was a manufactured product — engineered down to the sweater, propped up in part by a $319 million web of media funding that left the press structurally disinclined to scrutinize him. The product held because the story stayed inside the system the money controlled.

In 2026, the story escaped. It moved from the newsroom to the subpoena, from the editor’s desk to the committee transcript, from a venue Bill Gates funds to one he must simply answer. The mannequin can still pick the outfit. It cannot pick the questions.

On June 10, for the first time, Bill Gates will face a room he didn’t buy.

This piece relies on documented public records and primary reporting. Where the underlying evidence is disputed — such as draft emails of contested authorship in the Epstein files — those claims have been deliberately excluded. The argument here rests only on what is verifiable: the grant record, the on-the-record congressional schedule, and the published reporting of the very outlets that received Gates funding.

Share the X thread dedicated to this post here.

The Story at a Glance

• The claim in one breath. Modern medicine explains illness with two stories — genes and germs. A third, the exposome (the lifetime load of chemicals a body absorbs, including the ones we’re prescribed and injected), is real, large, and badly undercounted. While it may not itself replace germ theory, it at least deserves to sit alongside it.

• The mechanism. Cells injured by a toxicant don’t suffer in silence — they package distress signals into tiny vesicles called exosomes and ship them through the bloodstream. Those signals can injure cells the chemical never touched. So a local poisoning can travel, and can look, to an epidemiologist, unsettlingly like contagion. This is mainstream cell biology, shown for arsenic, cadmium, lead, air pollution, and microplastics.

• The history. Toxic outbreaks have repeatedly been misread as infections — sometimes for decades (Minamata, Itai-Itai, Toxic Oil Syndrome, the 1989 tryptophan epidemic, EVALI). The WHO and CDC now have formal protocols for telling the two apart, because the mistake is that common.

• The case that matters this week. Reaching for acetaminophen at the first sign of a child’s fever rests on two assumptions — that the fever is the problem, and that the drug is free of cost. Both are shakier than they look. Fever is a coordinated defense, and the evidence that suppressing it is harmless is not established. Acetaminophen works partly by consuming glutathione, the body’s master antioxidant — exactly the reserve the immune response depends on. None of this requires any contested theory; it’s pharmacology and pediatrics. The conservative conclusion: “treat the number on the thermometer” is a habit, not settled science.

• Where it gets contested. The same lens, applied to the polio epidemic, suggests a multi-causal picture — a viral particle plus a heavy chemical load (arsenicals, DDT, medical injections) — rather than a singular pathogen. This is a serious but genuinely disputed reinterpretation, flagged as such, and nothing else in the argument depends on it.

• What this is not. This article is not focused on the claim that viruses are fake, or that all disease is toxicant-originated. It’s a claim that we built our diagnostic instruments to find pathogens, and then mistook the limits of the instrument for the limits of causation.

When we ask why people get sick, the modern answer comes in two registers: genes and germs. A disease is inherited, or it is caught. This framing organizes our research funding, our diagnostic algorithms, our public-health reflexes, and our intuitions. It is also incomplete in a way that has become harder to defend with each passing year of toxicology research.

The missing register is the exposome — the lifetime sum of chemical and biological exposures a body must process. The word usually conjures the environmental exposome: heavy metals, pesticides, combustion particulates, plasticizers, industrial solvents. But it includes, just as fully, what we are given — the substances we inject, administer, and prescribe. A compound’s having a medical purpose does not exempt it from being an exposure the body has to metabolize, sequester, or be injured by; pharmacology is a subset of toxicology, separated only by intent and dose. Tens of thousands of synthetic chemicals are now in commerce, environmental and pharmaceutical alike; most have never been tested for their effects in combination, and many are invisible at the doses that matter. The argument of this article is narrow and, I think, defensible: toxic exposures — encountered or introduced — can produce systemic disease that looks infectious; there is now a well-characterized molecular mechanism explaining how a localized chemical injury propagates to distant organs in a way that superficially resembles contagious spread; and our diagnostic systems were largely not built to detect any of this.

This is not a claim that opportunistic or truly pathogenic germs can’t cause disease, that viruses are purely fictional, or that infection is an illusion. It is the opposite of a grand replacement theory. It is a claim that the exposome is a genuine, underweighted axis of causation that runs alongside the pathogen — sometimes amplifying it, sometimes mimicking it, and often hiding inside disease categories we have labeled infectious out of diagnostic habit. The most productive reframing is not “poisoned or infected.” It is the recognition that the toxic burden of the exposome shapes, amplifies, and sometimes produces from scratch the disease patterns we reflexively attribute to pathogens.

One distinction will keep this honest throughout. There is a general claim — that the exposome is a major, undercounted axis of disease causation — and there are specific claims that particular illnesses now attributed to pathogens are substantially toxic in origin. These are not the same proposition, and they do not stand or fall together. The general claim is close to unassailable on current evidence, as you will see documented through peer-reviewed findings below. The specific reattributions vary enormously in strength: the acetaminophen case below rests on mainstream pharmacology; the polio case is a serious but genuinely contested reinterpretation. A reader can accept the general thesis, and the strongest specific cases, while rejecting the weaker ones — and should. This article is ordered, deliberately, from its most defensible ground to its most contested, so that nothing essential depends on the parts most easily disputed.

Subscribe now

I. The mechanism: how a local chemical injury travels

The intuitive objection to any “toxic disease that spreads” claim is mechanical: a poison injures the cells it touches, and that should be the end of it. A chemical exposure to the liver should produce liver disease, not a whole-body syndrome, and certainly not damage in organs the chemical never reached. For most of the twentieth century, that intuition was sound enough to be load-bearing.

It is now wrong, and the thing that overturned it is one of the more important developments in cell biology of the last two decades: the discovery that cells under chemical stress actively package the molecular signatures of their injury into extracellular vesicles (EVs) — nano-scale, membrane-bound particles, the best-known subclass being exosomes— and ship them through the bloodstream to distant cells that were never exposed to the original toxicant.[^1][^2] When those vesicles are taken up by recipient cells, they can transfer the injury program itself: oxidative stress, inflammatory signaling, misfolded proteins, even the toxic metal atoms in physical cargo.

This is not a fringe mechanism. It is mainstream toxicology, and the evidence has converged from multiple independent laboratories using in-vitro models, animal studies, and human biomarker data.

The cleanest single demonstration comes from cadmium. Cadmium accumulates far more heavily in the liver than the kidney, yet it causes greater oxidative damage to the kidney — a longstanding paradox. A 2025 study resolved it: cadmium-stressed liver cells release exosomes enriched in a microRNA, miR-2137, that travels to the kidney and silences GPX4, an enzyme that suppresses ferroptotic cell death. The result is ferroptosis — a form of cell death — in an organ that was never directly exposed to the metal.[^3] Injury to a distant, unexposed organ, carried by a vesicular messenger. That is the entire thesis of this section in a single experiment.

The cadmium case does not stand alone:

• Lead. A 2024 study preloaded neuroblastoma cells with lead, isolated their small EVs, and applied those vesicles to lead-naïve recipient cells — producing a dose-dependent rise in intracellular lead in cells that had touched no metal, only the vesicles. The EVs were physically carrying the lead.[^4][^5]

• Arsenic. A 2023 study in Toxicological Sciences supplied unusually complete proof of the principle. Bioengineered muscle exposed to a low, human-relevant dose of arsenic released EVs; when those EVs were applied to entirely arsenic-naïve muscle constructs, the naïve tissue showed markedly impaired regeneration — roughly half the recovery of contractile force — despite never contacting the metal. The result held in living mice: EVs taken from arsenic-exposed mice and injected into never-exposed mice reproduced the same impairment, with mass spectrometry identifying hundreds of differentially loaded proteins in the arsenic-EV cargo.[^6][^7] The injured tissue here is skeletal muscle rather than motor neurons, so this is proof of the mechanism — reprogrammed EVs transmitting functional injury to unexposed cells and tissue, in vivo — not a polio-specific result. But it closes the loop the principle requires.

• Manganese. Manganese-exposed dopaminergic neurons release exosomes loaded with misfolded α-synuclein — the protein that aggregates in Parkinson’s disease — and those exosomes reproduce neuroinflammatory, Parkinson’s-like pathology in naïve neurons and in mice. Critically, the same exosomal markers have been detected in the blood of human welders occupationally exposed to manganese fumes, validating the animal models in living people.[^8]

• Fine particulate air pollution (PM2.5). PM2.5 particles are physically carried inside macrophage-derived exosomes to unexposed recipient macrophages, where they trigger a full inflammatory cascade — NF-κB activation, TNF-α, IL-6, IL-1β. Injected into mice, the particle-loaded exosomes alone produced lung inflammation comparable to direct inhalation. The authors named the phenomenon a “secretion–particle transfer–adverse outcome chain.”[^9][^10]

• Micro- and nanoplastics. The newest entry, and among the most striking. A 2024 study showed that polystyrene microplastics drive tubular kidney cells to release EVs that, applied to naïve renal fibroblasts, induced oxidative stress and fibrosis-related proteins — with the fibrotic phenotype confirmed in mice drinking water at human-relevant concentrations.[^11] A parallel finding is almost on the nose for this article’s thesis: nanoplastics internalized by brain astrocytes are exported again inside EVs, dispersing the plastic particles to neighboring cells — the vesicle acting, exactly as with lead, as a physical delivery vehicle for the toxicant itself.[^12]

If a skeptic wants the purest possible proof of concept — damage propagated to cells that received zero of the original insult — it comes from radiation biology, not chemistry. The radiation bystander effect is among the most replicated findings in the field: exosomes from irradiated cells transmit genomic instability, including DNA double-strand breaks, to cells that received no radiation, and the effect persists across more than twenty cell generations, with bystander cells in turn releasing damage-carrying vesicles to a third generation.[^13] The mechanism proposed for chemical toxicants is structurally identical to one that is already textbook for radiation.

The upshot: “spread” — injury appearing in new cells, in new organs, over time, propagating forward — is no longer a signature unique to replicating pathogens. The body’s own intercellular messaging system can carry a chemical injury in a pattern that, to an epidemiologist armed only with a case count and a clock, can look indistinguishable from contagion.

II. Toxic outbreaks misread as infection

If localized chemical injury can propagate, then a shared chemical exposure across a community should be able to produce something that looks, statistically, like an infectious outbreak: clusters of cases, family aggregation, a recognizable symptom profile, a temporal wave. The historical record confirms that this happens, that it has fooled investigators for periods ranging from weeks to decades, and that the major public-health institutions formally acknowledge the problem.

The acknowledgment is explicit. In 2021 the World Health Organization published a Manual for Investigating Suspected Outbreaks of Illnesses of Possible Chemical Etiology, which states plainly that a chemical release may not be obvious and that distinguishing a non-infectious toxic cluster from an infectious outbreak requires deliberate epidemiological, toxicological, and environmental methods that standard infectious-disease investigation will not supply.[^14][^15] The CDC’s Field Epidemiology Manual similarly instructs investigators that an unusual increase in acute symptoms across a population may originate in a chemical exposure — through air, water, soil, food, or consumer products — rather than a pathogen, and provides a differential framework for telling them apart.[^16]

The documented cases span a century and four continents:

• Minamata disease (Japan, 1956–1968). Methylmercury discharged into Minamata Bay produced ataxia, sensory loss, visual-field constriction, tremor, and death. The early framing was an endemic neurological disease of unknown cause, with infection among the hypotheses. It took twelve years for the government to officially attribute it to industrial mercury, by which point over two thousand were recognized as patients.[^17][^18]

• Itai-itai disease (Japan). Chronic cadmium poisoning from mine tailings caused severe bone pain and fractures. The first public explanation offered, in 1955, was that the disease was caused by a microorganism. Confirmation of the cadmium cause came only after decades of contested research.[^19]

• Toxic Oil Syndrome (Spain, 1981). More than twenty thousand people were affected and over three hundred died within months from rapeseed oil illegally denatured with aniline and sold as cooking oil. Because it presented as an acute lung illness and spread through communities with family clustering, it was initially investigated as a possible infectious respiratory disease.[^20]

• Eosinophilia-Myalgia Syndrome (USA, 1989). Over 1,500 people developed severe myalgia, eosinophilia, and neuropathy, with 37 deaths, in a pattern of rapid geographic spread. This one is the model investigation: epidemiologists ruled out a pathogen and traced the outbreak within weeks to a contaminated batch of L-tryptophan supplement from a single manufacturer.[^21][^22]

• EVALI (USA, 2019). The vaping-associated lung-injury outbreak presented as bilateral infiltrates, fever, and hypoxia — initially indistinguishable from an atypical or novel viral pneumonia. Systematic CDC investigation ruled out infection and identified vitamin E acetate, a diluent in illicit THC cartridges, as the cause.[^23]

EVALI and EMS are worth dwelling on, because they cut against any conspiratorial reading. They are cases of the system working: the infectious hypothesis was tested, found insufficient, and corrected through disciplined epidemiology. The point of this section is not that institutions are blind. It is that the toxic-versus-infectious differential is real, recurring, and difficult — difficult enough that the correct answer has sometimes taken fifty years to surface, and that an entire medical specialty, occupational and environmental medicine, exists substantially to handle it. The recurring finding from that specialty is that the most common direction of diagnostic error is toxic disease being misclassified as infectious, psychiatric, or idiopathic — not the reverse.[^24]

III. The case that matters this week: fever, acetaminophen, and the depletion of the body’s own defense

The previous sections describe a mechanism and a pattern. This one describes a decision that is being made, right now, in millions of homes — and it is the place where the exposome lens has the most immediate, actionable weight, precisely because it requires none of the contested historical claims that follow it. Everything in this section rests on mainstream pharmacology and mainstream pediatric literature. I am going to be equally careful about what it does not establish, because the stakes here are a child’s body and the wrong overcorrection is as dangerous as the status quo.

Start with the reflex. A child spikes a fever; a parent reaches for acetaminophen (paracetamol; Tylenol). This is among the most universal acts in modern medicine — acetaminophen is the most commonly used medication in children under twelve, with one survey finding weekly use in roughly a quarter of children under two.[^25] The reflex rests on two assumptions that feel like common sense: that the fever is part of the problem, and that the drug is essentially free of cost at normal doses. Both assumptions are shakier than the reflex suggests.

What fever actually is. Fever is not a malfunction; it is a coordinated, metabolically expensive immune response, conserved across vertebrates, that raises body temperature to impair pathogen replication and accelerate immune function. The relevant question is therefore not “how do we suppress it” but “what happens when we do.” The honest answer is that the evidence is mixed and genuinely unsettled — which is itself the point, because the reflex assumes the answer is settled in favor of suppression, and it is not. A systematic review and meta-analysis found that antipyretic treatment increased influenza mortality in animal models, with a pooled odds ratio of 1.34 — a signal worth taking seriously, though it is important to be clear that no equivalent human mortality trial has been done.[^26] A large prospective study of critically ill patients found that acetaminophen and NSAIDs were independently associated with increased mortality specifically in septic patients.[^27] Cutting the other way, a randomized controlled trial in adults with influenza found that regular paracetamol had no significant effect on viral load or clinical outcomes.[^28] The state of the evidence is not “fever suppression is proven harmful.” It is “the assumption that fever suppression is harmless is not established, and several lines of evidence suggest it may not be — while the definitive human trials have not been done.” For a near-universal intervention in children, that gap is itself the finding.

The hidden cost: glutathione. The deeper point is mechanistic, and it is not in dispute. Acetaminophen is cleared partly through a minor pathway that produces a reactive, toxic metabolite called NAPQI, which the body neutralizes by conjugating it with glutathione — the cell’s master antioxidant and a central node of its detoxification capacity.[^29] At overdose this consumes glutathione catastrophically, which is the textbook mechanism of acetaminophen liver failure. But the relevant fact for ordinary use is subtler: the depletion is not only an overdose phenomenon. Modeling and measurement indicate that chronic therapeutic dosing meaningfully lowers liver glutathione, with recovery taking days, and acetaminophen demonstrably depletes glutathione in the lung as well as the liver.[^30][^31] In other words, a drug given precisely when a child’s body is mounting an oxidatively demanding immune response also draws down the antioxidant reserve that response depends on. The two effects compound: suppress the fever, and deplete the defense, at the same moment.

Where this stops being speculative — and where it stops, period. This is the discipline the argument requires. The strong, defensible claims are: the glutathione-depletion mechanism is real; it operates to a degree at therapeutic and especially repeated doses; and it is plausibly more consequential in the settings where children most often receive the drug — during febrile illness, when appetite and therefore glutathione substrate are low, and in the subset of children with genetic variants (GST-null genotypes) that reduce their antioxidant capacity.[^32] The large international ISAAC study found a strong, dose-dependent association between childhood acetaminophen use and later asthma, and the proposed mechanism is exactly this glutathione/oxidative-stress pathway.[^33] That association is real and replicated.

And here is the boundary, stated plainly. The asthma association is observational, and the standard objection is confounding — respiratory infections both prompt acetaminophen use and independently relate to asthma, so the drug could be a marker of illness rather than its cause. But confounding-adjustment is not a neutral act, and this is where the conventional reading and the toxicological one genuinely collide. Adjusting for a true confounder removes a spurious signal; adjusting for a variable that lies on the causal pathway — a mediator — removes a real one. The distinction is not always knowable in advance, and the choice can decide a study's result. The clearest live example is acetaminophen and neurodevelopment: a large 2024 Swedish cohort reported no association after extensive adjustment and sibling comparison, a result widely read as reassurance — yet critics noted the analysis recorded acetaminophen use in only ~7.5% of mothers against population exposure of 40–65%, a misclassification that biases toward the null, and that several of the adjusted covariates (inflammation, oxidative stress) are precisely the conditions a toxic mechanism would act through, making them mediators rather than confounders. An earlier study measuring acetaminophen directly in umbilical-cord blood found a dose-dependent association with later diagnoses. The point here is not to declare the question settled in either direction — it is not — but to show that "the association disappears after adjustment" can mean a confound was removed or can mean a mechanism was adjusted out of view, and that distinguishing the two is exactly the kind of analysis our pathogen-shaped, single-cause habits perform badly.

Why this is the useful core of the whole argument. Notice what this section did not need. It did not need the claim that viruses are misidentified vesicles, or that polio was chemical, or any reinterpretation of infectious-disease history. It needed only mainstream pharmacology (NAPQI and glutathione), mainstream pediatrics (the asthma literature, the fever-outcome studies), and the willingness to notice that a reflex we treat as obviously safe has an unexamined toxic dimension — an exposome dimension — hiding in plain sight. A parent does not have to accept a single contested paradigm claim to draw a reasonable, conservative conclusion: that fever is often doing useful work, that reaching reflexively for a glutathione-depleting drug at the first sign of it is not the costless act it appears to be, and that “treat the number on the thermometer” is a medical habit, not a settled science. That is the exposome thesis made concrete, defensible, and immediately useful — and it is where this article most earns its title.

IV. A contested case: polio as a multi-causal phenomenon

The acetaminophen section stands on mainstream ground. This one does not, and I want to mark the change in footing honestly, because it is exactly the kind of claim that — if it fails — a reader will use to discard everything before it. So treat what follows as a harder, more contested application of the same lens, offered not as proof but as the most serious version of an argument that has a long heterodox history and a real evidentiary core. If you find it unpersuasive, the preceding sections stand entirely without it.

The toxic-cofactor reading of polio is not new, and intellectual honesty requires saying so rather than presenting it as fresh discovery. It has a heterodox lineage running from the early 1950s to the present, and that lineage is part of why the thesis is treated as fringe — some versions of it overreach badly, into outright denial that poliovirus causes disease.[^35] The version defended here is deliberately narrower than its predecessors: it keeps the virus as a genuine and necessary cause, and is built from the primary clinical and toxicological record rather than from the incidence-correlation graphs that the older literature leaned on. Where that literature says “pesticides, not virus,” this section says “virus and exposome, disaggregated” — a materially different and more defensible claim.

No disease illustrates the cost of single-pathogen thinking more sharply than paralytic poliomyelitis. The claim is narrower and fully sourced to mainstream literature — that “polio,” as historically counted, was a composite of causes, of which the virus while considered necessary from the mainstream perspective is insufficient alone according to our thesis, and that a heavy concurrent exposome load shaped who among the infected was actually paralyzed. That load was both environmental and introduced: the arsenicals physicians prescribed, the DDT sprayed on children, the injections and surgeries administered during viral circulation, and — later — the live vaccine itself are all exposures the body had to process, and all belong in the causal account.

The category was never one pathogen. Before 1958, “polio” was a clinical diagnosis — flaccid paralysis, no virological confirmation required. When 1,060 suspected cases in a 1958 Michigan epidemic were finally subjected to virological testing, more than half yielded no poliovirus at all; Coxsackie and ECHO viruses accounted for more of the “non-paralytic poliomyelitis” and “aseptic meningitis” cases than poliovirus did, and many paralytic patients had no identifiable viral cause.[^34] Whatever was being counted as polio, it was not a clean single-pathogen tally.

The 1955 reclassification. In 1955 — the year the Salk vaccine launched — the diagnostic threshold tightened: paralysis now had to persist and be confirmed at 60 days, and other enteroviruses had to be laboratory-excluded. Dr. Bernard Greenberg, head of biostatistics at the UNC School of Public Health and chair of the American Public Health Association’s Committee on Evaluation and Standards, testified to Congress in 1962 that the change in diagnostic criteria alone predetermined a decline in counted paralytic cases in 1955–1957, vaccine or no vaccine.[^36] This does not erase a real vaccine effect; it means the post-1955 statistical drop conflates a genuine intervention with a definitional artifact, and the two have rarely been disaggregated in the popular narrative.

Chemicals produce paralysis identical to polio. This is the part most likely to surprise, and it is not a fringe claim. A 1984 review in Reviews of Infectious Diseases — published under the Infectious Diseases Society of America — states that chemical poisons including arsenic, triorthocresyl phosphate, and organophosphorus insecticides were responsible for paralysis affecting groups of people.[^37] The mechanism is selective destruction of anterior horn motor neurons, the same cell population poliovirus targets, producing a clinically and pathologically overlapping flaccid paralysis. Arsenic neuropathy mimicking Guillain-Barré has been documented from a 1987 case series through 2025.[^38][^39] As early as 1908, a Massachusetts State Board of Health report concluded that metallic poisons including arsenic produced spinal-cord lesions that did not differ from those of anterior poliomyelitis.[^40] Arsenic exposure was not rare in the epidemic era: arsenical pharmaceuticals were AMA-endorsed, lead-arsenate was sprayed on produce, and arsenic pigments were in wide use.

DDT: a real correlation that must be stated with its caution. DDT was sprayed on children and at public venues as a supposed anti-polio measure in the 1940s and early 1950s, despite a lack of evidence it helped — a history documented in a 2017 peer-reviewed paper in Environmental History.[^41] That DDT is a serious neurotoxin was not a fringe view at the time: a 1955 JAMA editorial classified it as acting primarily on the central nervous system, producing — in its own list — hyperexcitation, tremors, “spastic or flaccid paralysis,” and convulsions.[^42] And DDT plugs into the vesicular mechanism of Section I: a 2017 paper links DDT to extracellular-vesicle biogenesis directly, proposing that the organochlorine raises neurodegeneration risk by inducing the vesicular budding that propagates misfolded proteins between neurons.[^43] That paper is a mechanistic hypothesis built on the authors’ bud-formation work, not proof of a DDT-to-paralysis exosomal chain — but it removes any claim that DDT sits outside the EV story; it does not. Two cautions still belong in the same breath as the JAMA quote, and dropping either is how the claim tips into overreach. First, scope: DDT’s characteristic toxicity is hyperexcitatory — tremor and convulsion-dominant — and the editorial names the central nervous system broadly, not the anterior horn specifically; the clean, selective anterior-horn destruction that pathologically mimics polio belongs to arsenic and the organophosphates discussed above, not to DDT. Second, causation: the overlap between peak DDT use and peak polio incidence (and between its phase-out and the decline) is a real correlation, but the Salk vaccine was deployed in the same window, and timeline alone cannot separate them. The most defensible statement by mainstreame standards is that DDT plausibly amplified neurological vulnerability during the epidemic era — not that it produced polio-like flaccid paralysis by the poliovirus mechanism, and not that it was the primary driver of the epidemics. That said, Dissolving Illusions: Disease, Vaccines, and The Forgotten History by Suzanne Humphries MD (, Roman Bystrianyk should be read to deepen one’s understanding of the possibility that the exposome and the live polio vaccines themselves were and still are the primary driver of today’s polio outbreaks.

Provocation poliomyelitis: the injection as an exposome event. Independent of any chemical claim, it is established clinical history that routine medical interventions raised paralysis risk — the clearest case of an introduced exposure shaping a disease blamed wholly on a pathogen. Tonsillectomy during poliovirus circulation was linked to bulbar polio beginning in 1910 and confirmed repeatedly since.[^44][^45] The mechanism for injection-provoked paralysis was worked out in a 1998 Journal of Virology paper: skeletal-muscle injury opens a route for retrograde axonal transport of poliovirus directly into the spinal cord, facilitating central-nervous-system invasion — and the authors noted the effect still causes childhood paralysis where unnecessary injections are given during poliovirus circulation.[^46] The epidemiology matches the mechanism: a 1995 New England Journal of Medicine study of vaccine-associated polio in Romania found that children given intramuscular injections within 30 days before onset had an odds ratio of 31.2 for paralytic disease — a more than thirty-fold increase.[^47] An injection is not inert. During viral circulation it was, for some children, the precipitating exposure.

The virus is mostly commensal. The WHO states roughly 1 in 200 poliovirus infections leads to any paralysis; the ECDC notes about 70% are entirely asymptomatic.[^48][^49] The decisive variable is therefore the host and its conditions, not mere exposure. The starkest illustration is a natural experiment: the remote Brazilian Xavante had antibodies to all three poliovirus serotypes in nearly every tested individual — and zero cases of paralytic polio.[^41] Universal infection, no paralysis. What determines paralysis among the infected, per peer-reviewed work, includes innate-immune genetic variants, nutritional status, prior injection or tonsillectomy, age at exposure, and concurrent toxic load — precisely an exposome story.[^50][^37]

The vaccine as an introduced exposure. A live vaccine is, by definition, a biological agent introduced into the body — and the polio vaccines carried documented exposure risks of their own, quite apart from their benefit. The first is the vaccine virus itself: the live oral vaccine (OPV) is genetically unstable and can revert to neurovirulence with as few as two nucleotide mutations, which is why the United States discontinued OPV in 2000.[^51] By 2022, more global paralytic cases were caused by vaccine-derived strains than by wild virus — a fact the WHO openly builds its “OPV endgame” strategy around.[^52][^48] In India, peer-reviewed surveillance by the Puliyel group found non-polio acute flaccid paralysis running far above the expected background rate and correlating with the number of OPV doses administered per region, with rates declining when dosing was reduced after 2012.[^53][^54] The caution belongs in the text: India’s unusually aggressive surveillance inflates raw rates relative to other countries — a legitimate objection — but it does not by itself explain the within-country, dose-response gradient or the temporal decline when dosing dropped, and the finding has not been formally refuted in the literature.

The second risk was a contaminant. Between 1955 and 1963, a substantial fraction of polio vaccine was contaminated with Simian Virus 40 (SV40), a monkey virus carried over from the cell cultures used in manufacture, and tens of millions of people were exposed before the contamination was identified and cleared.[^55] SV40 is oncogenic in animal models, and its DNA has since been reported in several human tumor types — but the epidemiology of human cancer risk has not borne out a clear population-level signal. The National Academies, reviewing the question in 2002, concluded that the evidence was inadequate to either accept or reject a causal link, while acknowledging a strong biological basis for concern.[^56] This is the honest status: an introduced biological contaminant, real and documented, whose downstream human consequence remains an open question rather than a demonstrated harm. It belongs in an exposome account precisely as that — an exposure, logged and unresolved, not a verdict.

The adjuvant as an introduced exposure. The principle generalizes beyond polio to the broader vaccine pharmacopeia, and the clearest worked example is the aluminum adjuvant used in many non-live vaccines — a case where the mechanism is well characterized even where downstream clinical consequences remain unsettled. Aluminum hydroxide is a deliberate immune irritant, and the molecular path by which it acts is now mapped. It activates the NLRP3 inflammasome — the same sterile-inflammation sensor triggered by the body’s most potent danger signals — driving release of IL-1β and IL-18 in an NLRP3- and ASC-dependent manner.[^57] NLRP3 activation in turn drives the secretion of ASC-laden extracellular vesicles, and those vesicles propagate the inflammasome-activation state to naïve recipient cells: EVs carrying inflammasome cargo activate NF-κB signaling in cells that were never exposed to the original trigger, whereas vesicles from unactivated cells do not.[^58] This is the same EV-mediated signal propagation documented for the chemical toxicants of Section I, arising here from an injected compound. And aluminum does not simply clear: adjuvant particles are phagocytosed by macrophages that biopersist and can traffic the metal through lymphatics toward the brain along a monocyte-chemoattractant pathway, with injection-site aluminum deposits documented years after administration.[^59] None of this, on its own, establishes a particular disease — the mechanism is what is established: an introduced adjuvant activating an inflammasome, propagating that activation cell-to-cell via vesicles, and distributing through the body in cells rather than being promptly excreted. Stated at that level, it is simply another, well-characterized instance of the exposome’s central mechanic — a local exposure broadcasting its signal beyond the cells it first touched.

Assembled, these are not directly a refutation of polio virology. They are a fuller causal picture: a largely commensal virus, necessary but not sufficient for paralysis in the overwhelming majority of cases; a disease burden amplified by a concurrent exposome — environmental and introduced alike — of arsenicals, DDT, nutritional depletion, medical provocation, and eventually the vaccine’s own viral risks. Polio was analyzed for decades through a single-pathogen lens. Standard environmental epidemiology, applied in retrospect, reveals a multi-causal phenomenon.

The pattern is not unique to polio. The most general version of this point is visible in mortality data that long predate any vaccine. Deaths from measles, whooping cough, scarlet fever, and diphtheria fell by 90 percent or more in the United States and United Kingdom before the respective vaccines were introduced — a decline that demographers attribute to improved nutrition, sanitation, housing, and supportive care rather than to immunization.[^60] The real mortality collapse that anchors so much of the popular narrative was largely accomplished by changing the conditions in which people lived — which is to say, by changing the exposome in its broadest sense, the total environmental load a body must withstand. The single-pathogen lens credits the pathogen’s removal; the fuller picture credits the terrain. Both matter. Only one has been counted by the medical establishment.

V. Why the blind spot persists

The exposome’s invisibility in our causal accounting is not the product of a conspiracy. It is the product of structure, and the structure is worth naming because it explains why correction is slow.

Our diagnostic tools are pathogen-shaped. A PCR assay, a culture, a serology panel — these instruments are built to find an organism, and an instrument built to find an organism will tend to return an organism or a blank, not a chemical. When the blank comes back, “idiopathic” is filed more readily than “we tested for the wrong category of cause.”

Chemicals are also genuinely harder to see. A pathogen is a discrete agent that can be isolated and named. The exposome is a diffuse, low-dose, lifelong mixture, and its most consequential effects may be synergistic — the combined action of compounds that are individually below their no-effect thresholds. These mixture effects, sometimes called the problem of “ghost molecules,” are almost never tested, because the regulatory and toxicological apparatus evaluates chemicals one at a time, each assigned its own threshold as though it acted alone. A body, by contrast, experiences them all at once, and the interactions can be more than additive: a compound that depletes glutathione lowers the threshold at which an unrelated oxidative toxicant causes harm, so two exposures each individually “safe” combine into one that is not. The regulatory regime has almost no machinery for detecting this, because testing every pairwise and higher-order combination of tens of thousands of chemicals is combinatorially impossible — which means the interactions are not so much judged safe as never examined at all.

Funding compounds the bias. Large trials are financed by sponsors who can own the result. A pathogen invites a patentable countermeasure; a diffuse environmental exposure invites expensive regulation and uncompensated remediation. The economic gradient runs steeply toward the infectious framing and away from the toxic one.

And underneath all of it sits an epistemic habit inherited from microbiology: one cause, one disease. It was a spectacularly misleading simplification. It is also the reason a multi-causal, exposure-weighted picture of illness reads as heterodox even when every individual claim in it is mainstream.

Conclusion

The phrase I have used in earlier pieces — “poisoned or infected?” — is the perhaps the wrong question, because it preserves the very either/or that has kept the exposome out of our causal accounting. The body does not experience pathogens and chemicals in separate compartments. They act together — a virus or exosome made more dangerous by an arsenical (or intentionally weaponized via gain-of-function research), a lung primed for pneumonia by particulate load, a paralysis that required both a commensal enterovirus and a toxic threshold to cross.

What the evidence supports is that the exposome is a co-author of the disease patterns we have spent a century attributing to pathogens alone. Localized chemical injury can travel through the body’s own vesicular messaging and mimic spread; shared exposures can mimic outbreaks well enough to fool investigators for decades. And the lens is not only historical — it reaches into the medicine cabinet, where a reflexive remedy for childhood fever turns out to suppress a functional defense and draw down the body’s antioxidant reserve at the same moment, with population-scale consequences we have barely begun to study. That last case asks nothing of the reader but mainstream pharmacology and a willingness to question a habit.

The practical implication is not alarm. It is instrumentation — and, in the meantime, humility about reflexes we have mistaken for settled science. We built a diagnostic and epidemiological apparatus exquisitely tuned to find singular pathogen (even in the absence of the fulfilment of the Koch postulates), and then mistook the limits of the instrument for the limits of causation. A medicine that could actually see the exposome — that tested chemicals in the mixtures bodies meet them in, that ran the toxic differential as reflexively as the infectious one, that paused before suppressing a fever it had never proven was harmless — would not be a medicine that had abandoned germ theory*. It would be a medicine that had finally stopped looking for its keys only under the streetlight.

*Germ theory would preserve a modicum of it credibility if it acknowledged the microbiome and the tendency towards the overgrowth of normally neutral or beneficial microorganisms or biological microvessicles in dysbiosis — often driven by the exposome or conventional interventions themselves — leading to “pathogenic” expression, instead of demonizing aspects of our micro- and macro-ecological/holobiont constitution itself.

Share

Share the X thread dedicated to this post below:

Notes

[^1]: Exosomes as mediators of chemical-induced toxicity, Current Environmental Health Reports 6, no. 2 (2019): 152–159. PubMed 31102182.

[^2]: Role of extracellular vesicles in cell–cell communication and inflammation following exposure to pulmonary toxicants. PubMed 31901309.

[^3]: Hepatocyte-derived exosomal miR-2137 mediates cadmium-induced renal ferroptosis via GPX4 suppression, Frontiers in Cell and Developmental Biology (2025), article 1585106.

[^4]: Small extracellular vesicles contain metals and transfer them to recipient cells, Journal of Extracellular Biology(University of Melbourne, 2024). PubMed 39403171.

[^5]: Small extracellular vesicles contain metals and transfer them to recipient cells (full text), PMC11472423.

[^6]: Clemens, Wang, Ambrosio & Barchowsky, Arsenic disrupts extracellular vesicle-mediated signaling in skeletal muscle, Toxicological Sciences (2023), PMC10535782 / PubMed 37527016.

[^7]: Same study (in-vivo confirmation: EVs from arsenic-exposed mice injected into naïve mice reproduced impaired muscle regeneration; ~222 differentially abundant EV cargo proteins by mass spectrometry).

[^8]: Harischandra et al., Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein, Science Signaling 12, no. 572 (2019); see also Exosomes as mediators of chemical-induced toxicity (note 1).

[^9]: The exosome-mediated cascade reactions for the transfer and inflammatory responses of fine atmospheric particulate matter in macrophages, Environmental Science & Technology (ACS, 2023). PubMed 37163641.

[^10]: Same study, ACS publication record, doi:10.1021/acs.est.3c01436.

[^11]: Polystyrene microplastic-induced extracellular vesicles cause renal fibroblast activation, Ecotoxicology and Environmental Safety (2024), PubMed 38368757; renal fibrosis confirmed in vivo at human-relevant exposure.

[^12]: Plastic nanoparticles interfere with the extracellular vesicle pathway in brain astrocytes — astrocyte EVs export internalized nanoplastics to neighboring cells, Ecotoxicology and Environmental Safety (2024).

[^13]: Reviewed in the EV/radiation bystander literature; exosome-transmitted genomic instability to unirradiated cells persisting across multiple cell generations.

[^14]: WHO, Manual for Investigating Suspected Outbreaks of Illnesses of Possible Chemical Etiology (2021).

[^15]: WHO chemical-etiology outbreak guidance, companion summary materials (2021).

[^16]: CDC, Field Epidemiology Manual, chapter on acute environmental and chemical exposure investigation.

[^17]: Minamata disease historical and clinical record; official attribution to Chisso Corporation methylmercury discharge, 1968.

[^18]: Computational phenotyping of Minamata symptomatology against known disease space (2026), mapping closest matches to toxic-origin neurological disease rather than infectious encephalitis.

[^19]: Itai-itai disease historical record; 1955 microorganism hypothesis and subsequent cadmium confirmation.

[^20]: Toxic Oil Syndrome (Spain, 1981): aniline-denatured rapeseed oil; initial infectious-respiratory framing.

[^21]: Hartzema et al., Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome (1991).

[^22]: L-tryptophan and the eosinophilia-myalgia syndrome. PubMed 8423409.

[^23]: CDC investigation of e-cigarette/vaping product use-associated lung injury (EVALI), 2019; identification of vitamin E acetate.

[^24]: Misdiagnosis in occupational and environmental medicine: scoping review (2021), PMC8383455.

[^25]: Raissy & Blake, Acetaminophen and asthma in children: association or causality?, Pediatric Allergy, Immunology, and Pulmonology (2017); weekly acetaminophen use ~26% in children under 2.

[^26]: Eyers, Weatherall, Shirtcliffe, Perrin & Beasley, The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis, Journal of the Royal Society of Medicine (2010), PubMed 20929891; pooled odds ratio 1.34 (95% CI 1.04–1.73). The abstract is explicit that no human studies met inclusion criteria — the pooled figure is animal-only, and the authors call for human trials that have still not been done. The body text reflects this accurately.

[^27]: Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis, Critical Care (2012), PMC3396278; acetaminophen and NSAIDs independently associated with increased 28-day mortality in septic patients.

[^28]: Randomized controlled trial of the effect of regular paracetamol on influenza infection, Respirology (2015), PubMed 26638130 / PMC4738455; no significant effect on viral load or clinical outcomes in adults.

[^29]: Acetaminophen toxicity, StatPearls (NIH/NCBI Bookshelf); NAPQI formation, glutathione conjugation, and the noted lower hepatotoxicity risk in children under 5 due to greater glutathione regeneration and sulfation capacity. See also mechanisms reviews, PMC5489132.

[^30]: Biochemistry of acetaminophen hepatotoxicity and rescue: a mathematical model, Theoretical Biology and Medical Modelling (2012); therapeutic dosing lowers liver glutathione modestly, chronic dosing ~30%, with multi-day recovery.

[^31]: Dimova et al., Acetaminophen decreases intracellular glutathione levels and modulates cytokine production in human alveolar macrophages and type II pneumocytes in vitro, International Journal of Biochemistry & Cell Biology(2005), PubMed 15878691; glutathione depletion documented in lung cells.

[^32]: Early-life acetaminophen exposure, glutathione S-transferase (GST) genotypes, and asthma risk; prenatal/infant acetaminophen, antioxidant gene polymorphisms and childhood asthma, PMC4907348; GST-null genotypes reduce antioxidant capacity. Glutathione substrate depletion worsened by fasting/malnutrition during febrile illness.

[^33]: International Study of Asthma and Allergies in Childhood (ISAAC); dose-dependent association between childhood acetaminophen use and asthma, rhinoconjunctivitis, and eczema. Association observational and confounded (notably by respiratory infection as a shared cause); causality not established. See “The acetaminophen and asthma hypothesis 10 years on: a case to answer,” Journal of Allergy and Clinical Immunology (2009).

[^34]: Nonpolio causes of polio-like paralytic syndromes, Reviews of Infectious Diseases (1984), PubMed 6740077; 1958 Michigan epidemic virological testing data.

[^35]: The heterodox lineage runs from Dr. Morton Biskind’s writings in the early 1950s through Jim West’s “Pesticides and Polio” (2000, republished by the Weston A. Price Foundation) and Forrest Maready’s The Moth in the Iron Lung(2018). These works vary widely in rigor, and several make the stronger, unsupported claim that poliovirus is not a genuine cause of paralysis; the argument in this section explicitly rejects that stronger claim.

[^36]: Testimony of Dr. Bernard Greenberg, U.S. Congressional hearing, 1962, on the effect of 1955 diagnostic-criteria changes on counted paralytic case totals.

[^37]: Nonpolio causes of polio-like paralytic syndromes, Reviews of Infectious Diseases (1984), PubMed 6740077.

[^38]: Acute arsenic intoxication presenting as Guillain-Barré-like syndrome (four-patient series), Muscle & Nerve(1987), PubMed 3029587.

[^39]: Arsenic-induced polyneuropathy mimicking Guillain-Barré syndrome (2025), PMC12417313.

[^40]: R. W. Lovett, Massachusetts State Board of Health report (1908), on metallic-poison spinal-cord lesions resembling anterior poliomyelitis.

[^41]: Polio, DDT, and disease risk in the United States after World War II, Environmental History 22, no. 4 (2017), University of Chicago Press; includes DDT anterior-horn animal data, epidemic-curve correlation, and Xavante seropositivity natural experiment.

[^42]: “Chlorophenothane (DDT) — A Blessing or a Menace?” (editorial), JAMA 158, no. 15 (1955): 1370–1371, doi:10.1001/jama.1955.02960150040014. The editorial classifies DDT as acting primarily on the central nervous system, producing hyperexcitation, generalized tremors, “spastic or flaccid paralysis,” and convulsions.

[^43]: Rossi, Scarselli, Fasciani, Maggio & Giorgi, Dichlorodiphenyltrichloroethane (DDT) induced extracellular vesicle formation: a potential role in organochlorine increased risk of Parkinson’s disease, Acta Neurobiologiae Experimentalis (2017), PubMed 28691715. (Mechanistic hypothesis grounded in the group’s prior work on DDT-induced vesicular budding; not a demonstration of a DDT→paralysis exosomal chain.)

[^44]: Polio provocation and tonsillectomy: University of Cambridge history-of-medicine account.

[^45]: Tonsillectomy and poliomyelitis: development of causality (2022), PubMed 36067711.

[^46]: Gromeier & Wimmer, Mechanism of injury-provoked poliomyelitis, Journal of Virology 72, no. 6 (1998): 5056–5060, PMC110068 / PubMed 9573275.

[^47]: Intramuscular injections as a risk factor for vaccine-associated paralytic poliomyelitis, Romania study, New England Journal of Medicine (1995), PubMed 7830731 (odds ratio 31.2).

[^48]: WHO, poliomyelitis fact sheet (infection-to-paralysis ratio; eradication status of wild types).

[^49]: ECDC, factsheet on poliomyelitis (≈70% asymptomatic infection).

[^50]: Host genetics, innate immune responses, and cellular death pathways in poliovirus paralysis, Frontiers in Immunology (2019), PMC6629967.

[^51]: Vaccine-derived poliovirus reversion to neurovirulence; two-nucleotide mutation threshold, Virology (1993); CDC discontinuation of OPV in the U.S., 2000.

[^52]: CDC, polio disease and poliovirus containment; vaccine-derived versus wild-type case burden and OPV endgame rationale.

[^53]: Vashisht & Puliyel, Trends in non-polio acute flaccid paralysis incidence in India, Indian Journal of Medical Ethics (2012). (Note: the Puliyel group’s figures vary across publications; this article uses the directional finding — a dose-correlated NPAFP rate that declined when dosing was reduced — rather than any single disputed point estimate.)

[^54]: Dhiman et al., Correlation between non-polio acute flaccid paralysis rates and OPV pulse rounds, International Journal of Environmental Research and Public Health (2018), PubMed 30111741.

[^55]: SV40 contamination of polio vaccine, 1955–1963: historical record of cell-culture carryover and exposure scale.

[^56]: National Academies / Institute of Medicine, Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer (2002): evidence inadequate to accept or reject a causal link, with acknowledged biological basis for concern.

[^57]: Eisenbarth et al., Crucial role for the Nlrp3 inflammasome in the immunostimulatory properties of aluminium adjuvants, Nature / European Journal of Immunology (2008), PubMed 18624356; NLRP3- and ASC-dependent IL-1β/IL-18 release. See also NLRP3-dependent responses to aluminium adjuvants confirmed in later macrophage/dendritic-cell work.

[^58]: Inflammasome-derived exosomes activate NF-κB signaling in recipient cells, Journal of Proteome Research(2016), doi:10.1021/acs.jproteome.6b00599; ASC-laden EVs released upon NLRP3 activation propagate inflammasome state to naïve cells. Reviewed in “Exosomes regulate NLRP3 inflammasome in diseases,” PMC8762245.

[^59]: Gherardi et al. (INSERM), Biopersistence and brain translocation of aluminium adjuvants of vaccines, Frontiers in Neurology (2015), PMC4318414; macrophage-mediated transport via a CCL2/monocyte-chemoattractant pathway; injection-site aluminium deposits (macrophagic myofasciitis) documented years post-administration.

[^60]: Pre-vaccine decline in mortality from measles, pertussis, scarlet fever, and diphtheria; see e.g. measles mortality analysis, Population Association of America (2019), and CDC, “Achievements in Public Health, 1900–1999.” Mortality decline preceded vaccines; case-rate (morbidity) decline followed them.

[^61]: Poliovirus cell entry and CD155 receptor structural characterization, PMC1500891.

STORY AT A GLANCE

• A landmark UCL trial presented at ASCO 2026 confirms that 90% of breast cancer patients given chemotherapy received no benefit — a confession of systematic harm on a mass scale, reported by the BBC as a “breakthrough.”

• The cancer stem cell (CSC) hypothesis explains why: chemotherapy targets fast-replicating bulk tumor cells while leaving the slow-replicating, treatment-resistant cancer stem cells intact — and in many cases making them 30x more malignant.

• Radiation therapy has been shown to reprogram benign breast cells into induced breast cancer stem cells (iBCSCs), enriching the tumor with its most dangerous population while the overall tumor volume shrinks — creating a false impression of success.

• Natural compounds including curcumin, resveratrol, sulforaphane, and EGCG demonstrate selective cytotoxicity against cancer stem cells — targeting the root of malignancy while sparing healthy tissue, at a fraction of chemotherapy’s toxicity.

• The new Prosigna DNA test tells doctors which patients won’t benefit from chemotherapy. The cancer stem cell hypothesis tells us why almost none of them did — and what genuine cancer resolution requires.

• The MAHA imperative: there is nothing more aligned with making America healthy again than demanding accountability for an iatrogenic crisis in which millions of women received toxic, unnecessary treatment while the root causes of their cancer went entirely unaddressed.

I. The Confession

What the BBC Reported as a Breakthrough Is Actually an Indictment

On May 30, 2026, the BBC reported that scientists at University College London had developed a DNA test — the Prosigna gene activity assay — capable of identifying breast cancer patients who will not benefit from chemotherapy. The international trial involved more than 4,000 newly diagnosed patients across six countries. Its finding: more than two-thirds of participants could be safely spared chemotherapy, treated with hormone therapy alone, with virtually identical survival outcomes.^[1]

Professor David Miles summarized the clinical reality with startling candor: “We used to give chemotherapy to 100 women to benefit 10, knowing that 90 didn’t need it.”^[2]

— Professor David Miles, UCL, quoted by BBC News, May 2026 ^[1]

This statement is one of the most significant admissions in the history of modern oncology. It means that the standard of care for the most common cancer affecting women — applied to millions of patients over decades — was providing meaningful benefit to fewer than one in ten recipients, while subjecting the remaining nine to fatigue, nausea, hair loss, immune destruction, fertility damage, and in some cases permanent organ injury.

This is not a breakthrough. It is an indictment. And the question that must follow is not how to celebrate the new test — but how to reckon with what the old practice did, why it persisted for so long, and what the biology has been telling us, unheeded, for decades.

90% of breast cancer patients given chemotherapy received no benefit from it, according to trial results presented at the American Society of Clinical Oncology annual meeting, 2026.^[1]

II. The Overdiagnosis Pipeline

From Mammography to Mastectomy: How the Harm Accumulates

To understand why 90 women out of 100 were receiving unnecessary chemotherapy, you have to trace the pipeline upstream — to the screening procedure that found their cancer in the first place. Mammography, mandated as routine care under USPSTF guidelines, has generated one of the largest overdiagnosis crises in medical history.

A 2012 analysis in the New England Journal of Medicine found that in the three decades following the widespread adoption of mammography screening, the rate of early-stage breast cancer diagnoses doubled, while the rate of late-stage cancer decreased by only a small fraction.^[2] The conclusion: most of the additional diagnoses were overdiagnoses — cancers found by screening that would never have caused symptoms or death in the woman’s lifetime.

The Cochrane Collaboration concluded that for every woman whose death is avoided through mammography, approximately ten are unnecessarily diagnosed and treated, and 200 experience lasting psychological trauma from false positives.^[3] This ratio has been known since 2011. The screening machine ran unimpeded.

Ductal carcinoma in situ — DCIS — is the single largest driver of this overdiagnosis epidemic. Virtually unknown before widespread screening, DCIS today accounts for roughly 20% of all breast cancer diagnoses in the United States, with more than 50,000 women diagnosed annually.^[4] The COMET trial has now confirmed what advocates including this author have argued since 2008: active monitoring is equally safe as surgery for most DCIS.^[5]

III. The Cancer Stem Cell Indictment

Why Chemotherapy Was Always Fighting the Wrong Enemy

The Prosigna test tells oncologists which women won’t benefit from chemotherapy. The cancer stem cell hypothesis tells us why almost none of them did — and the biology has been accumulating in the peer-reviewed literature for well over a decade.

Conventional chemotherapy operates on a fatally flawed model of what a tumor actually is. Tumors are not simply the result of one or more mutated cells “going rogue” and producing exact clones of themselves. They are ecologically diverse communities of cells with radically different characteristics, behaviors, and responses to treatment.^[6]

Within that diverse tumor population lives a subpopulation that chemotherapy and radiation cannot touch: cancer stem cells (CSCs) — the most deadly cell type within a tumor, with the ability to give rise to all cell types found within that cancer and to theoretically limitless supplies of daughter cells.^[7] They are slower-replicating than the bulk tumor cells that chemotherapy targets — which means they are precisely the cells most likely to survive treatment. And survival, for a cancer stem cell, means one thing: the capacity to reseed the entire tumor from scratch.

EVIDENCE NOTE — THE 30× MALIGNANCY FINDING (UCLA / JOURNAL CANCER)

A study from the UCLA Jonsson Comprehensive Cancer Center, published in Cancer (American Cancer Society’s journal), found that even when radiation killed half the tumor cells treated, the surviving induced breast cancer stem cells (iBCSCs) were up to 30 times more likely to form tumors than non-irradiated breast cancer cells.^[8]

A companion study in Stem Cells confirmed that ionizing radiation reprogrammed less malignant breast cancer cells into iBCSCs — meaning both the screening tool (mammography) and the treatment tool (radiotherapy) deliver ionizing radiation that can convert benign or low-risk tumor cells into cancer’s most dangerous phenotype.^[9]

The radiation treatment regresses the total population of cancer cells, generating the false appearance that the treatment is working — while actually increasing the ratio of highly malignant to benign cells within that tumor, eventually leading to the iatrogenic death of the patient.^[10]

This phenomenon explains something oncology has struggled to name honestly: multi-drug resistant cancer. The cancer stem cell hypothesis reveals the more accurate explanation: the treatment itself selected for and enriched the most malignant cells in the tumor, while eliminating the benign majority that was never the real threat.^[6]

Learn more about cancer stem cells and the problem with conventional treatment approaches in my interview for the Truth About Cancer series filmed in 2014 below.

IV. Nature’s Answer

What Plants Do That Chemotherapy Cannot

The cancer stem cell hypothesis does not only indict conventional treatment. It points precisely toward what works instead — and the GreenMedInfo database, containing over 14,000 peer-reviewed abstracts on natural cancer interventions, documents that evidence in granular detail.^[11]

Natural compounds demonstrate three properties that chemotherapy categorically lacks: a high margin of safety (often two orders of magnitude less toxic); selective cytotoxicity (targeting cancerous cells while sparing healthy ones); and direct CSC targeting — the ability to selectively eliminate the treatment-resistant cancer stem cells that are the root of malignancy and recurrence.^[12]

The evidence is specific. Turmeric extract (curcumin) was found to be approximately 100 times less toxic than chemotherapy, and more effective at killing colorectal cancer stem cells from actual patient-derived cell lines than a leading combination of conventional drugs.^[13] Graviola fruit extract has been documented at up to 10,000 times more effective at killing certain cancer cells than adriamycin — the chemotherapy drug known as “the red devil” for its lethal side effects.^[14]

Blueberry phytocompounds including resveratrol induce programmed cell death in triple-negative breast cancer cell lines — the most treatment-resistant subtype.^[15] Sulforaphane, EGCG (green tea), and berberine have each been shown to reduce the expression of proteins associated with cancer stem-cell-like properties — reducing “stemness” itself, rather than merely reducing tumor volume.^[12]

NATURAL CSC-TARGETING COMPOUNDS

• Curcumin (Turmeric) — 100× less toxic than chemo; superior colorectal CSC elimination in patient-derived cell lines.

• Resveratrol (Blueberry/Grape) — Apoptosis in triple-negative breast CSCs; reduces stemness markers.

• Sulforaphane (Broccoli) — Targets BCSC subpopulation; reduces stemness expression.

• EGCG (Green Tea) — CSC sensitization; active across multiple cancer types.

• Graviola Extract — Up to 10,000× adriamycin in certain cancer cell lines.

• Berberine — Reduces cancer stem cell phenotype; metabolic reprogramming.

V. The Copernican Moment

The Mainstream Is Arriving at a Biology We Documented in 2012

The BBC’s Prosigna story is being reported as a triumph of precision medicine. It is that. But it is also the first mainstream clinical acknowledgment of a principle the cancer stem cell literature has been demonstrating since at least 2012, when GreenMedInfo published its landmark analysis of the UCLA radiation study.^[8] That principle: the bulk of conventional cancer treatment has been targeting the wrong cells, with the wrong tools, while the cells most responsible for cancer mortality survived, adapted, and returned stronger.

The Prosigna test tells doctors which patients won’t benefit from chemotherapy. It does not ask why the cancer arose. It does not address the Western Pattern Diet, the endocrine-disrupting chemical burden, the leaky gut-driven oncogenic microenvironment, or the microRNA depletion (or synthetically altered microRNAs) from processed and/or genetically modified food. It is a better way to manage a disease whose root causes remain entirely unaddressed.^[17]

VI. The MAHA Imperative

There Is Nothing More MAHA Than This

The Make America Healthy Again movement claims to be about root causes — about asking why chronic disease exploded, why the healthcare system produces sickness as reliably as it produces revenue, why the bodies of American women have become a profit center for an industry that begins with a carcinogen and ends with a mastectomy.

If that vision means anything, it must mean this: that 90 women out of 100 receiving toxic, unnecessary chemotherapy — while the cancer stem cells driving their malignancy were being enriched by that very treatment — is one of the largest iatrogenic crises in American medical history. It demands not a “breakthrough” headline but a reckoning.

The USPSTF firings by RFK Jr. triggered outrage because they threatened access to mammography screening. But mammography screening feeds the overdiagnosis pipeline that leads to the chemotherapy that 90% of recipients didn’t need. The outrage is aimed in exactly the wrong direction.^[18] Reforming this system — from root-cause prevention through CSC-targeted natural therapeutics — is the most coherent expression of what a health-first movement could actually accomplish.

There is nothing more MAHA than asking why cancer arises, demanding accountability for the treatments that made it worse, and directing resources toward the biology — epigenetic, metabolic, nutritional — that actually resolves it.

Learn more by reviewing the GreenMedInfo.com breast cancer database and reading our recent article on the topic below.

Subscribe now

Share

ENDNOTES & CITATIONS

[1] BBC News. (2026, May 30). Millions of breast cancer patients could safely avoid chemotherapy, study suggests. BBC Health. Trial led by University College London, presented at ASCO Annual Meeting, Chicago, 2026. Prof. David Miles: “We used to give chemotherapy to 100 women to benefit 10.” www.bbc.com/news/health

[2] Bleyer, A., & Welch, H.G. (2012). Effect of three decades of screening mammography on breast-cancer incidence. New England Journal of Medicine, 367(21), 1998–2005. GreenMedInfo analysis. greenmedinfo.com/blog/30-years-breast-screening-13-million-w

[3] Gøtzsche, P.C., & Nielsen, M. (2011). Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews. 10 women overtreated per 1 life saved; 200 experience false-positive trauma.

[4] American Cancer Society. (2024). Breast Cancer Facts & Figures. DCIS accounts for 18–25% of new breast cancer diagnoses; 50,000+ women diagnosed annually. greenmedinfo.com/blog/x-ray-mammograms-starting-40-new-recom

[5] COMET Trial. San Antonio Breast Cancer Symposium. Principal Investigator: Dr. Shelley Hwang, Duke Cancer Institute. Ji, S. (2024). Reclassifying DCIS. Sayer Ji’s Substack, December 13, 2024.

[6] Ji, S. (2012). Are Cancer Stem Cells the Key to Discovering a Cure? GreenMedInfo. greenmedinfo.com/blog/are-cancer-stem-cells-key-discovering-

[7] Ji, S. (2012). Does Chemo/Radiation Actually Make Cancer More Malignant? GreenMedInfo. greenmedinfo.com/blog/does-chemo-radiation-actually-make-can

[8] UCLA Jonsson Comprehensive Cancer Center. Published in Cancer (ACS journal). Surviving induced breast cancer stem cells (iBCSCs) up to 30x more likely to form tumors. Ji, S. (2012). Study: Radiation Therapy Can Make Cancers 30x More Malignant. GreenMedInfo. greenmedinfo.com/blog/study-radiation-therapy-can-make-cance

[9] Radiation-induced reprogramming of breast cells. Stem Cells journal. Ionizing radiation reprogrammed less malignant breast cancer cells into iBCSCs. Ji, S. Hidden Dangers of Mammograms. GreenMedInfo. greenmedinfo.com/blog/hidden-dangers-mammograms-every-woman-

[10] Ji, S. (2012). Research: Radiotherapy Causes Cancer, Blueberry Kills It. GreenMedInfo. greenmedinfo.com/blog/research-radiotherapy-causes-cancer-bl

[11] GreenMedInfo Cancer Stem Cells Database. Over 14,000 peer-reviewed abstracts on natural cancer interventions. greenmedinfo.com/disease/cancer-stem-cells

[12] GreenMedInfo. (2024). Nature’s Cancer-Fighting Arsenal: How Plant Compounds Target Highly Malignant Cancer Stem Cells. greenmedinfo.com/content/natures-cancer-fighting-arsenal-how

[13] Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases. Cancer Letters. Ji, S. Better Than Chemo: Turmeric Kills Cancer Not Patients. GreenMedInfo. greenmedinfo.com/blog/better-chemo-turmeric-kills-cancer-not

[14] Graviola (Annona muricata) fruit extract up to 10,000x more effective at killing certain cancer cells vs adriamycin. GreenMedInfo. greenmedinfo.com/blog/does-chemo-radiation-actually-make-can

[15] Ji, S. (2012). Research: Radiotherapy Causes Cancer, Blueberry Kills It. Blueberry phytocompounds including resveratrol shown to cause apoptosis in triple-negative breast cancer cell lines. greenmedinfo.com/blog/research-radiotherapy-causes-cancer-bl

[16] Ji, S. (2025). The Cancer Deception: How Modern Medicine’s Fundamental Misunderstanding of Cancer’s True Causes Created a $43 Billion Overdiagnosis Industry. Sayer Ji’s Substack, July 17, 2025.

[17] Ji, S. (2020). Regenerate: Unlocking Your Body’s Radical Resilience through the New Biology. Hay House. regenerateproject.com

[18] Ji, S. (2026). The Mammography Deception: Why RFK Jr. Is Right for the Wrong Reasons. Sayer Ji’s Substack.

Adapted from Regenerate: Unlocking Your Body’s Radical Resilience through the New Biology by Sayer Ji (Hay House, 2020). GreenMedInfo.com.

The new White House executive order, blandly titled “Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries,” is far more than bureaucratic housekeeping. Buried in the legal language is a historic admission: the U.S. childhood vaccine schedule is an outlier among peer nations, and federal agencies are now being directed to realign it with international best practices while re‑centering parental authority and religious freedom.

This did not happen in a vacuum. It is, in many ways, the fruit of decades of work by grassroots health‑freedom advocates, organizations like The National Vaccine Information Center (NVIC), Stand for Health Freedom, Health Freedom Defense Fund, MAHA Action, and Children’s Health Defense, and too many citizen-led organizations to name here, as well as the millions of moms and dads who refused to surrender their children’s health to one‑size‑fits‑all mandates.

From U.S. Outlier to Global Norms

The order is grounded in an HHS “scientific assessment” comparing the U.S. childhood schedule to those of other developed countries. It examines how many vaccines are recommended, how many doses, and at what ages they are given, and concludes that the United States recommends substantially more shots—and often more doses—than many European and other high‑income nations.

Crucially, the assessment identifies a smaller “core” set of vaccines that most peer countries share, with additional products layered more cautiously or not at all. The executive order explicitly treats this assessment as a guiding document for federal policy, signaling that “more” is no longer assumed to be synonymous with “better,” and that being an outlier should invite scrutiny rather than reflexive pride.

Trust and Education Instead of Coercion

One of the most remarkable lines in the order notes that “instead of implementing vaccination mandates, most peer nations maintain high childhood vaccination rates through public trust and education.” In a single sentence, this overturns the long‑standing assumption that coercion—via school mandates, employment requirements, or social exclusion—is the only reliable way to maintain coverage.

The order states that U.S. policy should be to align the “core childhood vaccine schedule” with scientific evidence and with best practices from peer countries, while “preserving access to vaccines currently available to Americans.” Access is protected, but the moral architecture changes: trust, transparency, and informed consent are explicitly elevated over compulsion.

CDC, ACIP, and a Mandate for Flexibility

The Centers for Disease Control and Prevention (CDC) and its Advisory Committee on Immunization Practices (ACIP) are instructed to review the assessment, consider “the latest clinical data,” and “take any appropriate steps to update the United States childhood and adolescent vaccine schedule” consistent with the law.

This is not symbolic. These are the very bodies that set the official schedule. The order goes further by explicitly asking ACIP to consider how to provide “maximum flexibility to parents and doctors through recommendations for timing and sequencing of the administration of routine immunizations.”

In practical terms, that opens room for:

• Slower, more individualized schedules

• Greater acceptance of spacing and deferral

• A smaller “core” schedule that better reflects genuine international consensus

After decades in which the schedule only ratcheted in one direction—more products, more doses, earlier and earlier—this is a top‑down instruction to reconsider that trajectory.

Parental Rights and Religious Liberty Center Stage

Another striking feature of the order is its repeated emphasis on “religious liberty and parental authority.” It directs federal agencies to ensure that all actions, regulations, and coverage decisions related to child and adolescent immunizations are consistent not only with the official schedule, but also with legal protections for parents, religious freedom, disability accommodations, and equal protection.

This is more than rhetoric. Federal agencies set the tone for state health departments, school systems, and healthcare institutions. When Washington explicitly reaffirms parental rights and religious liberty in this context, it provides powerful language that families and advocates can invoke wherever local policies overreach.

Coverage Without Cost, Choice Without Penalty

Some may worry that revisiting the schedule could be used as a pretext to reduce access. The order anticipates this by requiring that all vaccines remaining anywhere on the CDC childhood/adolescent schedule continue to be covered without cost‑sharing by private insurance, Medicaid, the Children’s Health Insurance Program (CHIP), and the Vaccines for Children Program.

The message is clear: parents who, in consultation with their physicians, choose additional vaccines that remain on the schedule will not face new financial barriers. The shift is not toward scarcity, but toward genuine choice—preserving access while removing the presumption that a single, highly aggressive template is universally appropriate.

Covid Shots: The Next Essential Step

If this order is truly the beginning of a course correction, then an honest reassessment of the Covid‑19 shots on the childhood schedule is indispensable. The emergency, mandate‑driven rollout of these products, and their rushed incorporation into the pediatric schedule, became a symbol of everything that was wrong with the last administration’s approach: disregard for long‑term safety data, censorship of dissenting voices, and punishment of families who chose a precautionary path. To continue “righting the wrongs” of that era, federal agencies must be willing to revisit those decisions openly, restore full transparency around risks and benefits, and seriously consider removing Covid shots from the childhood schedule entirely.

Grassroots Health Freedom: The Unsung Architects

The real story behind this executive order is the decades of patient, often painful work by grassroots organizers and families.

• Stand for Health Freedom has built easy‑to‑use digital tools that help citizens track legislation, contact lawmakers, and mobilize quickly in defense of medical choice.

• MAHA Action has focused on mobilizing citizens around a broader “Make America Healthy Again” vision, connecting chronic disease, toxic exposures, and public‑health policy to the need for deep structural reform.

• Health Freedom Defense Fund has brought impact litigation against mandates and discriminatory policies, helping to establish legal boundaries on what governments and corporations can demand of individuals’ bodies.

• Children’s Health Defense, founded by Robert F. Kennedy Jr., has become a central hub for exposing regulatory capture, environmental and pharmaceutical harms, and the chronic disease epidemic in children, through lawsuits, Freedom of Information Act requests, education, and media.

• The National Vaccine Information Center (NVIC), founded by Barbara Loe Fisher and the late Kathi Williams in 1982, deserves special recognition as one of the earliest and most influential organizations advocating for informed consent in vaccination. For more than four decades, NVIC has provided vaccine education, tracked vaccine legislation, defended exemption rights, supported injured families, and helped establish the ethical principle that parents have the right to make fully informed medical decisions for their children. Long before health freedom became a national movement, NVIC was laying much of its intellectual and organizational foundation.

Behind these organizations stand millions of parents who have written letters and affidavits, testified at hearings, joined lawsuits, and endured social and professional costs simply for defending their children and insisting on informed consent. They have been smeared, censored, and dismissed—yet they did not stop.

It is impossible to imagine this executive order without acknowledging the cumulative pressure generated by this movement.

RFK Jr. and the Political Breakthrough

Robert F. Kennedy Jr. deserves special mention in this context. Through his leadership at Children’s Health Defense and his broader political advocacy, he has relentlessly challenged the “safe and effective, don’t ask questions” narrative, and insisted on connecting the explosion of chronic childhood illness to toxic exposures and regulatory failure.

As his health‑freedom platform gained national visibility, many grassroots organizations invested enormous energy in pushing for genuine reform of agencies like CDC, FDA, and NIH. Even when specific electoral or appointment outcomes remained uncertain, the political space that Kennedy helped create has forced institutions to respond. This executive order reads, in part, as a response to that relentless demand for transparency, accountability, and respect for bodily autonomy.

Jeffrey Tucker’s Signal and the Civil‑Liberties Frame

Economist and civil‑liberties advocate Jeffrey Tucker captured the broader significance of this shift in a widely shared tweet, praising the order as a long‑overdue correction to an overgrown, coercive childhood vaccine regime and a step toward restoring informed consent and trust in medicine.

By situating the order within a wider civil‑liberties context—alongside free speech, free association, and the right to refuse unwanted medical interventions—Tucker and others are helping more people see what health‑freedom advocates have long argued: vaccine policy is not a narrow technical question but a frontline issue in the struggle over self‑ownership and parental sovereignty.

Where the Movement Goes From Here

For readers of this Substack, this moment is both vindication and invitation.

It vindicates the claims that:

• The U.S. childhood schedule has been unusually aggressive compared with peer nations

• Mandates and coercion are not necessary for high coverage or good outcomes

• Parental rights and religious liberty must be central, not peripheral, to health policy

And it invites us into a new phase of work. CDC and ACIP must now translate this directive into actual changes. States will have to revisit their mandate structures. Schools and healthcare systems will need to align policies with an emerging norm that values flexibility, transparency, and informed consent—and that includes a hard, honest look at the Covid era, including whether those shots belong on the childhood schedule at all.

The executive order is a crack in the wall. Grassroots advocates, organizations like The National Vaccine Information Center (NVIC), Stand for Health Freedom, Health Freedom Defense Fund, MAHA Action and Children’s Health Defense, and leaders like Robert F. Kennedy Jr. have been hammering at that wall for years. The task now is to widen the opening—patiently, persistently—until a truly humane, evidence‑honest, rights‑respecting model of children’s health ceases to be the exception and becomes the norm.

Share

A novel class of genetically engineered food has quietly colonized the American diet since 2017. It doesn’t make a poison. It switches off genes. And there is no label telling you it’s there.

Dinner, Disrupted

Picture a family eating dinner in the American Midwest. The kids are having corn chips and juice. Dad’s eating a pork chop. Mom reaches for the salsa — corn-based, like nearly everything on the table. It’s an ordinary evening in the most ordinary country in the world.

Now consider what might be happening at the molecular level inside that corn.

Embedded in the genome of the corn plants that grew those chips — the same corn that makes the high-fructose syrup in that juice, the same corn silage that fed that pig — is a genetic sequence encoding a molecule called double-stranded RNA, or dsRNA. Think of dsRNA as a search-and-destroy code for genes: a precisely designed molecular message that, when read by a cell’s machinery, identifies a target gene and shuts it down. The target, in this case, is a gene in the western corn rootworm — a devastating agricultural pest. The technology is called RNA interference, or RNAi. The corn is called SmartStax PRO, and it was approved by the EPA in June 2017.

Since that near-silent approval, RNAi crops have expanded to somewhere between 20 and 30 million acres of American farmland. A sprayable version — a gene-silencing aerosol applied directly to potato fields — has been commercially available since 2024. A second sprayable product, this one fed directly to honeybee colonies to kill varroa mites, received federal registration in September 2025. RNA-based fungicides are now before regulators in the US, the EU, and Brazil. An RNA herbicide that silences genes in weeds rather than insects is moving through development.

The family at the dinner table knows none of this. There is no label. There is no mandatory disclosure. There is, to all appearances, just dinner.

This is the story of how we got here, what the science actually says, and why the window to demand a different answer is closing faster than anyone in Washington will admit.

What RNAi Is — and Why It’s Different From Every GMO Before It

To understand why this moment matters, you need to understand what makes RNAi agriculture genuinely unprecedented.

Every GMO that came before it — herbicide-tolerant soybeans, Bt corn, Golden Rice — worked by adding or deleting a protein. The engineered gene produced a new protein, or it knocked out a protein the plant already made. Proteins are the workhorses of biology, and their effects, while sometimes complex, can in principle be tested with standard toxicological tools: feed it to rats, measure the outcomes.

RNAi works at an entirely different level of biology. It doesn’t produce a protein at all. It produces RNA — specifically, double-stranded RNA — which acts not as a building block but as an instruction. RNA is the software running on the DNA hardware of a cell. And double-stranded RNA, in particular, is something mammalian biology has evolved to treat with extreme caution.

Here’s why. Long before the first drug or pesticide was ever invented, viruses were invading cells and replicating using double-stranded RNA as part of their life cycle. Mammalian immune systems evolved a hair-trigger response to any long, perfectly duplexed RNA in the cellular environment, treating it as a viral alarm signal — what immunologists call a PAMP, or Pathogen-Associated Molecular Pattern. When the immune system detects a PAMP, it doesn’t pause to sequence it or identify its source. It responds: shutting down protein synthesis, degrading cellular RNA, triggering interferon, and, in severe or sustained cases, initiating cell death.

The DvSnf7 dsRNA in SmartStax PRO corn — the active genetic payload in the world’s first commercial RNAi crop — is a 240 base-pair hairpin. The threshold for triggering the mammalian interferon response is 30 base pairs. The threshold for maximal activation of PKR, the immune kinase that halts all protein translation in an affected cell, is 85 base pairs. SmartStax PRO’s payload clears both thresholds by a wide margin.

This is not a theoretical concern invented by critics. It is established molecular biology, documented in peer-reviewed literature, and identified in the canonical risk analysis of RNAi crops by independent scientists Jonathan Latham and Allison Wilson of the Bioscience Resource Project. Their framework — which I first reported on in my 2015 GreenMedInfo article on the EPA’s silent approval — identified three distinct mechanisms by which RNAi crops could harm non-target organisms, including humans. Nearly a decade later, none of the three mechanisms has been adequately addressed by regulators.

And meanwhile, the food supply has been transformed.

The Gene That Never Asked Permission

The story of how RNAi corn entered American agriculture without public knowledge begins with a regulatory decision in June 2017 that Bill Freese of the Center for Food Safety, reporting to The Atlantic, called a masterpiece of bureaucratic invisibility.

The EPA offered just 15 days of public comment on SmartStax PRO — compared to the standard 60 days for significant regulatory actions. The agency did not post the approval to the Federal Register, the standard mechanism by which the public and Congress are notified of major regulatory decisions. The technology landed in American cornfields with the quiet authority of a memo circulated among insiders — which is essentially what it was.

SmartStax PRO was not a simple product. As I documented in that 2015 article, the approved stack contained six separate modes of action stacked into a single corn variety: the DvSnf7 dsRNA RNAi payload, three separate Bt proteins for rootworm and above-ground pest control, glyphosate tolerance, and glufosinate tolerance. This complexity was not incidental. Embedding the RNAi trait within an already-complex toxicological cocktail made it impossible to isolate RNAi-specific effects in any subsequent field monitoring. If something went wrong in the populations eating this corn, identifying dsRNA as the cause would require a level of molecular epidemiology that the United States has never performed for any agricultural biotechnology.

The EPA’s own Scientific Advisory Panel had flagged “ongoing areas of uncertainty” in its 2016 meeting minutes — concerns that dated back to a 2014 SAP meeting and had not been resolved. The approval went forward anyway.

No new RNAi-specific SAP meeting appears on the EPA’s advisory panel list for 2025 or 2026. The scientific review has not kept pace with the commercial expansion.

Since 2017, Bayer has steadily expanded SmartStax PRO acreage. By the 2024 growing season, Bayer’s seed lineup featured 25 new DeKalb hybrids carrying SmartStax PRO or the related VT4PRO RNAi technology — a second Bayer trait launched commercially in Eastern Canada in 2025. Corteva launched its own competing RNAi corn product, Vorceed Enlist, in 2023, targeting the same DvSnf7 gene sequence in corn rootworm. Both companies’ RNAi acres are additive. The total US footprint of RNAi corn in 2025 is conservatively estimated at 20 to 30 million acres — roughly 20 to 30 percent of the total US corn crop.

That corn is the genomic backbone of approximately 75 percent of processed foods sold in American supermarkets.

Read more

The Clock That Couldn’t Be Drawn

In May 2008, Dr. Newport — a Florida neonatologist — watched her 58-year-old husband Steve try, and fail, to draw a clock. He drew “a few little circles and several numbers just in a very random pattern.” The doctor pulled her aside and told her Steve was “beyond moderate” Alzheimer’s, on the verge of severe (US Against Alzheimer’s). The tremors had started. The reading was gone. The man she had married 40 years earlier was disappearing.

Two days later, after staying up reading patent applications instead of sleeping, she began adding coconut oil to his breakfast. Two weeks later he drew the clock again — recognizably a clock (TEDx: Mary Newport). Within months he was running. He could read. His humor came back (CBN News, 2013).

This is the story of what Newport found in that patent application — and why, eighteen years later, pharma’s $42 billion Alzheimer’s bet is collapsing while a tropical fat in every grocery store keeps outperforming expectation.

The 99% Failure Pharma Doesn’t Like to Talk About

Since 2003, approximately 99% of Alzheimer’s drug trials have failed to live up to expectations (Cummings, Alzheimer’s Research & Therapy, 2019); one analysis pegs the pipeline failure rate at 99.6% (Life Sciences, 2022). For disease-modifying therapies the failure rate has been 100% (Cummings, 2019) approved despite

The drugs that reached market — aducanumab, lecanemab, donanemab — were all built on the amyloid hypothesis: sticky beta-amyloid plaques cause cognitive decline. Aducanumab failed both Phase 3 trials, was resurrected via accelerated FDA approval in 2021 despite the overwhelming opposition from the FDA’s advisory committee regarding the evidence of efficacy, then quietly discontinued. Lecanemab and donanemab clear plaques and slow decline by margins most clinicians call marginal — at a documented cost in brain swelling (ARIA-E) and brain bleeds (ARIA-H). In CLARITY AD, 17.3% of lecanemab patients developed brain bleeds and 12.6% developed brain swelling (van Dyck et al., NEJM, 2023; Eisai trial summary). In the high-dose aducanumab Phase 3 trials, 41% developed ARIA (Salloway et al., JAMA Neurology, 2022).

In TRAILBLAZER-ALZ 2, ARIA-E occurred in approximately 24% of donanemab-treated participants, while ARIA-H occurred in roughly 31%, including several treatment-related deaths. (Sims et al., JAMA, 2023; biochempeg summary).

Worse, the foundational science is under formal investigation. A 2022 Science exposé revealed image manipulation in the 2006 Nature paper that became the most-cited foundation of the amyloid model (Piller, Science, 2022). HHS Secretary Robert F. Kennedy Jr. has described the amyloid pipeline as built on “utter corruption” (Science, May 14, 2025), and in January 2026 he appointed a new Federal Alzheimer’s Advisory Council chair and ten new members tasked with broadening the agenda beyond amyloid. To Senator Susan Collins he committed: “We have an opportunity now to do really good science and find a cure very quickly, and also find out, equally importantly, why so many people are getting Alzheimer’s in this generation” (Collins press release, May 14, 2025).

The pushback was swift, coordinated, and almost entirely from “patient advocacy” organizations whose financial dependencies merit a closer look. The Alzheimer’s Association issued a June 2025 statement explicitly accusing Kennedy of “mischaracterizing” Alzheimer’s research — singling out his invocation of the Type 3 diabetes framing as “inaccurate and misleading,” with CEO Maria Carrillo insisting that “calling insulin dysfunction in the brain ‘diabetes’ obscures and oversimplifies complex diseases and risks misinforming the public.” That is a striking position to take against twenty years of peer-reviewed neurometabolic literature.

The context the press release omits is who pays the rent. The Alzheimer’s Association’s own FY25 industry contributions disclosure — voluntarily published on its website — shows the organization received $1.28 million from Eisai, $875,000 from Biogen, and $1.08 million from Eli Lilly in a single fiscal year. Eisai and Biogen co-market lecanemab. Biogen developed aducanumab. Eli Lilly developed donanemab. These three companies — the makers of the entire amyloid-antibody franchise Kennedy is now questioning — are the Association’s three largest pharmaceutical donors, contributing over $3.2 million combined. Add Genentech/Roche, AbbVie, Johnson & Johnson, Novartis, Merck, Takeda, and the rest of the disclosed roster and the Alzheimer’s Association looks less like an independent patient-advocacy group and more like the public-relations arm of the amyloid pipeline. Its defense of the orthodoxy is not science. It is a balance sheet.

What Kennedy is pointing at, whether he names it or not, is the same biology Mary Newport found in a patent application in 2008.

Type 3 Diabetes: The Real Story of the Failing Brain

In 2005, Brown University researchers led by Dr. Suzanne de la Monte examined the brains of Alzheimer’s patients with no history of diabetes. They found insulin resistance and insulin deficiency in every brain, and coined the term Type 3 diabetes (de la Monte & Wands, J. Diabetes Sci. Tech., 2008). The dysfunction begins 10 to 20 years before symptoms (de la Monte, 2014).

Glucose entry into a neuron depends on insulin signaling. When signaling fails, the cell starves in a sea of sugar — and decreased cerebral glucose metabolism is one of the earliest Alzheimer’s signs on PET, visible years before symptoms (Cunnane et al., Annals NYAS, 2016).

But neurons have a backup fuel. Within ~36 hours of carbohydrate restriction, the liver converts fatty acids into ketone bodies — beta-hydroxybutyrate, acetoacetate, acetone — water-soluble molecules that cross the blood-brain barrier and enter mitochondria without requiring insulin. The starving brain switches fuel and lights back up.

This single insight explains both why the amyloid drugs have failed and why a spoonful of coconut oil produces changes visible within hours.

How Coconut Oil Becomes Brain Fuel

Coconut oil is roughly 66% medium-chain triglycerides (MCTs) by weight — predominantly caprylic acid (C8), capric acid (C10), and lauric acid (C12). Unlike long-chain fats, MCTs bypass bile-salt absorption, travel directly from gut to liver via the portal vein, and are oxidized into ketone bodies within minutes (Cunnane, 2016).

A landmark 2004 NIH-on-Aging study gave 20 adults with Alzheimer’s or MCI a single dose of MCTs. Within 90 minutes, beta-hydroxybutyrate rose significantly — and on cognitive testing, paragraph recall improved in direct proportion to the ketone rise (Reger et al., Neurobiology of Aging, 2004; GreenMedInfo). One dose. Two hours. Measurable improvement.

In 2017, a Journal of Alzheimer’s Disease study exposed live rat cortical neurons to amyloid-beta — the same molecule pharma has spent decades trying to clear — and found that coconut oil rescued the neurons from amyloid-induced mitochondrial damage, preserving normal mitochondrial shape (Nafar et al., reviewed at GreenMedInfo). Not plaque clearance — metabolic rescue.

GreenMedInfo’s coconut oil database now indexes nearly 100 studies across 88 disease states, with neurological benefits the largest category (Stroke entry); the MCT page compiles human trials in epilepsy and dementia. Even coconut water — fat-free, containing the cytokinin trans-zeatin — inhibits amyloid-beta neurotoxicity and acetylcholinesterase in preclinical models (GreenMedInfo).

The University of South Florida’s Byrd Alzheimer’s Institute eventually launched the first randomized crossover trial of coconut oil in mild-to-moderate Alzheimer’s (USAA, March 2015) — a quiet concession that the anecdotal signal could no longer be ignored.

Why You’ve Never Heard of It

Coconut oil sells for fifteen dollars a jar. It is unpatentable. It generates no royalty stream, supports no sales force, funds no CME credits, underwrites no journal supplements. The economic logic of pharmaceutical research is structurally incapable of metabolizing it.

Compare it to lecanemab: $26,500 per patient per year, infusion infrastructure, MRI surveillance for brain bleeds, a clinical effect most geriatricians call marginal. Compare it to the Ketone Ester developed by Prof. Kieran Clarke at Oxford — roughly 10× more potent than coconut oil at raising blood ketones. As Clarke noted in 2013, her lab cannot scale because “there’s no profit in manufacturing stuff like that” (CBN News). The molecule that would most directly deliver Newport’s intervention sits stranded for lack of a business model.

This is what people mean when they say the medical-industrial complex has structural blind spots. It is not a conspiracy. It is a bookkeeping problem with neurological consequences — and exactly the kind of problem any serious NIH reform the new Advisory Council claims to pursue would have to confront to be more than rhetoric.

What To Do, Practically

The protocol Newport developed and that subsequent research has refined:

• Begin with 1–2 teaspoons of organic, non-hydrogenated, virgin coconut oil per meal, working up to 4–6 tablespoons daily as tolerated. Avoid hydrogenated coconut oil (trans fats) (CBN News).

• Combine with MCT oil (caprylic/capric acid) for faster, higher ketone elevation (Reger, 2004).

• Reduce dietary sugar and refined carbohydrate to address the underlying insulin resistance, not just supply backup fuel.

• Layer the broader neuroprotective evidence base: turmeric/curcumin, Mediterranean diet, B vitamins, resveratrol, ginkgo — full database here.

None of this is a cure. None replaces clinical care. But it is a metabolic intervention grounded in published biology, available at any grocery store, costing less than a co-pay, with eighteen years of accumulating evidence behind it.

The Question Behind the Question

The deepest lesson of the Newport story isn’t that coconut oil treats Alzheimer’s. It’s that the question pharma asked for thirty years was the wrong question. The amyloid plaque is not the fire. It is the smoke. The fire is metabolic — a slow starvation of neurons cut off from their fuel by insulin signaling that the modern diet, environmental toxic load, and chronic inflammation have systematically corrupted (de la Monte, 2014).

You cannot solve a metabolic disease with a monoclonal antibody. You solve it by restoring the metabolism — feeding the cell what it can still burn, removing what is poisoning the signaling pathways, and treating the brain as the energetically expensive organ it has always been.

Mary Newport found this at three in the morning because her husband was running out of time. The pharmaceutical industry has had every dollar, every researcher, every regulatory advantage, and eighteen years — and what it delivered costs $26,500 a year and bleeds into the brain.

The coconut was in the kitchen the whole time.

Learn more by watching below Dr. Mary Newport’s video below.

Interested in learning more about natural approaches to dementia and Alzheimer’s? Join the GreenMedInfo.com community here and support our free service giving access to over 100,000 studies to the world by doing so.

Become a GreenMedInfo Member

Share the X thread dedicated to this article on X:

Sayer Ji is the founder of GreenMedInfo.com. The full coconut oil research database — nearly 100 indexed studies across 88 health conditions — is available at greenmedinfo.com/substance/coconut-oil. The companion Alzheimer’s disease research portal is at greenmedinfo.com/disease/alzheimers-disease.

The substrate is not a side note. It’s the story behind CardioNK.

Our wildly popular CardioNK product has a powerful central starter ingredient — natto — and it accounts for why we have received so much customer feedback already on its beneficial effects for digestion and regularity. And one of the most consistent questions we have received is: does it contain soy?

Indeed, when most people picture natto, they picture soybeans — slimy, pungent, threaded together with the unmistakable strings of Bacillus subtilis var. natto at work. That image is a thousand years old, and it has shaped the entire modern nattokinase and vitamin K2 (MK-7) supplement category. Walk down any cardiovascular aisle and the soybean is the silent assumption behind every capsule.

We chose to break that assumption. Our fermented natto is built on chickpeas (Cicer arietinum), and the decision was not aesthetic. It was driven by what the bacterium actually needs to produce a high-activity enzyme, by what the consumer actually needs in a daily delivery vehicle, and by what the published science says about the substrate as a living matrix — not merely a food for the microbe, but a structural partner in the final product.

This is the long-form explanation of why.

1. The substrate is the bacterium’s environment — and chickpea is the better one

The first thing to understand is that nattokinase and MK-7 are not chickpea molecules or soybean molecules. They are Bacillus subtilis molecules. The legume is the bacterium’s habitat — its food, its scaffold, its signaling environment. Change the habitat, and you change the bacterium’s behavior.

When researchers actually run the comparison head to head, chickpea wins on the metrics that matter:

• In an optimized solid-state fermentation, cracked chickpea produced nattokinase activity of ~356 FU/g — about 22% higher than cracked soybean under identical conditions, with only ~28% of the γ-PGA (poly-γ-glutamic acid) byproduct that soy fermentation generates (Toku Health summary of Wei et al.).

• A separate Chinese patent on a high-yielding B. subtilis DC-Tx strain reported fibrinolytic activity up to 3,000 FU/g on chickpea substrate, with hydroxyl-radical scavenging of 88.5% and iron-reducing power 3.33× that of unfermented chickpea — i.e. the fermentation itself amplifies the antioxidant chemistry of the bean (CN104212741A patent).

• A comparative study of ten plant substrates fermented by B. subtilis var. natto showed MK-7 yields are not soy-exclusive — most legumes and seeds support strong menaquinone-7 biosynthesis, and several non-soy substrates outperformed soy (Sciendo, 2021).

The takeaway is plain: the long-held assumption that “soy = best substrate” is a cultural inheritance, not a biochemical one. Chickpea matches or exceeds soy on enzyme activity while shedding most of soy’s downsides.

2. Chickpea fibers actively trigger Bacillus subtilis biofilm formation

This is the part of the science that genuinely surprised us, and it is the reason chickpea became non-negotiable for us.

A 2021 study in Nutrients — Amoah et al., “Chickpea-Derived Prebiotic Substances Trigger Biofilm Formation by Bacillus subtilis“ — demonstrated that chickpea-derived fibers (CPF) are not a neutral growth medium. They are a signaling molecule. (PMC8704855)

Specifically, the researchers showed:

• Chickpea fiber upregulates the tapA operon — one of the master biofilm-matrix genes in B. subtilis — in a dose-dependent manner. Cellulose and other generic fibers do not produce the same effect.

• CPF triggers robust pellicle formation (the air–liquid biofilm) and the production of pulcherrimin, an iron-binding antimicrobial pigment that protects the colony from pathogenic competitors.

• Scanning electron microscopy showed B. subtilis cells physically embedding onto and into the chickpea fibers — not just floating in suspension. The fiber becomes part of the bacterial architecture.

Why does this matter for a finished natto product? Because biofilm-encapsulated B. subtilis is a fundamentally different organism than planktonic B. subtilis. It is more metabolically active, more resistant to environmental stress, and — critically for a supplement — more likely to survive the trip through the stomach.

3. Chickpea fiber acts as a protective matrix through digestion

The Amoah team did not stop at imaging. They ran the chickpea-encapsulated B. subtilis through a simulated digestion system and measured survival.

The result: chickpea-fiber-grown B. subtilis survived simulated gastric and intestinal digestion at roughly 100-fold higher rates than control cells — a 2-log CFU/mL increase over standard media, and significantly better than wheat fiber (0.6 log) or cellulose fiber (1 log) (PMC8704855).

This is the protective-matrix claim, validated experimentally. Chickpea is not just a food the bacterium grows on. It is:

• A biofilm inducer (via tapA upregulation and pulcherrimin synthesis)

• A physical scaffold the cells colonize and adhere to

• A gastric shield that carries viable, metabolically competent B. subtilis into the lower GI tract, where it can continue to produce metabolites, support the microbiome, and exert downstream effects

For a fermented natto product whose value proposition includes both the enzyme (nattokinase, MK-7) and the living organism (probiotic B. subtilis), this is a substrate that does double duty. Soy does not do this. Cellulose does not do this. Wheat fiber does not do this. Chickpea does.

4. The allergen, phytoestrogen, and γ-PGA problem

There is also what chickpea doesn’t bring with it.

Soy allergy. Soy is one of the U.S. “Top 9” allergens. For a daily cardiovascular supplement intended for long-term use, building it on one of the most common food allergens is a design choice with consequences. Chickpea is not on the Top 9 list and represents a completely different allergen class.

Phytoestrogens. Soy carries one of the highest dietary isoflavone loads of any common food — daidzein and genistein in totals that routinely reach 100–200 mg per 100 g in soy flour, per the USDA Isoflavone Database. Chickpea’s profile is dominated by biochanin A and formononetin — different isoflavones, at substantially lower concentrations in the unsprouted bean (Yang et al., J. Agric. Food Chem. 2015). For consumers and clinicians concerned about long-term hormonal exposure from daily supplementation, this is a meaningful reduction.

γ-PGA (poly-γ-glutamic acid). This is the sticky, stringy polymer that gives traditional natto its signature texture — and it is also the byproduct most associated with natto’s allergenic reactions and the purification headaches that plague commercial nattokinase manufacturing. Chickpea fermentation generates roughly 72% less γ-PGA than soy fermentation under matched conditions (Toku Health summary). Less PGA means cleaner extraction, lower allergenicity, and a more stable final product.

5. The phytoestrogen story is better than “less” — it’s “the right ones, made bioavailable”

There is a subtlety worth drawing out, because it is one of the most interesting things about building natto on chickpea rather than soy — and it deserves to be stated plainly rather than buried.

Section 4 noted that the raw chickpea carries a far lighter isoflavone load than soy. That is true of the bean as it sits in the bag. But CardioNK is not raw chickpea — it is fermented chickpea, and processing changes the phytoestrogen picture substantially. Germination alone can increase chickpea isoflavone content by over 100-fold, with germinated chickpea surpassing germinated soybean roughly five-fold in total isoflavonoid content (Wu et al., J Agric Food Chem 2012). The “low-phytoestrogen” intuition applies to the raw seed, not to processed chickpea.

The body sees the same molecules. It simply arrives at them from a precursor that is gentler on the way in.

Chickpea’s two signature isoflavones are biochanin A and formononetin. Soy’s are genistein and daidzein. For years these were treated as different families with different effects. They are not. In the gut and liver, biochanin A is O-demethylated into genistein, and formononetin into daidzein — meaning the chickpea isoflavones converge on the same bioactive end-products as soy at the systemic level (Megías et al., J Funct Foods 2016).

What fermentation adds is bioavailability. Microbial β-glucosidases cleave the bound glucoside forms of these isoflavones into free aglycones — the form the small intestine absorbs fastest and most completely (Hsiao et al., J Funct Foods 2020). Significant levels of these absorbable aglycones are found almost exclusively in fermented foods like tempeh and miso. A fermented chickpea is therefore not a weaker phytoestrogen source than soy; it is a cleaner-precursor, higher-bioavailability one — the same beneficial end-products, in their most absorbable form, without soy’s allergen profile and with a fraction of the γ-PGA.

The clinical literature on these isoflavones is not soft. Biochanin A and formononetin show documented anti-inflammatory activity (COX-2, iNOS, NF-κB, and NLRP3 inflammasome suppression), cardiovascular effects (reduced LDL oxidation and lower VCAM-1/ICAM-1/MCP-1 expression on vascular endothelium), insulin-sensitizing action, bone-protective effects in ovariectomized models, and neuroprotective signaling through the PI3K/AKT and Nrf-2/HO-1 pathways (de Camargo et al., Int J Mol Sci 2019; Yang et al., Int J Mol Sci 2022). These are precisely the cardiometabolic and vascular targets CardioNK is built around — which means the substrate’s phytochemistry is pulling in the same direction as its enzyme and vitamin payload.

The honest version: Choosing chickpea did not mean giving up the documented benefits of dietary isoflavones. It meant keeping those benefits, converting them into their most absorbable form through fermentation, and shedding the allergen and texture-polymer liabilities bundled with soy. The phytoestrogen is not a cost we minimized — it is another instance of the substrate doing work.

6. Chickpea has its own clinical record — separate from the bacterium

Even before fermentation, chickpea is one of the most clinically studied pulses in the human diet. The PubMed clinical-trial record for chickpea includes randomized controlled trials demonstrating:

• Improved postprandial glycemic control and gut-hormone (GLP-1, PYY) secretion from chickpea-flour-enriched foods (Am J Clin Nutr, 2023; Food Res Int, 2024)

• Improved endothelial function — sprouted chickpea flour in pasta increased brachial artery flow-mediated dilation in a randomized trial (Physiology International, 2019)

• Cardiometabolic risk reduction in pulse-based dietary interventions for PCOS and metabolic syndrome (Nutrients, 2018)

• Lower metabolizable energy than predicted by Atwater factors — chickpea delivers ~10% fewer absorbed calories than the label implies, with the difference fermented in the colon to short-chain fatty acids (Nutrients, 2025)

For a product whose primary clinical targets are cardiovascular and metabolic — blood viscosity, fibrinolysis, arterial calcification (MK-7’s domain), endothelial health — building on a substrate with its own independent cardiometabolic clinical evidence is a compounding effect, not a coincidence.

7. Summary: why chickpea, in one breath

We chose chickpea as the base for our fermented natto because it is the only substrate we evaluated that simultaneously:

1. Yields higher nattokinase activity than soy under matched conditions (~22% higher FU/g in head-to-head studies, up to 3,000 FU/g with optimized strains)

2. Supports robust MK-7 (vitamin K2) biosynthesis by B. subtilis — the same metabolic pathway that operates on soy, with no penalty

3. Actively induces biofilm formation in B. subtilis via dose-dependent upregulation of the tapA matrix operon — a signaling effect specific to chickpea fiber

4. Functions as a protective matrix that delivers ~100-fold higher B. subtilis survival through simulated gastric digestion

5. Eliminates soy allergen exposure, drops phytoestrogen load substantially, and cuts γ-PGA byproduct by ~72%

6. Carries an independent clinical record for postprandial glucose, gut hormones, endothelial function, and cardiometabolic risk — all directly relevant to the populations we expect to use the product

In other words: the substrate is doing work. It is feeding the bacterium, signaling the bacterium, housing the bacterium, shielding the bacterium through the stomach, and contributing its own clinically demonstrated benefits to the person taking the final product.

A soy-based natto is a fermentation. A chickpea-based natto, as we’ve built it, is a synbiotic delivery system — enzyme, vitamin, viable probiotic, and prebiotic matrix in a single fermented food.

That is why we chose the chickpea. The bean is not the side note. It is the architecture.

If you are looking for a product that is focused on supporting healthy gut health and healthy circulation, learn more about CardioNK.

Selected references

Amoah YS, Rajasekharan SK, Reifen R, Shemesh M. Chickpea-Derived Prebiotic Substances Trigger Biofilm Formation by Bacillus subtilis. Nutrients. 2021;13(12):4228. doi:10.3390/nu13124228. PMID:34959781.

Wei X, Luo M, Xu L, et al. Production of Fibrinolytic Enzyme from Bacillus amyloliquefaciens by Fermentation of Chickpeas. J Agric Food Chem. 2011;59(8):3957–3963. doi:10.1021/jf1049535.

Liu et al. Bacillus subtilis Producing Fermented Chickpea Having Fibrinolytic and Antioxidant Function. Patent CN104212741A, 2014.

Method for Producing Nattokinase by Fermenting Chickpea. Patent CN103387970A, 2012.

Berenjian A, et al. Advances in Enhanced Menaquinone-7 Production From Bacillus subtilis. Front Bioeng Biotechnol. 2021;9:679970. doi:10.3389/fbioe.2021.679970.

Popa A, et al. Preparation of Vitamin K2 MK-7 by Fermentation of Various Plant Materials by Bacillus subtilis var. natto. Acta Universitatis Cibiniensis. 2021.

Mahanta N, et al. Development of Menaquinone-7 Enriched Nutraceutical. J Food Sci Technol. 2014. PMCID:PMC4519498.

Wu Z, Song L, Feng S, et al. Germination Dramatically Increases Isoflavonoid Content and Diversity in Chickpea Seeds. J Agric Food Chem. 2012;60(35):8606–8615. doi:10.1021/jf3021514. PMID:22816801.

Gao Y, Yao Y, Zhu Y, Ren G. Isoflavone Content and Composition in Chickpea Sprouts Germinated under Different Conditions. J Agric Food Chem. 2015;63(10):2701–2707. doi:10.1021/jf5057524. PMID:25630489.

Megías C, Cortés-Giraldo I, Alaiz M, Vioque J, et al. Isoflavones in Chickpea Protein Concentrates. J Funct Foods. 2016;24:330–337. doi:10.1016/j.jff.2015.12.042.

Hsiao YH, Ho CT, Pan MH. Bioavailability and Health Benefits of Major Isoflavone Aglycones and Their Metabolites. J Funct Foods. 2020;74:104164. doi:10.1016/j.jff.2020.104164.

de Camargo AC, Favero BT, Morzelle MC, et al. Is Chickpea a Potential Substitute for Soybean? Phenolic Bioactives and Potential Health Benefits. Int J Mol Sci. 2019;20(11):2644. doi:10.3390/ijms20112644. PMID:31146372.

Yang SE, Lien JC, Tsai CW, Wu CR. Therapeutic Potential of Novel Simple O-Substituted Isoflavones against Cerebral Ischemia Reperfusion. Int J Mol Sci. 2022;23(18):10394. doi:10.3390/ijms231810394. PMID:36142301.

Clark JL, Taylor CG, Zahradka P. Insulin-Sensitizing Actions of Soybeans, Chickpeas, and Their Bioactive Compounds. Nutrients. 2018;10(4):434. doi:10.3390/nu10040434. PMID:29601521.

Milán-Noris AK, Gutiérrez-Uribe JA, Santacruz A, et al. Peptides and Isoflavones in GI Digests Contribute to the Anti-Inflammatory Potential of Cooked or Germinated Chickpea. Food Chem. 2018;268:66–76. doi:10.1016/j.foodchem.2018.06.068. PMID:30064805.

Ali SE, El Badawy SA, Elmosalamy SH, et al. Reproductive and Metabolic Effects of Cicer arietinum L. Extract on Letrozole-Induced PCOS in Rat Model. J Ethnopharmacol. 2021;278:114318. doi:10.1016/j.jep.2021.114318. PMID:34111539.

Novotny JA, et al. Metabolizable Energy Value of Chickpeas and Lentils. Nutrients. 2025. PMID:40944115.

Toku Health. Soy-Free Nattokinase: Chickpea vs Soy Fermentation. 2026.

Updated May 30, 2026 • Based on peer-reviewed literature indexed in PubMed/NCBI and publisher databases • For educational purposes only • Consult a healthcare professional before making dietary or therapeutic decisions.

There is a question that almost no physician asks the chronically fatigued patient sitting across from them: What kind of water are you drinking?

Not how much. What kind.

Because here is the problem that most hydration conversations — even the good ones — never reach: drinking more water is not the same as hydrating your cells. The two can diverge dramatically depending on the mineral matrix, ionic structure, and biological compatibility of what you are actually consuming. A person who faithfully drinks eight glasses of reverse osmosis water every day may still be operating in a state of chronic cellular dehydration — because the water they are drinking water that carries no mineral signal the cell can read, leaching minerals on its way through, and never reaches the structured, bioavailable form that the body evolved to use.¹

This is the distinction I have come to call biological water — and understanding it changes everything about how we think about fatigue, cellular energy, and what genuine hydration actually requires.

The Energy Crisis Nobody Is Diagnosing

Chronic fatigue is one of the most common complaints in modern clinical medicine. It has generated an entire diagnostic ecosystem: adrenal fatigue, mitochondrial dysfunction, thyroid dysregulation, chronic fatigue syndrome, post-viral syndromes, and a sprawling supplement market offering solutions to a problem the model may never have correctly identified.

The question that rarely gets asked is the most elementary one: Is the cell short on the substrate it needs to generate ATP in the first place?

Not the nutrient substrate. The water substrate.

Dr. Fereydoon Batmanghelidj — the Iranian-American physician whose book Your Body’s Many Cries for Water first surfaced this architecture in clinical terms — spent decades arguing that chronic, low-grade, unrecognized dehydration underlies a far wider range of degenerative disease than medicine has been willing to examine.² His clinical observations were striking. Patients who had made no progress on intensive supplement programs suddenly showed dramatic shifts — in cholesterol, in energy, in cognition — within weeks of correcting their water intake.

But the deeper story is not simply about volume. It is about the mechanism. And the still largely underreported mechanism begins inside the mitochondria.

What the Textbooks Left Out

Open any biochemistry textbook and you will find the same architecture repeated without qualification.

Energy comes from food. Glucose — a six-carbon sugar derived from the breakdown of carbohydrates, proteins, and fats — enters glycolysis, a ten-step enzymatic sequence that yields two molecules of ATP. The pyruvate that results moves into the mitochondria, threads through the citric acid (Krebs) cycle, and finally, via oxidative phosphorylation on the inner mitochondrial membrane, generates 34 more ATP molecules. Total: 38 ATP per glucose molecule — presented as the primary and essentially sole source of bioenergetic currency in every cell in the body.³

This framing is not wrong, exactly. It is radically incomplete.

The Krebs cycle releases approximately 20 neutral hydrogen atoms per revolution. These atoms are the essential feedstock for the 34-ATP windfall of oxidative phosphorylation. Without them, the entire downstream energy cascade fails. The question of where those hydrogen atoms come from is treated in textbooks as a footnote — mentioned almost in passing.

They come from water.

Specifically, from hydrolysis — the chemical reaction in which water molecules react with the intermediary metabolites of glucose breakdown, releasing hydrogen atoms into the chain.⁴ As Dr. Batmanghelidj observed in his clinical review of the literature: water is not a passive solvent in this process. It is as critical to ATP production as glucose itself — because without sufficient water available at the mitochondrial level, insufficient hydrogen atoms are generated to run the oxidative phosphorylation chain at full capacity.⁵

This means that the energy you experience as vitality, cognition, motivation, and muscular strength depends not only on what you eat, but on how hydrated your cells are at the biochemical level.

That is not a wellness claim. That is standard biochemistry — with a piece missing from the standard telling.

The Hydroelectric Architecture: Your Cells Are Powered by Water

The mechanism runs deeper still.

The interior of the cell maintains a higher osmolality — a higher solute concentration — than the surrounding extracellular fluid. Scientists have precisely calculated this ratio at approximately 1.1 (intracellular) to 0.8 (extracellular) in a healthy cell.⁶ Because water flows from lower to higher concentration across a permeable membrane, water continuously passes inward through the cell wall — 24 hours a day, for the entire life of the cell.

To manage this constant inward flow, cell membranes operate the sodium-potassium ATP pump — a system every first-year medical student learns. But here is the piece the professors typically omit, and which Batmanghelidj identified from the primary literature: the movement of water into the cell through the membrane does not merely create a problem the pump must solve. It generates an immense source of energy. The osmotic flow of water acts as a microscopic hydroelectric turbine — producing more ATP than the pump process itself consumes.⁷

This is not metaphor. It maps directly onto the electromagnetic physics inside the mitochondrion itself. As I explored in yesterday’s post on the methylene blue debate, the inner membrane of a single mitochondrion maintains an electric field of approximately 30 million volts per meter — comparable in density to a lightning bolt — arising from a voltage of roughly 150 millivolts across a membrane just 5 nanometers thick.⁸

Harnessing this gradient is a molecular turbine called ATP synthase, whose rotor spins at up to 9,000 RPM as protons cascade down the electrochemical gradient — minting three molecules of ATP per rotation, recycling roughly the body’s own weight in ATP every single day.⁹ Water is the medium through which this entire electromagnetic architecture operates.

Dehydrate the system and you are not simply losing fluid. You are throttling the turbine.

Dr. Batmanghelidj proposed — drawing from primary literature — that up to 90% of all energy stored as ATP may derive not from the breakdown of glucose, but from the hydroelectric processes at the cell membrane’s cation pumps.¹⁰ If that figure is even directionally correct, the implications for how we understand fatigue, disease, and the role of water in human biology are profound.

And there is one further layer. ATP itself releases its stored potential energy through hydrolysis — the reaction of ATP with water to form ADP. Researchers have calculated that while ATP contains the equivalent of approximately 600 relative units of energy in its high-energy phosphate bond, the hydrolysis of ATP releases a total of approximately 6,435 units of usable energy — more than ten times the potential energy contained in the bond itself.¹¹ Water is embedded in the energy architecture not only at the input end (providing hydrogen for ATP synthesis) but at the output end (amplifying the energy released when ATP is spent). Dehydration compromises both ends of the system simultaneously.

The Brain Pays First

The body does not distribute the consequences of dehydration evenly.

The brain weighs roughly two and a half pounds, yet consumes 20 to 25% of the body’s entire energy output — making it the most metabolically expensive organ in the body relative to its mass.¹² Its neurons consist of approximately 85% water in their healthy state — significantly higher than the 75% water content of most other body cells.¹³

Even subtle, subclinical dehydration that reduces the water content of those neurons impairs glucose metabolism, ATP production, and cellular energetics. The consequence, at one end of the spectrum, is mild fatigue, depression, and cognitive malaise. At the more serious end of chronic water deficiency, the trajectory points toward neurological disease.¹⁴

The trajectory from “I’m tired all the time” to “I can’t concentrate” to “something is neurologically wrong” may not require a novel pathogen or a genetic misfortune. It may require only the sustained failure to provide the brain’s neurons with sufficient water — and, critically, with water structured in a form those neurons can actually absorb and use.

The Thirst Signal Has Already Failed

Here is the piece of the architecture that makes chronic cellular dehydration so difficult to self-diagnose.

In states of chronic dehydration, the thirst regulatory system in the brain downregulates. The body learns not to signal thirst, even when water is urgently needed.¹⁵ Most people suffering from chronic low-grade dehydration report no sensation of thirst whatsoever. The most intuitive measure of hydration status — “do I feel thirsty?” — is precisely the signal that fails first and most completely in the people who need water most.

The body is not broken. It is adapting to a sustained stress. But that adaptation, left unaddressed, cascades across energy production, membrane integrity, cholesterol metabolism, insulin signaling, and neurological function in ways that become progressively harder to reverse.

The Caffeine Trap: A Self-Reinforcing Architecture of Depletion

The modern response to low energy is a caffeinated beverage — coffee, black tea, energy drinks, wellness tonics branded as “natural energy.” The logic seems sound: caffeine increases alertness, and alertness feels like energy.

But caffeine is a well-established diuretic. For every 10 ounces of a caffeinated beverage consumed, the body can lose up to 12 ounces of water — a net deficit rather than a net contribution to cellular hydration.¹⁶ Even non-caffeinated herbal teas, widely assumed to count as healthy hydration, carry a diuretic load from the complex combination of bioactive compounds and high potassium levels they contain, creating an osmotic effect that draws water out rather than delivering it.¹⁷

The fatigued person drinks coffee to feel alert. Their cells become more dehydrated. ATP production declines. The fatigue deepens. They drink more coffee. The architecture of the problem self-reinforces, and the root cause — cellular water deficit — is never addressed, because the conventional conversation never identified it correctly in the first place.

What Cholesterol Is Actually Telling You

The water deficit leaves signatures across the body that get misread as independent disease states.

Water functions as the primary adhesive in cell membranes — its electrically charged polar surfaces maintain the complex lipid and protein molecules of the membrane structure in their proper positions, governing the movement of nutrients into cells and waste products out. In a state of chronic water deficiency, as water levels in the membranes fall, nutrient transport efficiency declines and the membrane structure itself becomes less stable.¹⁸

In this situation, the liver begins synthesizing and releasing cholesterol into the bloodstream. This lipid can substitute for water as a membrane adhesive — a last-resort structural solution that preserves cellular membrane function when water is insufficient.¹⁹

My colleague, the late Dr. Nicholas Gonzalez — whose clinical review of this mechanism appears at GreenMedInfo²⁰ — described one patient whose total cholesterol had continued climbing toward 300 mg/dL despite intensive nutritional supplementation and a rigorous organic diet. When the patient eliminated herbal tea and substituted adequate plain water with appropriate mineral support, total cholesterol dropped 63 points within six weeks, and HDL rose substantially. Water accomplished in six weeks what a year of supplementation had not.²¹

So elevated cholesterol, in the context of undiagnosed chronic dehydration, may not be a defect to be suppressed with a statin. It may be the body’s adaptive intelligence, clearly legible once you know how to read the signal.

The Problem Plain Water Cannot Solve

This is where the standard hydration conversation — even the good version of it — stops short.

Reverse osmosis filtration has become the gold standard for household water purification, and for legitimate reasons. It removes heavy metals, pharmaceutical residues, chlorine, fluoride, and a broad range of industrial and biological contaminants found in municipal tap water. The water it produces is chemically clean.

But chemical cleanliness is not the same as biological utility.

The World Health Organization, after decades of investigation, has raised formal concerns about long-term consumption of demineralized water — specifically commissioning the report Nutrients in Drinking Water to examine the health consequences of reverse osmosis and desalination.²² The core mechanism is documented: RO water removes 92–99% of dissolved minerals, including calcium, magnesium, and potassium.²³ When consumed, this mineral-depleted water does not simply fail to deliver minerals — it actively leaches them. Because the hypo-osmotic water seeks ionic equilibrium across tissue gradients, it pulls minerals out of bones, teeth, and soft tissue as it passes through.²⁴ Czech and Slovak populations who adopted RO systems for home drinking water in 2000–2002 reported cardiovascular disorders, fatigue, weakness, and muscle cramps within weeks to months of switching — symptoms consistent with acute magnesium and calcium deficiency.²⁵

Bottled water presents a parallel problem. Much of what is sold as premium bottled water is softened, demineralized, or processed in ways that strip the mineral matrix, and is contaminated with microplastics. The packaging may change. The biological deficiency may not.

There is a deeper dimension still — one that Dr. Gerald Pollack’s foundational research on the fourth phase of water has illuminated, and whose amazing Washington University laboratory I have had the immense privilege visiting in Seattle. The water inside healthy cells is not the same as the liquid water in your glass. It is a structured, gel-like, negatively charged phase — what Pollack calls Exclusion Zone (EZ) water — that forms at hydrophilic (water-loving) surfaces, including the inner surfaces of cell membranes and protein structures throughout the body.²⁶ EZ water excludes solutes, holds electrical charge, and stores energy in a way that bulk liquid water cannot. As Pollack has stated: understanding this fourth phase “may be the key to unlock the door” to many biological phenomena still not fully explained by conventional biochemistry.²⁷

What this means practically: the cellular goal is not simply consuming more liquid. It is consuming water — and mineral cofactors — that support the body’s capacity to build and maintain EZ water inside the cell. Plain RO water, stripped of the ionic mineral matrix that interacts with hydrophilic surfaces to generate structured water, may be fundamentally incompatible with that process.

This is the problem that biological water is designed to solve.

What Biological Water Actually Is

I have been developing and refining this concept for some time — and in the video below, I walk through it in detail, including the daily ritual I use and the specific formulation I rely on when traveling, training, or moving through intense work seasons:

🌊 The Hydration Hack That Changes Everything — watch the full interview here

Biological water is best obtained from water-rich foods such as watermelon, celery, apples, and all the wonderful foods our ancestors harvested in whole form directly from the Earth itself. Failing adequate levels of these, the solution begins with clean water — reverse osmosis, distilled, or high-quality filtered — as the base. The purification is not the problem. The stripping is. The solution is to restore what was removed: the mineral matrix, the ionic ratios, the organic acids, and the probiotic terrain support that together transform inert H₂O back into something the body evolved to recognize and use at the cellular level.

The analogy from nature is precise. Ancient spring water, water drawn from mineral-rich geological formations, the cellular fluid of marine organisms, and the water held inside living plants all carry this mineral complexity. Human physiology evolved alongside this kind of water across millions of years. The demineralized, processed, electrically inert water that fills most of our bottles and taps is, in evolutionary terms, an extremely recent novelty — and the body’s response to it may be showing up as the fatigue, the mineral deficiency, the dysregulated thirst, and the cascading cellular energy failures that the conventional model cannot explain.

Restoring the Architecture: ViCera HYDRATE

The product I use daily to convert purified water into biological water is ViCera’s HYDRATE. It does something the leading electrolyte and sports hydration brands do not: it reconstructs the biological water architecture across multiple simultaneous layers.

The mineral foundation: Celtic® Sea Salt — hand-harvested and unprocessed, containing 82 minerals and trace elements, including three distinct forms of magnesium (chloride, bromide, and sulfate) along with the specific ratios of sodium and potassium that the formula identifies as responsible for driving hydration at the cellular level.²⁸ This is not table salt processed into a single sodium chloride compound. It is a whole mineral matrix with the ionic complexity that approaches what is found in the original marine environment from which terrestrial life emerged.

Ocean-derived trace elements: Red algae contributes calcium, magnesium, and dozens of additional trace elements in naturally occurring form — not as isolated synthetic compounds but in the matrix in which they evolved to be bioavailable.²⁹

Organically chelated trace minerals: Organic spirulina provides chromium, selenium, and copper bound as multi-amino acid chelates — the organic binding that confers bioavailability, delivering trace minerals that perspiration and daily metabolic demand continuously deplete.³⁰ The spirulina in this formula also carries phycocyanin, the blue pigment I discussed at length in yesterday’s methylene blue piece — a molecule that donates electrons productively into the mitochondrial respiratory chain with a safety profile and evidence base that no synthetic electron-shuttle compound has approached.³¹

The living mineral liberation system: Bacillus subtilis AB22 — described by ViCera as a “mineral liberator” — and which we highlighted recently in our CardioNK flagship product generates enzymes that help unlock bound minerals from dietary plant foods throughout the day, extending the hydration and mineralization window far beyond the single moment of supplementation and delivering what they describe as round-the-clock mineral support.³² This is a critical distinction from static electrolyte formulas: a probiotic that actively improves the terrain of the gut through which all minerals must pass.

Humic soil extract: A broad array of organically bound minerals alongside humic and fulvic acids — functioning simultaneously as a mineral transport system, a prebiotic, and a postbiotic support mechanism that conditions the gut terrain for optimal mineral absorption.³³

Choline: Supporting neurotransmitter function and cognitive performance — a nutrient estimated to be deficient in approximately 90% of the US population.³⁴

The result, taken together, is water the cell can recognize. Not water that cycles through you and carries minerals out on its way.

HYDRATE is available in capsule form for those who want no sweeteners or flavors — ideal for use with a clean glass of water — and in Limeade and Very Berry powders for those who prefer a palatable daily drink. For the GreenMedInfo community, the greatest discount they have yet to offer — 40% off —is auto-applied through the link below, or use code HYDRATE40 at checkout:

👉 viceranutrition.com/collections/hydration

Your purchase directly supports GreenMedInfo’s research, education, and global mission.

The Complete Protocol

Synthesizing the clinical and biochemical evidence reviewed here, the practical framework is coherent:

Volume: 8 to 10 eight-ounce glasses of water daily — not substituted by tea, coffee, juice, or any other beverage. The first intervention is volume. The second is quality. [Note: I start my day by drinking a half a liter of Hydration packet infused RO-purified water, with two of the CardioNK capsules. The side benefit is that it helps with regularity, first thing in the morning - better than coffee.]

Mineral reconstitution: If your water source is RO or demineralized, a biological water formula that restores the complete ionic and organic mineral environment is the correction — not an optional enhancement. For each 10 glasses of water, Dr. Batmanghelidj also recommended approximately half a teaspoon of a full-spectrum sea salt to replace what increased urination removes.³⁵

Eliminate diuretics: Remove caffeinated beverages as primary liquid intake. Reduce herbal teas, particularly for those already experiencing fatigue.

Do not trust thirst alone: The signal has been downregulated. Drink on a schedule, not in response to a felt need.

Consider structure: Practices that build EZ water in the body — sunlight exposure, infrared light, grounding, and movement — work synergistically with mineral-rich hydration to support the cell’s capacity to maintain its structured water matrix.³⁶

The Body Has Not Forgotten How to Generate Energy

The fatigue that plagues modern life — the mid-afternoon collapse, the morning fogginess, the chronic malaise that no supplement entirely resolves — is not an unsolvable mystery.

In many cases, it is a water deficit expressing itself through the only language the body has: disrupted function. And in a significant subset of those cases, the water being consumed is not biological water. It is chemically clean but biologically inert — stripped of the mineral matrix, the ionic complexity, and the structural potential that the cell evolved to use as its primary energy substrate.

The mechanism is not speculative. The hydrogen atoms that feed oxidative phosphorylation come from water. The hydroelectric gradients at the cell membrane generate the majority of cellular ATP. The amplification of ATP’s energy potential through hydrolysis requires water. The structured EZ water inside healthy neurons requires a mineral-rich, ionically complex water environment to form and sustain itself. And the thirst signal that would alert us to any of this failure has already been silenced by the very dehydration it was designed to detect.

This is not a call to abandon every other intervention. It is a call to restore the most fundamental substrate first — before adding complexity to a system that may simply be running on the wrong kind of water.

The body is not broken. It is waiting for water it can recognize.

Leave a comment

Share

Subscribe now

For the full discussion of the biological water concept and the daily protocol I use personally, watch the interview: 🌊 The Hydration Hack That Changes Everything.

For the deeper dive into mitochondrial ATP dynamics — the 30-million-volt electric field, the ATP synthase rotor, and the energy architecture your mitochondria are running right now — read yesterday’s post: The Methylene Blue Mistake.

For the foundational clinical and biochemical review: Water, Energy, and the Perils of Dehydration at GreenMedInfo.

For biological water in practice: ViCera HYDRATE — code HYDRATE40 for 40% off.

Endnotes

¹ Kozisek F. Health Risks from Drinking Demineralised Water. World Health Organization, Nutrients in Drinking Water, 2005. Available at: https://www.who.int/water_sanitation_health/dwq/nutrientschap12.pdf

² Batmanghelidj F. Your Body’s Many Cries for Water. 3rd ed. Global Health Solutions; 2008. Available at: https://www.amazon.com/Your-Bodys-Many-Cries-Water/dp/0970245882

³ Berg JM, Tymoczko JL, Stryer L. Biochemistry. 8th ed. W.H. Freeman; 2015. Chapters 16–18 (Glycolysis, Citric Acid Cycle, Oxidative Phosphorylation). Available at: https://www.ncbi.nlm.nih.gov/books/NBK21154/

⁴ Ibid. The role of water molecules (hydrolysis) in releasing hydrogen atoms for the Krebs cycle and oxidative phosphorylation chain is described in the NAD⁺/NADH and FAD/FADH₂ reduction steps throughout Chapter 17.

⁵ Gonzalez NJ. Water, Energy, and the Perils of Dehydration. GreenMedInfo Blog, 2023. Available at: https://greenmedinfo.com/blog/water-energy-and-perils-dehydration

⁶ Batmanghelidj F. Your Body’s Many Cries for Water, op. cit. The 1.1:0.8 intracellular-to-extracellular density ratio is discussed in the context of the sodium-potassium pump and osmotic water flow.

⁷ Ibid. Batmanghelidj describes the osmotic flow of water through cell membranes as a “hydroelectric” energy-generating process, citing primary literature on cation pump energetics. See also the summary at: https://worldwidehealthcenter.net/bodys-many-cries-water/

⁸ Lane N, Martin W. The energetics of genome complexity. Nature. 2010;467:929–934. Mitochondrial membrane potential and the derived electric field (30 MV/m) are catalogued in the Harvard BioNumbers database, entry #105801. Available at: https://bionumbers.hms.harvard.edu/bionumber.aspx?id=105801&ver=6. Discussed in detail in: Sayer Ji. The Methylene Blue Mistake: How a 19th-Century Textile Dye Became a “Mitochondrial Medicine.” Sayer Ji’s Substack, May 26, 2026. Available at: https://sayerji.substack.com/p/the-methylene-blue-mistake-how-a

⁹ Boyer PD. The ATP synthase — a splendid molecular machine. Annual Review of Biochemistry. 1997;66:717–749. ATP synthase rotor speed (~100 rotations/sec = ~6,000 RPM under physiological load, with peak estimates to 9,000 RPM) is referenced in multiple biophysics sources. Available at: https://www.annualreviews.org/doi/10.1146/annurev.biochem.66.1.717

¹⁰ Batmanghelidj F. Your Body’s Many Cries for Water, op. cit. The 90% ATP-from-hydroelectric-processes claim is drawn from Batmanghelidj’s synthesis of cation pump energetics literature, discussed in Gonzalez, op. cit.

¹¹ George P, Witonsky RJ, Trachtman M, Wu C, Dorwart W, Richman L, Richman W, Shuray F, Lenowitz F. “Squiggle-H2O.” An enquiry into the importance of solvation effects in phosphate ester and anhydride reactions. Biochimica et Biophysica Acta. 1970;223(1):1–15. Available at: https://doi.org/10.1016/0005-2728(70)90126-5. Discussed in Gonzalez, op. cit., citing Batmanghelidj’s summary of George et al.: ATP hydrolysis releases ~6,435 relative energy units vs. ~600 stored in the bond itself.

¹² Raichle ME, Gusnard DA. Appraising the brain’s energy budget. Proceedings of the National Academy of Sciences. 2002;99(16):10237–10239. Available at: https://www.pnas.org/doi/10.1073/pnas.172399499

¹³ Gonzalez NJ, op. cit. The 85% water content of neurons is cited from neurophysiology references surveyed in Batmanghelidj’s clinical review.

¹⁴ Ibid.

¹⁵ Batmanghelidj F. Your Body’s Many Cries for Water, op. cit. Chronic dehydration and thirst-mechanism downregulation are central arguments of the book, discussed across multiple chapters.

¹⁶ Maughan RJ, Griffin J. Caffeine ingestion and fluid balance: a review. Journal of Human Nutrition and Dietetics. 2003;16(6):411–420. Available at: https://doi.org/10.1046/j.1365-277X.2003.00477.x. The 10-oz-in / 12-oz-lost estimate for caffeinated beverages is discussed in Batmanghelidj, op. cit., and Gonzalez, op. cit.

¹⁷ Gonzalez NJ, op. cit. The diuretic effect of herbal teas is attributed to the combined osmotic and bioactive compound burden of the brew.

¹⁸ Batmanghelidj F., op. cit. Cell membrane adhesion and the role of water’s polarity in maintaining membrane structure are discussed in the sections on cholesterol and water deficiency.

¹⁹ Ibid. The liver’s cholesterol-synthesis response to water deficiency — cholesterol as a substitute membrane adhesive — is a central mechanistic argument.

²⁰ Gonzalez NJ. Water, Energy, and the Perils of Dehydration. GreenMedInfo Blog, op. cit.

²¹ Ibid. The patient case with 63-point cholesterol drop following water correction is reported in this clinical review.

²² World Health Organization. Nutrients in Drinking Water. WHO Press; 2005. Available at: https://www.who.int/water_sanitation_health/dwq/nutrientschap12.pdf

²³ Kozisek F, op. cit. RO systems remove 92–99% of dissolved minerals. See also: ScienceInsights. WHO Reverse Osmosis Warning: Health Risks Explained. 2026. Available at: https://scienceinsights.org/who-reverse-osmosis-warning-health-risks-explained/

²⁴ Tyent USA. The Dangers of Reverse Osmosis Water. 2024. Available at: https://www.tyentusa.com/blog/dangers-of-reverse-osmosis-water/. Citing Kozisek F (National Institute of Public Health, Czech Republic): “Sufficient evidence is now available to confirm the health consequences from drinking water deficient in calcium or magnesium.”

²⁵ Kozisek F, op. cit. Czech and Slovak RO adoption cases, 2000–2002. Within weeks to months: cardiovascular disorders, fatigue, weakness, muscle cramps — consistent with acute magnesium and calcium deficiency. Cited also at: https://atlawater.com/blogs/discover/reverse-osmosis-water-filter-health

²⁶ Pollack GH. The Fourth Phase of Water: Beyond Solid, Liquid, and Vapor. Ebner & Sons; 2013. Overview available at: https://www.pollacklab.org/research

²⁷ Pollack GH, cited in: Biodiversity for a Livable Climate. Water Isn’t What You Think It Is: The Fourth Phase of Water. Available at: https://bio4climate.org/article/water-isnt-what-you-think-it-is-the-fourth-phase-of-water-by-gerald-pollack/. See also: Ji S. The Hydration Hack That Changes Everything. Sayer Ji’s Substack, Nov 25, 2025. Available at: https://sayerji.substack.com/p/the-hydration-hack-that-changes-everything

²⁸ ViCera Nutrition. HYDRATE — Product Description: Celtic® Sea Salt. Available at: https://viceranutrition.com/products/hydrate-capsules

²⁹ Ibid. Red algae ingredient description.

³⁰ Ibid. Organic spirulina and amino acid chelate description.

³¹ Xu C, Zhang J, Mihai DM, Washington I. Light-harvesting chlorophyll pigments enable mammalian mitochondria to capture photonic energy and produce ATP. Journal of Cell Science. 2014;127(2):388–399. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6518289/. Discussed in: Ji S. The Methylene Blue Mistake. Sayer Ji’s Substack, May 26, 2026. Available at: https://sayerji.substack.com/p/the-methylene-blue-mistake-how-a

³² ViCera Nutrition. HYDRATE — Product Description: Bacillus subtilis AB22. Op. cit.

³³ Ibid. Humic Soil Extract ingredient description.

³⁴ Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutrition Reviews. 2009;67(11):615–623. Available at: https://doi.org/10.1111/j.1753-4887.2009.00246.x. The ~90% population choline deficiency estimate is drawn from NHANES dietary intake data discussed in this review.

³⁵ Batmanghelidj F., op. cit. Half-teaspoon sea salt per 10 glasses of water is the supplementation protocol recommended to replace sodium lost through increased urine output during higher water intake.

³⁶ Pollack GH. The Fourth Phase of Water, op. cit. EZ water formation is driven by infrared energy from the environment, including sunlight and body heat. Grounding, movement, and infrared light exposure have all been proposed as mechanisms that support EZ water formation in cells, discussed in Pollack Lab research summaries at: https://www.pollacklab.org/research

This article is for educational purposes and does not constitute medical advice. Consult a qualified healthcare practitioner before making changes to your health regimen. These statements have not been evaluated by the Food and Drug Administration.

It is being sold across the wellness world as a daily brain booster. Meanwhile, the green pigment in your salad and the blue pigment in spirulina do the same thing — safer, with better evidence, and as the way your body was designed to harvest sunlight in the first place.

Scroll through wellness Substacks, biohacker podcasts, or longevity posts on X in 2026 and you cannot miss methylene blue. A tiny dropper bottle of deep navy liquid. A blue-tongued grin. Claims that it “supercharges mitochondria,” “uncloggs neurons,” and turns aging brains young again.

It is one of the strangest stories in the modern wellness movement.

Because methylene blue is not a botanical, not a peptide, not a mushroom extract. It is a synthetic phenothiazine dye, invented in 1876 by a German chemist named Heinrich Caro to color cotton and wool. It has been used to stain microscope slides, to disinfect aquariums, to treat malaria when nothing else was available in the 19th century, and — in modern emergency rooms — as an acute antidote for a rare blood disorder called methemoglobinemia.

It was never designed as a daily supplement. And once you look at what the toxicology literature actually says — the kind of literature that the FDA’s own regulators read before approving a new drug — the case for taking methylene blue as a nootropic falls apart.

Worse, it falls apart precisely because there is a better, safer, evolutionarily older molecule doing the same job in your mitochondria — and it is sitting in your refrigerator.

This is the story of how a textile dye got mistaken for a mitochondrial medicine, and why the chlorophyll in your spinach and the phycocyanin in spirulina are doing what methylene blue claims to do, without the genotoxicity.

The Three Molecules That Absorb the Same Light

Let me start with something striking. If you graph the wavelengths of light absorbed by chlorophyll-a (the green pigment in plants), phycocyanin (the blue pigment in spirulina), and methylene blue, the three curves overlap in two specific bands:

• Blue light, around 415–450 nanometers

• Red light, around 620–680 nanometers

These two bands are not arbitrary. They are the two windows where your mitochondria — the ‘energy factories’ inside every cell — are designed to receive light. Scientists call this photobiomodulation (PBM): the well-documented phenomenon that red and near-infrared light at non-thermal intensities can boost cellular energy production by stimulating an enzyme inside Complex IV of the mitochondrial respiratory chain (Hamblin 2017, AIMS Biophysics).

Red-light therapy panels work because of this. Sunlight contains these wavelengths. And so do — remarkably — chlorophyll, phycocyanin, and methylene blue.

So the wellness pitch makes a kind of intuitive sense. If red light boosts mitochondria, and methylene blue absorbs red light, then maybe methylene blue is like a sponge that helps your mitochondria capture more light. Right?

This is where the story takes a sharp turn.

First, the Awe

Before we get to the toxicology, you need to understand what is actually happening inside your cells. Not because it is interesting background, but because it changes the ethical logic of the entire debate.

The precautionary principle — the foundational standard in both medicine and environmental science — holds that the burden of proof falls on whoever proposes to intervene in a system, not on those who question the intervention. The more complex and finely tuned the system, the higher that burden becomes.

What follows is not a metaphor. It is a description of what your mitochondria are actually doing, right now, measured and published in peer-reviewed literature. Once you understand the precision of what is already running, the question stops being “does methylene blue help?” and becomes “what is the cost of interfering with this?”

The inner membrane of a single mitochondrion maintains an electric field of approximately 30 million volts per meter. For comparison, high-voltage power lines operate at 155,000 to 765,000 volts per meter. The field inside your mitochondria is comparable in density to a lightning bolt or a solar flare.

Here is why. The voltage across the mitochondrial membrane is modest — roughly 150 millivolts, less than a AA battery. But the membrane is only 5 nanometers thick — about 50,000 times thinner than a human hair. Divide that voltage by that distance and you get a gradient so steep it matches the field that ionizes air in a thunderstorm.

This is not metaphor. It is published, peer-reviewed measurement from Nick Lane and William Martin’s 2010 work in Nature, catalogued in the Harvard BioNumbers database. The “lightning bolt” comparison is in the original scientific literature.

And your body is not doing this in one place. The average cell contains 1,000–2,500 mitochondria. Your body has roughly 30 trillion cells. That is somewhere between 10¹⁶ and 10¹⁷ individual mitochondrial membranes, each sustaining a lightning-bolt-intensity electric field, simultaneously, right now, as you read this sentence.

This field is the engine. A molecular turbine called ATP synthase sits at the membrane and harnesses it. Protons are driven down the gradient like water over a dam — except the “dam” is 10 hydrogen atoms wide and the “water” is a torrent of charged particles responding to 30 million volts per meter. Each proton that crosses the membrane physically rotates the ATP synthase rotor at up to 9,000 RPM. Every rotation mints three molecules of ATP — the universal energy currency of life. Your body recycles roughly its own body weight in ATP every single day.

You are not just a biochemical machine. At the mitochondrial scale, you are an electromagnetic one.

Same Wavelength, Opposite Biology

When chlorophyll absorbs a red photon — whether it’s in a leaf or, as we’ll see, inside your liver mitochondria — it does what photosynthesis has done for two billion years: it kicks an electron into a productive cascade that ends with energy stored as ATP. This is called Type I photochemistry. The reaction does not generate reactive oxygen species. It is, in effect, a clean transfer of solar energy into biological currency.

When methylene blue absorbs that same red photon, something very different happens. Methylene blue is what photochemists call a Type II photosensitizer. Its excited state hands its energy not to a useful electron acceptor, but to ground-state molecular oxygen — converting it into singlet oxygen, a hyper-reactive form of oxygen that attacks DNA, oxidizes lipids, and damages proteins.

This is not a footnote. It is well-documented mainstream chemistry. The singlet-oxygen quantum yield of methylene blue is approximately 0.52 (Lutkus et al. 2019) — which is essentially the value that makes it the active ingredient in antimicrobial photodynamic therapy, where doctors deliberately use methylene blue plus red light to kill bacteria, fungi, and tumor cells.

Read that sentence again. The same chemistry that makes methylene blue an antimicrobial agent under red light — singlet oxygen production, oxidative DNA damage — is the chemistry that runs inside your cells when you take methylene blue and sit in front of a red-light panel.

Methylene blue and red-light therapy is a mechanism for photosensitized DNA damage.

“Higher concentrations produce inhibitory rather than augmentation effects on metabolism… the nootropic window lies at extremely small doses, significantly lower than those used clinically.” — Singh et al., J Cereb Blood Flow Metab, 2023

What the Toxicology Literature Actually Shows

I want to walk through the formal toxicology of methylene blue, because the wellness conversation has almost completely buried it. None of this is obscure. All of it is in the published peer-reviewed literature, and the foundational source is the U.S. National Toxicology Program’s two-year carcinogenicity study, NTP TR-540, published in 2008.

The NTP is the federal agency that the U.S. government funds specifically to identify chemicals that cause cancer. Their two-year rodent bioassay is the gold standard for predicting human carcinogenicity. Here is what NTP found when they fed methylene blue to rats and mice for two years:

• Ames mutagenicity test, positive across five Salmonella strains (TA98, TA100, TA1535, TA97, WP2). The Ames test is the most widely used early-warning screen for substances that damage DNA. Methylene blue was positive both with and without metabolic activation (NTP TR-540).

• Chromosomal aberrations and sister-chromatid exchanges in Chinese hamster ovary cells. These are direct measures of structural DNA damage.

• “Some evidence of carcinogenic activity” in male rats — specifically, pancreatic islet cell tumors.

• “Some evidence of carcinogenic activity” in male mice — specifically, small intestinal carcinomas.

• Equivocal evidence in female mice.

This is not a fringe paper. This is the federal government’s own carcinogenicity study, conducted to the standards used to regulate the chemical industry. It has been sitting in the public record since 2008.

To this we have to add three more layers that any honest discussion has to address:

1. Methylene blue is one of the most potent MAO-A inhibitors ever characterized. Its inhibition constant (Ki) is approximately 27 nanomolar (Ramsay et al., Br J Pharmacol, 2007), which makes it 740 times more potent than linezolid, the antibiotic that already carries serious serotonin-syndrome warnings. The UK MHRA has documented 33 cases of central-nervous-system toxicity from methylene blue combined with serotonergic drugs (MHRA Drug Safety Update, December 2014). Fatal cases have been reported in mainstream journals.

2. Methylene blue is contraindicated in G6PD deficiency. Glucose-6-phosphate dehydrogenase deficiency is the world’s most common enzyme deficiency, affecting an estimated 330–500 million people globally, with the highest prevalence in African, Mediterranean, Middle Eastern, and South Asian populations. In G6PD-deficient individuals, methylene blue can cause hemolytic anemia — destroying red blood cells. The wellness community does not routinely screen for G6PD status before recommending methylene blue.

3. A 2023 human PET imaging study examined methylene blue at doses overlapping with some reported nootropic use patterns.

In what may be one of the more important recent human studies on methylene blue, Singh and colleagues, publishing in the Journal of Cerebral Blood Flow & Metabolism, administered intravenous methylene blue to healthy volunteers at doses of 0.5 and 1 mg/kg and then measured cerebral metabolism using PET imaging.

The researchers found that methylene blue reduced cerebral metabolic rate of oxygen by approximately 7.9% at 0.5 mg/kg and 11.8% at 1 mg/kg. Cerebral blood flow also decreased at both doses.(Singh et al. 2023).

These findings challenge simplistic claims that methylene blue universally “boosts brain energy” or enhances cerebral metabolism in humans.

However, several important caveats should be noted:

• the study used intravenous administration, not oral dosing;

• the doses used (approximately 34–68 mg for a 150 lb adult) are substantially higher than the microdoses commonly reported by some wellness users;

• and reduced oxygen consumption does not automatically imply impaired brain function, as lowered metabolic demand can sometimes reflect altered efficiency or neurophysiological state rather than outright dysfunction.

Nonetheless, the study raises legitimate questions about methylene blue’s dose-dependent effects on human brain metabolism and underscores the lack of long-term safety data supporting widespread wellness use.

Learn more by reading my previous articles on this topic below.

The Hidden Story: Mammals Are Quietly Photosynthetic

Here is the part of this story that almost no one in the methylene blue community knows. It changes everything.

In 2014, a team of researchers at Columbia University — Xu, Zhang, Mihai, and Washington — published a paper in the Journal of Cell Science titled “Light-harvesting chlorophyll pigments enable mammalian mitochondria to capture photonic energy and produce ATP” (Xu et al. 2014).

This was not new to readers of GreenMedInfo. In 2015 — nearly a decade before methylene blue became a wellness phenomenon — I reported on this same discovery and proposed what the Columbia authors themselves implied: that mammals, including humans, should be reclassified as photoheterotrophs — organisms capable of deriving energy from both food and sunlight, depending on the chlorophyll content of their diet. The supplement industry spent that decade selling blue dye instead.

The findings, in plain language:

When mice — or, by extension, humans — eat green plants, the chlorophyll molecules do not simply pass through. Their breakdown products, specifically pyropheophorbide-a (a metabolite of chlorophyll that loses its central magnesium ion during digestion), are absorbed and selectively accumulate in mitochondria — specifically, at concentrations 2.3 times higher inside the mitochondria than in surrounding cellular fluid.

Once inside mitochondria, these chlorophyll metabolites do something remarkable:

• They donate electrons directly to coenzyme Q10, the universal mobile electron carrier in the mitochondrial respiratory chain — reducing CoQ10 by 46% in vitro.

• They boost ATP synthesis by 35% in mouse brain mitochondrial homogenates when exposed to red light.

• In whole-animal experiments using C. elegans (the standard worm model in aging research), supplementation with chlorophyll metabolites extended median lifespan by 17% in the presence of red light.

The Columbia authors wrote, in their abstract: “We propose that through consumption of plant chlorophyll pigments, animals, too, are able to derive energy directly from sunlight.”

This is not a fringe paper. This is a peer-reviewed, mechanistically detailed study in a respected cell biology journal. It is exactly the kind of paper that the methylene blue community could and should cite — except it does not, because it points to the obvious conclusion: the molecule that evolution designed to do this job is chlorophyll, not a phenothiazine dye.

We are quietly photosynthetic. Our mitochondria evolved alongside plant pigments for the entire history of mammalian life. Methylene blue did not exist anywhere in nature until 1876.

The Counter-Evidence That Wellness Skeptics Should Hear

Let me steelman the methylene blue case one more time, because readers and methylene blue proponents who have pushed back on my own earlier writings are right to ask: what if methylene blue has real benefits despite its toxicology?

The strongest evidence in MB’s favor is this:

• In cell culture and in isolated mitochondria, nanomolar to low-micromolar concentrations of methylene blue increase cytochrome c oxidase activity and ATP production.

• In rodent models of traumatic brain injury and Alzheimer’s disease, MB has shown neuroprotective effects.

• Some small human studies of MB in age-related cognitive decline have shown short-term cognitive improvements.

All of this is real. None of it is fabricated. The Gonzalez-Lima laboratory at the University of Texas has published reproducible mechanistic data showing that methylene blue can function as a partial electron shuttle, accepting electrons from NADH and donating them to cytochrome c.

But here is where the steelman breaks:

1. The 2023 human PET study showed the opposite. At doses overlapping with the higher end of some online nootropic and biohacker recommendations — 0.5 to 1 mg/kg — MB reduced measured brain oxygen metabolism in living humans, although many anecdotal users report substantially lower oral microdoses.

2. The dose-response is hormetic and narrow. Above ~10 µM, methylene blue inhibits mitochondrial function. Casual oral dosing easily overshoots the hypothetical sweet spot.

3. The benefits, even when present, do not erase the toxicology. A drug can both inhibit MAO-A and damage DNA and boost certain narrow biomarkers. The question is not “does it ever do anything good?” The question is “does it pass a real risk-benefit analysis for chronic daily use?” For methylene blue, the answer is no.

4. The genotoxic signal is not theoretical. Ames-positive in five strains. Chromosomal aberrations. Singlet oxygen production at the exact wavelength of red-light therapy. Some evidence of carcinogenicity in two species. These are not “what-ifs.” They are documented.

5. There is no long-term human randomized controlled trial. Zero. The entire nootropic-dose MB case for chronic use rests on in vitro data, short rodent studies, and acute human challenge experiments — never a year-long, adequately powered RCT with safety endpoints.

The Human Trial That Should Have Ended This Debate

In 2001, Patricia Egner and colleagues published a randomized, double-blind, placebo-controlled trial in the Proceedings of the National Academy of Sciences (Egner et al. 2001).

The setting: Qidong, in Jiangsu Province, China — a region with among the world’s highest rates of liver cancer, driven by unavoidable dietary exposure to aflatoxin, a powerful naturally occurring carcinogen.

The intervention: chlorophyllin, a water-soluble derivative of chlorophyll, 100 mg three times daily before meals, for 4 months.

The control: identical placebo.

The participants: 180 healthy adults randomized 1:1.

The primary outcome: urinary aflatoxin-N7-guanine adducts — chemical fingerprints of aflatoxin binding to DNA inside the participants’ livers, measured in their urine.

The result: Chlorophyllin reduced these DNA-damage biomarkers by 55%, compared to placebo (p = 0.036). Among samples where adducts were detectable, the geometric mean reduction was 49% (p < 0.001).

Adverse events: zero. Some participants reported green-tinged stool (cosmetic, expected). No serious side effects.

Let me restate that, because it is one of the cleanest pieces of preventive nutrition data ever published. In a 180-person randomized controlled trial, taking chlorophyllin for four months reduced direct biological markers of DNA damage in human beings by more than half, with zero side effects.

This is not animal data. This is not in vitro chemistry. This is in-vivo human DNA protection, randomized, placebo-controlled, peer-reviewed in one of the most prestigious general science journals in the world.

The comparison to methylene blue could not be more stark:

What About Phycocyanin?

The blue pigment in spirulina — phycocyanin — deserves its own paragraph, because it adds the second half of the algal-pigment case.

Phycocyanin’s chromophore, phycocyanobilin, is structurally similar to bilirubin (the molecule that gives bruises and jaundice their yellow color). Bilirubin is now recognized as a powerful endogenous antioxidant. Phycocyanobilin behaves the same way, and Mark McCarty’s group has published extensively on its role as a potent inhibitor of NADPH oxidase 2 (NOX2) — the enzyme that generates much of the inflammatory reactive oxygen species in vascular disease, diabetes, and neurodegeneration (McCarty et al.).

C-phycocyanin has been studied in dozens of human and animal trials for its anti-inflammatory and antioxidant effects. It received FDA GRAS (Generally Recognized as Safe) status in 2012 as a food ingredient. There is no documented analog of NTP TR-540 for phycocyanin — no two-year rodent carcinogenicity study showing mutagenicity, no MAO-A inhibition with fatal drug interactions, no G6PD contraindication.

Eat Light. Don’t Drink Dye.

Here is the bottom line, in the plainest English I can write:

Your mitochondria were designed to receive sunlight, and they were designed to do it through the same molecules that plants and cyanobacteria have used for two billion years: tetrapyrrole pigments like chlorophyll and the bilins. These molecules accumulate in your mitochondria, donate electrons productively, and have a clean toxicological profile that has been confirmed in randomized human trials.

Methylene blue is something else entirely. It is a synthetic textile dye that happens to absorb light in a similar region. Its biology under that same light is opposite — it makes singlet oxygen, damages DNA, and at the doses being recommended online, suppresses brain metabolism in living humans.

Methylene blue has a legitimate, narrow medical role as an emergency antidote for methemoglobinemia, and possibly as an investigational drug for specific neurodegenerative diseases under strict medical supervision. It does not belong in your morning supplement stack.

The food version of the same biology is sitting in your produce aisle and your spirulina jar. Eat green vegetables. Drink spirulina smoothies. Get sunlight on your skin. These are not mystical recommendations. They are what the published, peer-reviewed, randomized, controlled, human evidence supports.

Eat light. Don’t drink dye.

For the Skeptics: What Would Change My Mind

I want to be intellectually honest about this. Here is what would make me re-evaluate:

1. A long-term (≥1 year), randomized, placebo-controlled trial of nootropic-dose oral MB in humans with genotoxicity biomarkers, MAO-related adverse-event surveillance, and rigorous cognitive endpoints.

2. Human PET data showing that low-dose oral MB increases — not decreases — cerebral metabolic rate of oxygen.

3. A mechanistic study identifying a chronic-use MB dosing window with no DNA-adduct or singlet-oxygen signal in vivo.

4. A negative replication of the Egner et al. chlorophyllin trial or evidence of chronic toxicity from dietary chlorophyll.

None of these currently exist. Until they do, the evidence points one way.

The Companion White Paper

I’ve prepared a full, formally cited investigative white paper that lays out every claim above with primary sources, a full reference list of 38 numbered citations, and a publication-formatted figure mapping all three molecules onto the mitochondrial photobiomodulation windows. It’s available as a separate PDF for readers who want to verify each claim, share with clinicians, or use as a teaching document.

Download the White Paper

If you take methylene blue, share this post and paper with someone who can help you think through the risk-benefit math. If you recommend methylene blue professionally, please read the NTP TR-540 study and the Singh 2023 PET paper before your next consultation. And if, like me, you have watched this trend rise without ever endorsing it, this is the evidence base I wish had been in front of every wellness audience two years ago.

Share

The wellness movement has the right intuition: mitochondria matter, light matters, biology is exquisitely responsive to small inputs. But the molecule we should be elevating is not a 19th-century industrial dye. It is the same green pigment that powers every leaf on every tree, and that — quietly, mostly unnoticed by the supplement industry — already lives in your mitochondria when you eat your vegetables.

To learn more about photodynamic therapy, read my recent article on the topic below.

Sources & Further Reading

• NTP. Toxicology and Carcinogenesis Studies of Methylene Blue Trihydrate. NTP TR 540. 2008. https://ntp.niehs.nih.gov/sites/default/files/ntp/htdocs/lt_rpts/tr540.pdf

• Xu C, Zhang J, Mihai DM, Washington I. Light-harvesting chlorophyll pigments enable mammalian mitochondria to capture photonic energy and produce ATP. J Cell Sci. 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC6518289/

• Egner PA et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. PNAS. 2001. https://www.pnas.org/doi/10.1073/pnas.251536898

• Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of MAO-A confirms a theoretical prediction. Br J Pharmacol. 2007. https://pmc.ncbi.nlm.nih.gov/articles/PMC2078225/

• Singh N et al. The effects of acute methylene blue administration on cerebral blood flow and metabolism in humans and rats. J Cereb Blood Flow Metab. 2023. https://pubmed.ncbi.nlm.nih.gov/36803299/

• Lutkus LV, Rickenbach SS, McCormick TM. Singlet oxygen quantum yields determined by oxygen consumption. J Photochem Photobiol A Chem. 2019. https://par.nsf.gov/servlets/purl/10099815

• MHRA. Methylthioninium chloride (methylene blue): update on CNS toxicity. Drug Safety Update. December 2014. https://www.gov.uk/drug-safety-update/methylthioninium-chloride-methylene-blue-update-on-central-nervous-system-cns-toxicity

Companion white paper with full citations and figure available on request. Sayer Ji is the founder of GreenMedInfo and an investigative researcher in public health policy. He declares no financial interest in chlorophyllin, spirulina, or phycocyanin supplement products.

A Hypothesis Paper

Prepared for submission to Medical Hypotheses / Frontiers in Aging Neuroscience

Abstract

Background and Purpose

Pineal gland calcification (PGC) affects over 60% of adults globally yet is routinely classified as a benign incidental radiological finding. This paper argues that PGC represents a significant and underinvestigated convergent mechanism in age-related pathology, with downstream consequences spanning circadian dysregulation, melatonin decline, oxidative stress, amyloid-beta accumulation, and neuropsychiatric vulnerability.

Methods

We synthesize peer-reviewed evidence across five domains: (1) epidemiology of PGC prevalence; (2) biochemistry of hydroxyapatite formation and its inhibitors; (3) environmental and physiological contributors including fluoride exposure and chronic stress; (4) melatonin pathway disruption and its systemic consequences; and (5) associations between PGC and neurological disease, including Alzheimer’s disease, schizophrenia, bipolar disorder, and Parkinson’s disease.

Conclusions

Convergent mechanistic and epidemiological evidence supports reconceptualizing PGC as a modifiable pathological process rather than an incidental finding. Known crystallization inhibitors -- magnesium, phytate, pyrophosphate, and vitamin K2 -- represent plausible preventive interventions warranting prospective clinical investigation. We propose a unified three-stage mechanistic model and a research agenda for longitudinal and interventional studies.

Keywords

Pineal gland calcification; hydroxyapatite; melatonin; circadian dysregulation; Alzheimer’s disease; fluoride; magnesium; phytate; neurodegeneration; soft tissue calcification

1. Introduction

The pineal gland is a small, unpaired midline neuroendocrine organ whose primary function is melatonin synthesis -- the conversion of serotonin to melatonin in response to darkness, mediated by noradrenergic input from the suprachiasmatic nucleus via the superior cervical ganglion. Through this single pathway, the pineal gland serves as the organism’s principal interface between environmental light cycles and the circadian machinery of virtually every tissue in the body. Melatonin is not merely a sleep regulatory hormone; it is one of the most evolutionarily ancient molecules in biology, present in unicellular organisms, and functions as a potent antioxidant, immunomodulator, and neuroprotective agent with documented activity against over a hundred disease processes [1,2].

Despite this central physiological role, the pineal gland occupies a curiously neglected position in clinical medicine. Its most common pathological alteration -- calcification -- is routinely dismissed as a normal aging phenomenon with no clinical significance in the absence of overt neurological symptoms. This clinical consensus has persisted despite a growing body of evidence linking pineal gland calcification (PGC) to melatonin decline, sleep architecture disruption, psychiatric symptom burden, and neurodegenerative disease associations including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and bipolar disorder [3–8].

A 2023 systematic review and meta-analysis by Belay and Worku, encompassing eight cross-sectional studies representing over 5,500 patients, established a pooled global PGC prevalence of 61.65% (95% CI: 52.81–70.49%) in adults, with high heterogeneity between studies (I² = 97.7%) [9]. Reported prevalence ranged from 26.88% to 76.7% across countries, with consistent patterns of increasing prevalence with age, higher rates in males, and ethnic variation suggesting genetic, environmental, or dietary contributory factors. That over three-fifths of the adult human population carries detectable calcification in their primary melatonin-producing organ -- and that this finding is considered clinically unremarkable -- represents a significant gap in medical reasoning that this paper aims to address.

We propose that PGC is neither benign nor inevitable, but represents a convergent pathological mechanism at the intersection of mineral dysregulation, environmental exposure, dietary deficiency, and chronic physiological stress. We further argue that this mechanism is modifiable, that its consequences are clinically significant across multiple disease domains, and that it deserves urgent prospective investigation. To this end, we present a synthesis of the biochemical, epidemiological, and clinical evidence, propose a unified mechanistic framework, and outline a research agenda for the field.

2. Pineal Gland Anatomy, Physiology, and Unique Vulnerabilities

The pineal gland is a midline structure located in the posterior epithalamus, dorsal to the third ventricle and between the two cerebral hemispheres. Weighing approximately 150 mg in adults, it is composed primarily of pinealocytes (80–90% of cells) alongside interstitial cells, neurons, and mast cells. Pinealocytes contain cellular machinery for melatonin synthesis and bear structural resemblance to retinal photoreceptor cells -- a phylogenetic remnant of the pineal’s evolutionary origin as a direct light-sensing organ [10].

Two anatomical features render the pineal uniquely susceptible to calcification. First, unlike most brain structures, the pineal gland sits outside the blood-brain barrier. It is surrounded by fenestrated capillaries that allow free exchange with the systemic circulation, exposing pineal tissue to circulating ions, toxicants, and mineral concentrations that are tightly regulated elsewhere in the brain [11]. Second, pinealocytes contain high concentrations of hydroxyapatite-binding proteins and calcium-sequestering organelles, creating a microenvironment that is both necessary for melatonin synthesis (which requires calcium signaling) and inherently susceptible to pathological mineral accumulation when crystallization inhibitors are insufficient [12].

The blood supply to the pineal via posterior choroidal arteries is proportionally the highest per unit volume of any brain structure, reflecting its secretory demands. This high perfusion rate, while metabolically necessary, also maximizes exposure to circulating fluoride, heavy metals, and other agents that preferentially accumulate in calcified tissue. The combination of absent blood-brain barrier protection, high blood flow, and intrinsic calcium-handling machinery creates what might be described as a uniquely optimized calcification substrate -- one that requires active suppression by crystallization inhibitors to remain functional.

3. Biochemistry of Pineal Calcification: Hydroxyapatite Formation and Its Inhibitors

The calcium deposits found in pineal tissue on microscopic examination are primarily hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂), the same mineral that constitutes bone and dentin, alongside calcite (calcium carbonate) in smaller proportions [13]. This is not passive mineral precipitation but a regulated process -- the same process that builds bone and dentin, occurring in tissue that normally suppresses it through the activity of specific crystallization inhibitors.

Under physiological conditions, soft tissue calcification is prevented by three primary inhibitor classes. Pyrophosphate (PPi) competitively inhibits hydroxyapatite nucleation at calcium phosphate crystal surfaces and is continuously generated by cellular ATP metabolism. Phytate (inositol hexaphosphate, IP6) is a plant-derived compound with exceptional affinity for calcium ions; it adsorbs to crystal surfaces and arrests further growth. Magnesium competes with calcium at crystal nucleation sites, substituting at hydroxyapatite lattice positions and disrupting crystal propagation [14].

Galliani and Mongiorgi (1991) demonstrated in a human study that magnesium directly inhibits hydroxyapatite crystal formation in pineal tissue, providing the first direct mechanistic evidence for magnesium’s protective role in PGC specifically [15]. Grases, Costa-Bauzà, and Prieto (2007) extended this framework in a review proposing that declining phytate and pyrophosphate levels -- whether from dietary insufficiency, metabolic dysfunction, or age-related enzyme changes -- may be a primary driver of PGC, with implications for Alzheimer’s disease pathogenesis through the downstream consequences of melatonin loss [16].

This biochemical framework carries an important implication: PGC is not a passive consequence of aging but the outcome of a balance between calcifying pressures and inhibitory defenses. When inhibitors are adequate, calcification is suppressed regardless of age. When inhibitors are depleted -- by dietary insufficiency, fluoride competition, metabolic disease, or chronic inflammation -- calcification proceeds. This reconceptualization shifts PGC from an inevitable age marker to a potentially modifiable process.

Matrix Gla Protein (MGP) represents a fourth inhibitory mechanism of particular relevance. MGP is a vitamin K2-dependent protein expressed in vascular smooth muscle and other soft tissues that directly inhibits hydroxyapatite nucleation. In its carboxylated (active) form, MGP is a potent calcification suppressor; vitamin K2 deficiency produces undercarboxylated MGP that is functionally inactive [17]. While MGP’s role in pineal tissue specifically has not been directly studied, its well-established activity in preventing vascular calcification through identical hydroxyapatite inhibition mechanisms makes it a strong candidate for investigation in PGC prevention.

4. Environmental and Physiological Contributors to Pineal Calcification

4.1 Fluoride Accumulation

Fluoride’s preferential accumulation in the pineal gland is the most thoroughly documented environmental contributor to PGC. Luke (2001) analyzed pineal glands from eleven aged cadavers and found a significant positive correlation between pineal fluoride concentration and pineal calcium content (r = 0.73, p < 0.02), with no corresponding correlation between pineal fluoride and bone fluoride [18]. This dissociation is mechanistically significant: it indicates active pineal fluoride accumulation independent of general skeletal fluoride burden, and by old age the pineal’s fluoride-to-calcium ratio exceeds that of bone.

The mechanism is straightforward chemistry. Fluoride ions (F⁻) substitute for hydroxyl ions (OH⁻) in hydroxyapatite crystals to form fluorapatite (Ca₁₀(PO₄)₆F₂), which is thermodynamically more stable than hydroxyapatite. Once incorporated, fluoride stabilizes existing crystal structures and lowers the activation energy for further crystal growth, effectively promoting rather than inhibiting calcification. Concurrently, fluoride displaces magnesium from hydroxyapatite binding sites, reducing the inhibitory capacity of this protective cation [19].

The clinical significance of fluoride accumulation in the human pineal at population-level exposure doses remains genuinely uncertain and requires prospective investigation. What is established is the biochemical mechanism, the accumulation finding, and the theoretical consequence. The precautionary principle, combined with the absence of known benefit from systemic fluoride exposure beyond topical dental application, supports minimizing systemic fluoride burden in populations with risk factors for neurodegeneration.

4.2 Stress-Induced Calcification

Milin (1998) demonstrated in a gerbil model that acute psychological stress induces calcium concretion formation in the pineal gland, with a proposed mechanism involving stress-driven calcium flux, catecholamine-mediated pinealocyte activation, and altered crystallization inhibitor activity [20]. While this finding has not been replicated in humans, the mechanistic pathway is plausible: chronic sympathetic activation elevates circulating calcium, depletes magnesium (a well-documented consequence of chronic stress and cortisol elevation), and may directly activate pinealocyte calcium channels. Stress as a contributor to PGC has received essentially no follow-up investigation and represents a significant gap.

4.3 Artificial Light Exposure

Melatonin synthesis is acutely suppressed by light, particularly blue-wavelength light (450–490 nm), through the retinohypothalamic tract and suprachiasmatic nucleus pathway. Chronic nocturnal light exposure -- now ubiquitous in industrialized populations through screen use and urban light pollution -- chronically suppresses melatonin synthesis and dysregulates pineal activity patterns [21]. Whether chronic suppression of melatonin synthesis contributes directly to PGC through secondary effects on calcium handling and oxidative stress in pinealocytes, or whether the association between artificial light exposure and neurological disease operates independently of PGC, is unknown. This represents another underinvestigated mechanistic pathway.

4.4 Dietary Factors

Western dietary patterns are characterized by low phytate intake (reduced whole grain and legume consumption), low magnesium intake (soil depletion, food processing), and often low vitamin K2 intake (reduced fermented food consumption). Each of these deficiencies independently reduces crystallization inhibitor capacity. Excess supplemental calcium intake, particularly as inorganic calcium carbonate, in the absence of adequate magnesium and vitamin K2 co-factors, may further promote ectopic calcification by providing substrate without adequate inhibitory infrastructure [22]. The intersection of these dietary patterns with increasing PGC prevalence in industrialized populations warrants epidemiological investigation.

5. Melatonin Pathway Disruption: Mechanisms and Systemic Consequences

The primary functional consequence of PGC is reduction in melatonin production. Kunz et al. (1999) demonstrated an inverse correlation between degree of pineal calcification and nocturnal melatonin secretion in human subjects, establishing the direct functional link between structural calcification and hormonal output [23]. This finding has been replicated across multiple studies and is now considered well-established, though the dose-response relationship between calcification volume and melatonin suppression has not been characterized with precision.

Melatonin’s physiological roles extend well beyond sleep regulation. It is one of the most potent endogenous antioxidants, capable of directly scavenging hydroxyl radicals, superoxide anions, and singlet oxygen -- all three primary reactive oxygen species. It also upregulates endogenous antioxidant enzyme systems including superoxide dismutase, glutathione peroxidase, and catalase. This antioxidant function is not merely systemic but is particularly relevant to the brain, where oxidative stress is a primary driver of neurodegeneration [24].

Melatonin further functions as an immunomodulator, inhibits pro-inflammatory cytokine release, modulates mitochondrial function, and -- crucially for Alzheimer’s disease pathogenesis -- directly suppresses amyloid-beta (Aβ) production and aggregation. Multiple studies have demonstrated that melatonin inhibits β- and γ-secretase activity (reducing Aβ production), prevents Aβ fibril formation, and reduces existing plaque burden in animal models of Alzheimer’s disease [25,26].

Mahlberg et al. (2009) demonstrated that PGC in human subjects is associated with reduced REM sleep percentage, decreased total sleep time, poorer sleep efficiency, greater sleep disturbance, and increased daytime tiredness [27]. Sleep disturbance is now recognized as more than a symptom of neurodegeneration -- it is a driver. Wakefulness increases Aβ burden through impaired glymphatic clearance, while sleep reduces it. The glymphatic system, which clears metabolic waste from the brain during slow-wave sleep, requires melatonin-entrained sleep architecture to function adequately [28]. PGC → melatonin decline → sleep disruption → impaired glymphatic clearance → Aβ accumulation represents a mechanistically coherent causal chain from structural calcification to neurodegenerative pathology.

6. Neurological Disease Associations

6.1 Alzheimer’s Disease

The association between PGC and Alzheimer’s disease is the most developed in the literature and is supported by multiple converging lines of evidence. Alzheimer’s patients demonstrate higher degrees of PGC than patients with other dementia subtypes, including vascular dementia [29]. Melatonin deficiency is a consistent finding in Alzheimer’s patients and correlates with disease severity and ApoE ε4/ε4 genotype [30,31]. The capacity of melatonin to suppress Aβ production, inhibit fibril formation, and reduce plaque burden has been demonstrated across multiple laboratory and animal studies [25,26].

Grases et al. (2007) proposed a complete mechanistic hypothesis: pineal injury (from aging, environmental toxicants, or inflammatory processes) initiates calcification when crystallization inhibitors -- particularly phytate and pyrophosphate -- are insufficient. Calcification reduces melatonin output, which both increases oxidative injury (through loss of antioxidant capacity) and increases Aβ deposition (through loss of secretase inhibition). The resulting Aβ accumulation drives progressive Alzheimer’s pathology [16].

This hypothesis is testable and has not been adequately tested. No prospective study has examined whether interventions that reduce PGC progression are associated with reduced Alzheimer’s risk or delayed onset. No randomized trial has tested whether melatonin supplementation modifies Aβ burden in humans with measurable PGC. The existence of this mechanistic pathway, supported by multiple independent lines of evidence, combined with the absence of targeted investigation, represents one of the more significant gaps in Alzheimer’s disease research.

6.2 Psychiatric Conditions

Multiple cross-sectional studies have identified associations between PGC and schizophrenia, bipolar disorder, and Tourette syndrome [3,5,6]. The proposed mechanistic pathway involves circadian rhythm disruption affecting dopaminergic and serotonergic neurotransmission -- both of which are entrained by melatonin-synchronized circadian machinery. Circadian dysregulation is now recognized as a feature of multiple psychiatric conditions rather than merely a symptom, raising the possibility that PGC-driven melatonin decline may contribute to pathogenesis rather than simply co-occurring with it.

Shomrat and Nesher (2019) advanced a more speculative but peer-reviewed hypothesis: that abnormal endogenous N,N-dimethyltryptamine (DMT) metabolism, potentially involving the pineal gland, may contribute to the neuroplasticity disturbances observed in autism spectrum disorder [32]. The pineal has been proposed as a site of endogenous DMT synthesis, and DMT’s structural similarity to melatonin (both are tryptamine derivatives) raises questions about whether calcification-driven disruption of pineal tryptamine metabolism extends beyond melatonin to other neuroactive compounds. This hypothesis is highly speculative but deserves controlled investigation given its potential clinical implications.

6.3 Stroke and Vascular Disease

The association between PGC and stroke may reflect shared pathophysiology rather than direct causation. Vascular calcification and pineal calcification share the same hydroxyapatite chemistry and are suppressed by the same inhibitors -- magnesium, phytate, pyrophosphate, and MGP. A systemic state of inadequate crystallization inhibitor capacity would produce calcification in multiple tissues simultaneously, making PGC a potential biomarker for concurrent vascular calcification risk rather than a direct stroke contributor [33]. This interpretation, if correct, makes PGC a clinically useful marker for cardiovascular risk that is currently being ignored.

7. A Unified Mechanistic Framework

We propose a three-stage model of PGC and its consequences:

Stage 1 -- Initiating Conditions: Environmental exposures (fluoride accumulation, chronic artificial light, heavy metal burden), physiological stressors (chronic sympathetic activation, magnesium depletion via cortisol elevation), and dietary insufficiencies (low phytate, magnesium, and vitamin K2 intake) individually or in combination reduce crystallization inhibitor capacity in pineal tissue. Concurrent or antecedent pinealocyte injury from inflammatory mediators, oxidative stress, or cytotoxic agents may accelerate this process. This stage is largely asymptomatic and occurs progressively from early adulthood.

Stage 2 -- Progressive Calcification: In the absence of adequate crystallization inhibitors, hydroxyapatite nucleation proceeds in pineal tissue. Fluoride incorporation stabilizes forming crystals and displaces protective magnesium. Calcification volume increases with age as the cumulative deficit in inhibitory capacity exceeds compensatory mechanisms. Melatonin production begins to decline as functional pinealocyte mass is replaced by calcified material. This stage remains largely subclinical, though subtle sleep architecture changes and reduced antioxidant capacity may be detectable.

Stage 3 -- Functional Consequences: As melatonin production falls below threshold levels, circadian synchronization degrades, sleep architecture deteriorates, glymphatic clearance declines, antioxidant defense capacity falls, and Aβ clearance is impaired. These consequences interact with and accelerate other aging pathologies: reduced sleep worsens Aβ burden, which increases neuroinflammation, which further suppresses melatonin synthesis, creating a self-reinforcing cycle. Concurrent vascular calcification, sharing the same inhibitor deficiency substrate, may amplify cerebrovascular risk.

This model is consistent with the observed epidemiology -- increasing PGC with age, earlier onset in populations with higher fluoride exposure or lower dietary inhibitor intake, and higher disease association in populations with advanced calcification -- and generates multiple testable predictions.

8. Therapeutic and Preventive Implications

8.1 Crystallization Inhibitor Supplementation

Magnesium is the most immediately actionable intervention. Deficiency is prevalent in Western populations (estimated at 45–68% depending on the assessment threshold used), the mechanism of hydroxyapatite inhibition is established, and its safety profile is well-characterized. Galliani and Mongiorgi’s direct demonstration of magnesium’s inhibitory effect on pineal hydroxyapatite formation provides specific mechanistic rationale beyond magnesium’s general cardiovascular and neurological benefits [15]. Optimal forms and doses for PGC prevention have not been investigated.

Phytate (IP6) has documented inhibitory effects on renal and cardiovascular calcification through the same crystallization inhibition mechanism. Dietary sources include whole grains, legumes, nuts, and seeds. Western dietary patterns are associated with substantially reduced phytate intake compared to traditional diets, and this reduction coincides with the industrialization-associated increases in cardiovascular and potentially neurodegenerative disease burden [16].

Vitamin K2 (menaquinone, particularly MK-7) activates Matrix Gla Protein, the primary soft tissue calcification inhibitor. Beulens et al. (2009) demonstrated that high dietary menaquinone intake is associated with a 52% reduction in coronary calcification, providing clinical validation of MGP-mediated inhibition [34]. The same mechanism applies wherever hydroxyapatite formation occurs in soft tissue, including the pineal. Vitamin K2 is found in fermented foods (natto, certain cheeses) and is often deficient in populations consuming industrialized diets.

8.2 Melatonin Supplementation

Exogenous melatonin supplementation represents a compensatory strategy for the consequences of PGC rather than a preventive one. Its evidence base for sleep architecture support, antioxidant activity, and neuroprotection is substantial. Several studies have examined melatonin in Alzheimer’s disease models with promising results, though large-scale human trials have not established definitive clinical benefit [35]. Critically, the optimal dosing strategy for neuroprotective versus sleep-regulatory endpoints may differ, and this has not been systematically investigated. Physiological nocturnal peaks are in the range of 100–200 pg/mL; typical supplemental doses of 1–10 mg produce supraphysiological levels that may not optimally mimic endogenous patterns.

8.3 Environmental Modification

Reducing fluoride exposure through water filtration, selection of low-fluoride beverages, and avoidance of high-fluoride medications where alternatives exist represents a low-risk intervention with mechanistic rationale. Managing nocturnal artificial light exposure through blue-light filtering, reduction of screen use before sleep, and use of blackout conditions supports melatonin synthesis and may reduce stress on the pinealocyte secretory machinery. Stress reduction through any evidence-based approach addresses the sympathetic activation -> magnesium depletion -> calcification pathway.

8.4 Curcumin as a Supporting Agent

Curcumin, the primary polyphenol of turmeric (Curcuma longa), demonstrates multiple mechanisms relevant to PGC-associated neurodegeneration: direct free radical scavenging with documented activity against hydroxyl radicals, superoxide, and singlet oxygen; NF-κB inhibition with downstream suppression of pro-inflammatory cytokines; upregulation of endogenous antioxidant systems including glutathione; and direct inhibition of Aβ aggregation [36,37]. Wang et al. (2020) demonstrated inhibition of arterial calcification by curcumin through anti-inflammatory and calcium regulatory pathways in animal models, providing mechanistic basis for potential applicability to pineal calcification [38]. Curcumin’s primary clinical limitation is poor oral bioavailability in standard formulations; enhanced bioavailability preparations (phytosomes, nanoparticles, piperine combinations) warrant investigation in the context of PGC-related neurodegeneration.

8.5 What Cannot Yet Be Claimed

Several important limitations must be acknowledged. Reversibility of established PGC in humans has not been demonstrated; animal evidence (Mrvelj and Womble, 2020, showing fluoride-free diet stimulating pineal growth in aged animals) suggests partial reversibility is possible but has not been translated to human studies [39]. The clinical significance of fluoride accumulation at population-level exposure doses remains uncertain. Whether PGC causally drives neurodegeneration or is an epiphenomenon of shared underlying processes cannot be established without prospective interventional data. The optimal combination, timing, and dosing of preventive interventions has not been investigated.

9. Research Agenda

The mechanistic and epidemiological evidence presented in this review supports the following priorities for future investigation:

1. Longitudinal cohort studies examining whether PGC progression (measured by serial neuroimaging) correlates with melatonin level decline, sleep architecture deterioration, cognitive performance, and Alzheimer’s biomarker accumulation (CSF Aβ42/tau, PET amyloid imaging). Such studies would establish whether the mechanistic relationships proposed here are clinically significant at population level.

2. Interventional trials testing crystallization inhibitors -- specifically magnesium supplementation, phytate supplementation, and vitamin K2 -- on PGC progression rates in adults with early or moderate calcification. Primary outcome: change in calcification volume on MRI over 24–36 months. Secondary outcomes: melatonin levels, sleep parameters, cognitive performance, and inflammatory markers.

3. Epidemiological studies examining whether populations with naturally high phytate intake (traditional diets rich in whole grains and legumes) show lower PGC prevalence or slower progression rates, controlling for age, sex, and fluoride exposure.

4. Mechanistic investigation of stress-induced PGC in humans, including examination of whether chronic sympathetic activation markers correlate with calcification volume and whether stress reduction interventions attenuate progression.

5. Investigation of whether PGC volume serves as a biomarker for concurrent vascular calcification risk, potentially enabling its use as a non-invasive cardiovascular risk indicator.

6. Animal studies examining whether MGP-activating vitamin K2 supplementation inhibits PGC specifically, extending the well-established vascular calcification findings to pineal tissue.

10. A Note on Historical and Philosophical Context

No review of the pineal gland would be complete without acknowledging the distinctive philosophical history that has attached to this organ. René Descartes, writing in the seventeenth century with a sophisticated understanding of neuroanatomy acquired through extensive dissection, identified the pineal as the ‘seat of the soul’ on the basis of a precise anatomical observation: it is the only unpaired midline structure in the brain, and therefore the only candidate for the point of unity required by his dualist framework -- where res cogitans (thinking substance) must interface with res extensa (extended matter) at a single location [40].

Descartes was wrong about dualism, and the pineal is not the seat of the soul in any metaphysically meaningful sense. But his selection was not arbitrary. The pineal is genuinely unusual: unpaired, centrally located, without blood-brain barrier protection, with photoreceptor-like cellular architecture and a primary role in converting environmental light signals into biochemical time -- a function that might reasonably be described as the interface between the cosmic and the cellular.

The persistence of philosophical and cultural interest in the pineal gland -- across Eastern meditative traditions, Western esoteric thought, and contemporary popular health discourse -- reflects, we suggest, an intuition that is not entirely mistaken. If the pineal’s functional integrity is necessary for the quality of sleep, the depth of circadian synchronization, and the adequacy of antioxidant defense against neurodegeneration, then the progressive calcification of this organ in the majority of aging adults represents something genuinely worth attending to -- not as a metaphysical but as a neurobiological and public health matter. The appropriate response to this intuition is not mysticism but rigorous science.

11. Conclusion

Pineal gland calcification is simultaneously one of the most prevalent and most neglected findings in adult neuroimaging. The convergence of epidemiological, biochemical, and clinical evidence presented in this review supports reconceptualizing PGC as a modifiable pathological process with significant downstream consequences for circadian function, melatonin-dependent neuroprotection, glymphatic clearance, and neurodegeneration risk -- rather than an incidental age marker of no clinical consequence.

The mechanistic foundation for this reconceptualization is solid: hydroxyapatite formation in soft tissue is an actively suppressed process requiring adequate crystallization inhibitors; the inhibitors are known; their depletion pathways are understood; and the downstream consequences of melatonin loss are well-characterized. What is missing is the prospective clinical evidence that would establish whether this mechanistic chain is clinically significant at population level and whether it is modifiable through targeted intervention.

Given the prevalence of PGC, the global burden of Alzheimer’s disease and related dementias, and the low risk and high availability of the proposed preventive interventions, we argue that this evidence gap represents a disproportionate opportunity for high-impact research. Longitudinal studies and interventional trials targeting PGC progression should be regarded as a priority in aging and neurodegeneration research.

Subscribe now

Share

References

[1] Tan DX, Hardeland R, Manchester LC, et al. The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness. Biol Rev. 2010;85(3):607-623.

[2] Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem. 2013;13(3):373-384.

[3] Bumb JM, Brockmann MA, Groden C, Nolte IS. Smaller pineals with more calcification in schizophrenia spectrum disorder? Neuropsychobiology. 2014;69(2):88-94.

[4] Mahlberg R, Walther S, Kalus P, et al. Pineal calcification in Alzheimer’s disease: an in vivo study using computed tomography. Neurobiol Aging. 2008;29(2):203-209.

[5] Sandyk R, Kay SR, Merriam AE. Pineal calcification in Tourette’s syndrome. Int J Neurosci. 1990;54(1-2):27-33.

[6] Sandyk R, Kay SR. Pineal melatonin in schizophrenia: a review and hypothesis. Schizophr Bull. 1990;16(4):653-662.

[7] Barrenetxe J, Delagrange P, Martínez JA. Physiological and metabolic functions of melatonin. J Physiol Biochem. 2004;60(1):61-72.

[8] Srinivasan V, Pandi-Perumal SR, Trakht I, et al. Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res. 2009;165(3):201-214.

[9] Belay DG, Worku MG. Prevalence of pineal gland calcification: systematic review and meta-analysis. Syst Rev. 2023;12(1):32. doi:10.1186/s13643-023-02205-5.

[10] Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004;25(3-4):177-195.

[11] Chlubek D, Sikora M. Fluoride and the pineal gland. Appl Sci. 2020;10(8):2885.

[12] Tan DX, Manchester LC, Reiter RJ, et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta. 1999;1472(1-2):206-214.

[13] Schmid HA. Decreased melatonin biosynthesis, calcium flux, pineal gland calcification and aging: a hypothetical framework. Gerontology. 1993;39(4):189-199.

[14] Grases F, Millan A, Conte A, Prieto R. Pathological calcifications and crystallization inhibitors. Urol Res. 1991;19(6):371-374.

[15] Galliani I, Mongiorgi R. Pineal gland calcification with calcium hydroxyapatite may be inhibited by magnesium. Boll Soc Ital Biol Sper. 1991;67(9):837-844.

[16] Grases F, Costa-Bauzà A, Prieto RM. Pineal concretions and Alzheimer disease: possible key relations. Front Biosci. 2007;12:4451-4458.

[17] Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Haemostasis. 2000;30(6):298-307.

[18] Luke J. Fluoride deposition in the aged human pineal gland. Caries Res. 2001;35(2):125-128.

[19] Everett ET. Fluoride’s effects on the formation of teeth and bones, and the influence of genetics. J Dent Res. 2011;90(5):552-560.

[20] Milin J. Stress-reactive response of the gerbil pineal gland: concretion genesis. Gen Comp Endocrinol. 1998;110(3):237-251.

[21] Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980;210(4475):1267-1269.

[22] Payne ME, Anderson JJB, Steffens DC. Calcium and vitamin D intakes may be positively associated with brain lesions in depressed and nondepressed elders. Nutr Res. 2014;34(3):285-295.

[23] Kunz D, Schmitz S, Mahlberg R, et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology. 1999;21(6):765-772.

[24] Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61(3):253-278.

[25] Pappolla MA, Simovich MJ, Bryant-Thomas T, et al. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res. 2002;32(3):135-142.

[26] Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J. Mechanisms of melatonin in alleviating Alzheimer’s disease. Curr Neuropharmacol. 2017;15(7):1010-1031.

[27] Mahlberg R, Kalus P, Gossler A, Srinivasan V, Pandi-Perumal SR. Pineal calcification, melatonin production, aging, associated health consequences and rejuvenation of the pineal gland. Molecules. 2021;26(9):2634.

[28] Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377.

[29] Mahlberg R, Walther S, Kalus P, et al. Pineal calcification in Alzheimer’s disease: an in vivo study using computed tomography. Neurobiol Aging. 2008;29(2):203-209.

[30] Liu RY, Zhou JN, Van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-ε4/4 genotype. J Clin Endocrinol Metab. 1999;84(1):323-327.

[31] Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer’s disease. Exp Gerontol. 2003;38(1-2):199-206.

[32] Shomrat T, Nesher N. Updated view on the relation of the pineal gland to autism spectrum disorders. Front Endocrinol. 2019;10:37.

[33] Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag. 2009;5:185-197.

[34] Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009;203(2):489-493.

[35] Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer’s disease progression. Curr Neuropharmacol. 2010;8(3):218-227.

[36] Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol. 2008;11(1):13-19.

[37] Bhatnagar M, Sharma D, Salvi M. Neuroprotective effects of Withania somnifera dunal.: a possible mechanism. Neurochem Res. 2009;34(11):1975-1983.

[38] Wang CL, Liu JF, Sang YF, et al. Curcumin inhibits arterial calcification through anti-inflammatory and calcium regulatory pathways. Front Pharmacol. 2020;11:826.

[39] Mrvelj A, Womble MD. Fluoride-free diet stimulates pinealocyte proliferation and pineal gland growth in aged gerbils. Biol Trace Elem Res. 2020;197(1):175-183.

[40] Descartes R. Passions of the Soul (Les Passions de l’âme). Amsterdam: Louis Elzevier; 1649. Article 31.

In May 2026, RFK Jr. fired two vice chairs of the U.S. Preventive Services Task Force (USPSTF) — the body whose letter grades legally determine what preventive care your insurance must cover — and the medical establishment and its media apparatus erupted in performative outrage. The concern was presented to the public in the following terms: that political operatives would replace evidence-based scientists, that mammograms and colonoscopies would go the way of vaccine recommendations. But in the ensuing media storm, almost no one stopped to ask a harder question. What if the evidence base for mammography screening was already contested, complicated, and in some dimensions, quietly devastating — long before any politician arrived to interfere?

I. Detection Is Not Prevention

The War on Cancer’s Category Error

When the USPSTF issues an “A” or “B” grade for mammography, it is grading a screening procedure — the capacity to detect abnormal cells in breast tissue before they produce symptoms. What it is emphatically not grading is any intervention that reduces the biological conditions in which breast cancer arises. This is the foundational category error of modern oncological prevention: it conflates early detection with prevention, and treats the two as equivalent.

They are not equivalent. A mammogram cannot reduce systemic inflammation. It cannot reverse intestinal hyperpermeability — the “leaky gut” phenomenon through which microbial products translocate into systemic circulation and drive the chronic immune dysregulation that provides fertile terrain for cancer proliferation.^[1]

It cannot alter the epigenetic expression of tumor-suppressor genes. It cannot change the microRNA profile of a woman’s cells, which determines whether oncogenic pathways are silenced or amplified.^[2] What a mammogram can do is find something — and in finding it, set in motion a cascade of interventions whose benefits, when examined rigorously, are far more modest than their cultural mythology suggests.

Estimated number of American women overdiagnosed by mammography screening over a 30-year period — treated for cancers that would never have caused symptoms or death — according to a landmark 2012 analysis in the New England Journal of Medicine.^[3]

II. The Overdiagnosis Problem

When Finding Is Not the Same as Saving

Overdiagnosis in breast cancer screening refers to a specific, clinically documented phenomenon: the detection by mammography of a cancer — a real cluster of abnormal cells — that would never, in the lifetime of that woman, have caused symptoms, spread, or killed her. Her body’s immune surveillance was managing it. Her epigenetic terrain was containing it. Once detected, however, it becomes a diagnosis. A breast cancer diagnosis. And the institutional logic of oncology treats that diagnosis with the full arsenal: biopsy, surgery, radiation, and often years of hormone suppression therapy.^[4]

The woman is counted as a “breast cancer survivor.” She credits the mammogram with saving her life. The system counts her as a success. In fact, she may have been harmed — treated for a condition that posed no threat, subjected to interventions whose aggregate toxicities are not trivial — while the conditions that created her abnormal cell population remain completely unaddressed.

Estimates of overdiagnosis magnitude range from 11% to over 50% of screen-detected breast cancers.^[5] A 2012 analysis in the New England Journal of Medicine found that in the three decades following the widespread adoption of mammography, the rate of early-stage breast cancer diagnoses doubled, while late-stage cancer decreased by only a small fraction — suggesting that most of the additional diagnoses were overdiagnoses, not cancers caught early enough to prevent metastasis.^[3]

III. The DCIS Epidemic

A Diagnosis Created by the Technology That Finds It

The single largest driver of mammographic overdiagnosis is ductal carcinoma in situ — DCIS. Virtually unknown before widespread screening, DCIS is now the fourth most common cancer diagnosis in women in the United States, accounting for roughly 20% of all breast cancer diagnoses.^[7] DCIS describes the proliferation of abnormal cells within the milk duct — not invasive cancer. A cellular abnormality. A tissue-level change. A finding.

The standard of care for DCIS has been aggressive: lumpectomy or mastectomy, followed by radiation, followed often by years of tamoxifen. Women have lost breasts for DCIS. And the evidence is now accumulating — from randomized controlled trials, from natural history studies — that the majority of low- and intermediate-grade DCIS lesions do not progress to invasive cancer.^[8] The body, in many cases, was containing them.

Learn more by reading my article below:

This author has tracked this evidence since 2008 — and the landmark COMET trial, presented at the San Antonio Breast Cancer Symposium, has now validated what a decade of advocacy argued: active monitoring is equally safe as surgery for most DCIS.

This maps directly onto the framework of epigenetics and genetic penetrance: having a gene variant does not mean the disease will express. Having abnormal cells in a duct does not mean they will invade. The epigenetic terrain — the inflammatory milieu, the microbiome integrity, the dietary information environment, the toxicant burden — determines whether latent dysregulation progresses or resolves. As I wrote in Regenerate: “Genes load the gun, but environment pulls the trigger.”^[9]

IV. The BRCA Mythology

Prophylactic Surgery and the Genetics of Fear

No dimension of mammographic overtreatment is more dramatic than the story of prophylactic mastectomy in BRCA-positive women. Following Angelina Jolie’s widely publicized decision in 2013 to have both breasts and her ovaries surgically removed based on BRCA1 status, rates of contralateral prophylactic mastectomy in the United States increased sharply.^[10] The procedure — permanent, irreversible, with significant complication profiles — was embraced as rational prevention.

As documented in my 2023 analysis, the USPSTF's own draft modeling report explicitly acknowledged it did not consider "potential risk of breast cancer due to screening-related radiation" — meaning the carcinogenic risk to BRCA-positive women from the screening tool itself was never factored into its recommendations.

The biology, however, does not support the cultural narrative. According to data published in The Lancet Oncology, BRCA-positive women with breast cancer have higher survival rates than BRCA-negative women diagnosed with the same disease.^[11] Thousands of polymorphisms in the BRCA1 and BRCA2 genes have been identified — some inversely related to cancer risk, and some, like the BRCA1 subtype K1183R, that actively increase breast cancer survival.^[12]

EVIDENCE NOTE — THE BRCA RADIATION IRONY

BRCA1 and BRCA2 are DNA repair genes — specifically, they facilitate repair of double-strand DNA breaks caused by ionizing radiation and oxidative damage. A BRCA-variant woman has impaired capacity to repair this class of DNA damage.

The irony: mammography delivers ionizing radiation to breast tissue. Annual screening over decades provides cumulative radiation exposure to the very women most biologically vulnerable to radiation-induced DNA damage — those with BRCA variants that impair exactly that class of genomic repair.^[13] The epigenetic factors that actually determine whether BRCA’s cancer-protective function is “knocked out” — micronutrient deficiencies, endocrine disruptors, chronic inflammation — are entirely absent from the prophylactic mastectomy risk-benefit equation.

Moreover, the rhetoric of BRCA in a cancer-phobic patient generates a cascade of stress physiology that is not benign. Studies show that low perception of control — the defining psychological signature of genetic determinism — is associated with greater cancer recurrence and cancer deaths.^[14]

The clinical data behind this is stark: women with false-positive mammography findings — even after being cleared of cancer — showed psychospiritual damage across 12 measurable outcomes equivalent to an actual breast cancer diagnosis, with suicide risk spiking 16-fold and cardiac death risk rising 26.9-fold in the week following a positive result. The full documentation is in our foundational investigation: "'Hidden Dangers' of Mammograms Every Woman Should Know About."

The fear that a BRCA diagnosis provokes triggers “aberrant secretion of stress hormones which further magnifies risk in a vicious cycle” — the diagnosis can become causally implicated in the very disease progression it purports to prevent.^[9]

The full radiobiological evidence base is catalogued in the GreenMedInfo X-Ray Mammography Dangers Database.

V. The Profitable Cascade

Why Overdiagnosis Persists When the Evidence Is Clear

The overdiagnosis literature is not obscure. It has been published in the New England Journal of Medicine, The Lancet, the British Medical Journal, and the Cochrane Collaboration — the gold standard of evidence synthesis — has explicitly stated that for every woman who avoids a breast cancer death through mammography, approximately ten are unnecessarily diagnosed and treated.^[6] This ratio has been known for years. And yet the screening machinery continues.

In 2018, Goldman Sachs issued an internal report asking whether curing patients was a “sustainable business model,” noting that one-shot cures “quickly exhaust recurrent revenue streams.”^[15] The mammography-to-treatment pipeline illustrates the point precisely: screening mammograms generate revenue. Abnormal findings generate diagnostic mammograms. Biopsies generate DCIS diagnoses. DCIS diagnoses generate surgeries. Surgeries generate radiation. Radiation generates follow-up imaging. Hormone suppression therapy generates five to ten years of pharmaceutical revenue. A woman who is overdiagnosed with DCIS and overtreated is not a failure of the system — she is, in a precise financial sense, the system working as designed.^[16]

This profit architecture has a origin story: Breast Cancer Awareness Month itself was co-founded in 1985 by Imperial Chemical Industries — a manufacturer of carcinogenic chemicals including paraquat and trichloroethylene — whose pharmaceutical division stood to profit from every mammogram that generated a diagnosis requiring treatment. The same company that may have contributed to the breast cancer epidemic helped design the awareness campaign that never once mentioned the word carcinogen. The full investigation is in “Stop Pinkwashing: The Truth Breast Cancer Charities Bury.”

For the complete evidentiary case — including the COMET trial, the DCIS radiation irony, and the 20-footnote scientific record — see "The Cancer Deception."

VI. The Biology That Goes Unasked

Why Does Breast Tissue Become Cancer-Permissive?

The New Biology — the emerging synthesis of epigenetics, microRNA biology, microbiome science, and systems physiology — offers a framework for the question that mammography screening never asks: why does breast tissue become cancer-permissive in the first place?

The answers are increasingly specific. The Western Pattern Diet generates chronic systemic inflammation through multiple intersecting mechanisms. Gluten-containing grains drive intestinal hyperpermeability, allowing bacterial endotoxins to translocate into systemic circulation and trigger persistent immune activation — providing an oncogenic microenvironment.^[1] Conventional dairy products deliver exosomes that skew immune differentiation toward the pro-inflammatory Th17 lineage.^[17]

Meanwhile, the microRNAs present in cruciferous vegetables — particularly a broccoli-derived microRNA recently shown to inhibit breast cancer cell growth through its effect on the TCF7 gene^[18] — are absent from processed food. The food environment is not a background variable in breast cancer risk. It is an active upstream determinant. Completely unaddressed by any screening guideline, any USPSTF grade, or any political debate about task force membership.

Endocrine-disrupting chemicals — phthalates, bisphenol A, synthetic estrogens from plastics and personal care products — are documented drivers of epigenetic dysregulation in breast tissue, capable of altering gene methylation patterns and activating oncogenic pathways.^[19] Exposure to these compounds can reprogram the germline — affecting not just the exposed individual but subsequent generations.^[20] This is the biology of breast cancer prevention. None of it involves a mammography machine.

VII. The Real Crisis

Beyond the Task Force Battle

RFK Jr.’s firings at the USPSTF are alarming if we accept the media’s superficial conventional medical political framings: the replacement of independent scientists with ideological allies represents a real threat to the integrity of public health guidance. If true, and the author believes they are not, these concerns deserve the outrage they have received.

The truth is that there is nothing more MAHA than what Secretary Kennedy is doing. The Make America Healthy Again movement claims to be about root causes — about asking why chronic disease exploded, why the healthcare system produces sickness as reliably as it produces revenue, why the bodies of American women have become a profit center for an industry that begins with a carcinogen and ends with a mastectomy. If that vision means anything, it must mean this: that the most important reform in breast cancer policy is not who sits on the task force, but whether the task force is finally empowered to ask why breast cancer arises in the first place.

Overdiagnosis and overtreatment are not rogue outcomes of a broken system — they are the system operating exactly as designed. Reforming them is not a fringe position. It is the most coherent expression of what a health-first movement could actually accomplish.

But the carefully engineered outrage is effective because it has had a blinding effect. It has made it impossible, in the current political atmosphere, to say what the evidence has been saying for two decades: that the mammography-to-treatment pipeline produces substantial harm alongside its benefits; that overdiagnosis and overtreatment are not edge cases but central features of how the system operates; and that the entire framework of cancer “prevention” has been captured by a detect-and-treat model that leaves the actual causes of cancer entirely intact. And that does not account for the growing body of preclinical and clinical evidence that lifestyle, mindset, natural and integrative medicine has a fast-growing body of compelling research indicating that they may constitute safe, effective, affordable and easily accessible approaches to breast cancer prevention and treatment, as meticulously indexed on projects like my own: GreenMedInfo.com. There are 3,200 studies you can peruse and share below.

The USPSTF — however expertly composed, however methodologically rigorous — grades screening procedures. It does not grade dietary intervention. It does not grade reduction of endocrine-disrupting chemical exposure. It does not grade microbiome restoration. It does not ask why a million American women develop breast cancer each year, or what has changed in their food environment, their toxicant burden, their epigenetic terrain, that makes them susceptible.

Until those questions are asked — and funded, and clinically prioritized — the battle over who sits on the task force is a battle over the rearrangement of furniture in a burning house.

Do dive deeper into chronic conditions like cancer through the lens of the New Biology, read:

Read and share this thread on X:

Share

FOOTNOTES & CITATIONS

[1] Fasano, A. (2012). Leaky gut and autoimmune disease. Clinical Reviews in Allergy and Immunology, 42(1), 71–78. Suzuki, T. (2013). Regulation of intestinal epithelial permeability by tight junctions. Cellular and Molecular Life Sciences, 70(4), 631–659.

[2] Ji, S. (2020). Regenerate: Unlocking Your Body’s Radical Resilience through the New Biology. Hay House. Chapter 1. Dolati et al. (2017). Curcumin restores microRNA expression patterns dysregulated in multiple sclerosis. Journal of Cellular Biochemistry.

[3] Bleyer, A., & Welch, H.G. (2012). Effect of three decades of screening mammography on breast-cancer incidence. New England Journal of Medicine, 367(21), 1998–2005.

[4] Welch, H.G., & Black, W.C. (2010). Overdiagnosis in cancer. Journal of the National Cancer Institute, 102(9), 605–613.

[5] Zackrisson, S., et al. (2006). Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial. BMJ, 332(7543), 689–692. Jorgensen, K.J., & Gotzsche, P.C. (2009). Overdiagnosis in publicly organised mammography screening programmes. BMJ, 339, b2587.

[6] Gotzsche, P.C., & Nielsen, M. (2011). Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews. Gotzsche, P.C. (2012). Mammography screening is harmful and should be abandoned. Journal of the Royal Society of Medicine, 105(2), 51–59.

[7] American Cancer Society. (2024). Breast Cancer Facts & Figures. DCIS accounts for approximately 20% of new breast cancer diagnoses.

[8] Narod, S.A., et al. (2015). Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncology, 1(7), 888–896. Esserman, L.J. (2014). Rethinking screening for breast cancer and prostate cancer. JAMA, 302(15), 1685–1692.

[9] Ji, S. (2020). Regenerate. Part One: ‘Genes load the gun, but environment pulls the trigger.’ On BRCA: ‘epigenetic exposures can knock out the cancer-protective function of the BRCA genes.’

[10] Borzekowski, D.L.G., et al. (2014). The Angelina effect. Genetics in Medicine, 16(7), 516–521. Documents increased BRCA testing and prophylactic mastectomy rates following Jolie’s disclosure.

[11] Copson, E.R., et al. (2018). Germline BRCA mutation and outcome in young-onset breast cancer (POSH). The Lancet Oncology, 19(2), 169–180.

[12] BRCA1 polymorphism K1183R associated with increased breast cancer survival. NCBI PubMed ID: 24600974. Ji, S. (2020). Regenerate.

[13] Brenner, D.J., & Hall, E.J. (2007). Computed tomography — an increasing source of radiation exposure. NEJM, 357(22), 2277–2284. On radiation risk in BRCA-positive women who carry impaired DNA repair capacity.

[14] Henderson, B.N., & Donatelle, R.J. (2002). The relationship between cancer locus of control and CAM use. Psycho-Oncology, 12(1), 59–67. Low perceived control associated with greater recurrence and psychiatric morbidity.

[15] Richter, S. (2018). The genome revolution. Goldman Sachs equity research report. Internal analysis cited in Ji, S. (2020). Regenerate, Chapter 1.

[16] Brownlee, S. (2007). Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer. Bloomsbury. Economic analysis of overtreatment incentive structures.

[17] Exosomal content of commercial dairy and Th17 immune skewing. Ji, S. (2020). Regenerate. NCBI PubMed ID: 25822997.

[18] Broccoli microRNA inhibiting breast cancer via TCF7 gene. Ji, S. (2020). Regenerate, Chapter 2. Endnote fn. 89.

[19] Soto, A.M., & Sonnenschein, C. (2010). Environmental causes of cancer: endocrine disruptors as carcinogens. Nature Reviews Endocrinology, 6(7), 363–370.

[20] Anway, M.D., et al. (2005). Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science, 308(5727), 1466–1469.

Adapted from Regenerate: Unlocking Your Body’s Radical Resilience through the New Biology by Sayer Ji (Hay House, 2020). GreenMedInfo.com.

View the thread on X:

Thomas Massie began his concession speech with an apology for being late.

He had to call his opponent to formally concede the race, he explained — and it took a while, because Ed Gallrein was in Tel Aviv.

The room laughed, the way rooms laugh when a man they’ve come to comfort turns out to be the funniest person there. And from that opening line — dry, surgical, technically a concession speech but spiritually something else entirely — Massie proceeded to deliver 27 minutes of arguably the best political speech he has ever given. From a podium he was walking away from. On an election night he lost.

The man has a gift. The question is what he’s going to do with it now.

“Longer Than Vietnam”

Before any thank-yous, before any policy, before any tears, Massie set the table with a historical comparison that left the room no choice but to start laughing and not really stop.

“Welcome to the most expensive congressional primary ever in the 250-year history of this country. It’s not just the most expensive. This thing went on longer than Vietnam. It started nine months ago and they didn’t even have a candidate — they just decided they wanted to take me out.”

Vietnam. He compared his primary to Vietnam. Not hyperbolically — contextually.

The campaign lasted nine months. They had no candidate when they started. They just had a mission: Thomas Massie must go. And so they built a candidate, funded a war chest that swelled to somewhere north of $35 million by his estimate, and ran the most expensive congressional primary in American history — in a rural Kentucky district — to defeat one man they found inconvenient.

He accepted the result, called to concede, and opened with Vietnam.

The Epstein Files: A Two-Page Bill That Toppled a Dynasty

The crowd was already warmed up when Massie arrived at the topic that lit up the room: the Epstein Files Transparency Act. Two pages long. Introduced, passed, signed. And in his telling, a bill that brought down — with remarkable efficiency — the CEO of the World Economic Forum.

“By the way, do you know how many pages the Epstein Files Transparency Act was? Two pages... Guess what happened to Klaus’s CEO? He was in the Epstein files. He had to resign. We took out the CEO of the World Economic Forum with a two-page bill.”

This was the rhetorical pivot of the evening. Massie had spent much of the speech cataloguing what he’d fought for and against — foreign aid, the draft, the WEF’s eat-bugs agenda. But here he landed the punch: they’d all told us you’ll own nothing and be happy. Well — guess what happened to them.

Then he started reading the box score:

“We’ve taken out two dozen CEOs, an ambassador, a prince, a prime minister, a minister of culture — and that was just six months. I’ve got seven months left in Congress.”

He announced this like a man not conceding a race but filing a progress report. The Epstein Files Act’s six-month anniversary, he noted, happened to fall on this exact primary election night.

He seemed to find that timing meaningful. So did the crowd.

MAHA: Does Anybody Want to Eat Poison?

Massie has been making the rounds of the health freedom coalition for years — long before it was politically fashionable, long before Make America Healthy Again had a mascot. He was there when it was just lonely votes. So when he turned to this section of the speech, it hit differently than campaign-trail boilerplate.

“MAHA — is anybody here for MAHA? Does anybody want to eat poison? Do you want the government telling you what to eat? Do you want the government telling you to put a needle in your arm? I don’t either. And that’s why I’ve been fighting all of that stuff. We need food freedom. We need medical freedom. We need all of those freedoms.”

He’d been fighting vaccine mandates, jury trial rights for vaccine injury, and seed oil and food additive exposure — all years before MAHA gave it a brand name. He was pointing out that he arrived at this table early.

He then pivoted to the 7th Amendment — the right to a jury trial — which he noted with some genuine surprise he’d been forced to fight for:

“They’ve taken it away for vaccines. If you get hurt, you can’t sue for vaccines. They’re trying to take it away for pesticides. They’re trying to take it away for data centers. These corporations want get-out-of-court-free cards. We’re not going to give them one.”

The Amish Cartel and the Lactose Lobby

If the Epstein Files section was the night’s signature political moment, what came next was its signature comedic one.

Massie called a toast. He wanted to raise a glass in honor of his late wife. And then — in a moment of genuine tenderness threaded through genuine absurdism — he explained what was in the glass.

“This is the one scandal. This is the one scandal they never figured out on me. I get my milk from the Amish cartel. And I don’t pay for it with Federal Reserve notes. I trade peaches — peaches for dairy.”

The word cartel was exquisite. Technically accurate — it describes a supply-coordinating organization — but freighted with enough DEA energy to make a roomful of Kentucky Republicans howl. The man barters with Amish farmers in a black-market exchange of peaches for raw milk, denominated outside the Federal Reserve system. And he is apparently very proud of this.

He then toasted his wife, who had weathered the raw milk battle with him — watching his Google Alerts explode with bad press from Washington about his legislation, texting him one of the stories with a single observation:

“OMG — I didn’t realize the lactose lobby was so intolerant.”

A perfect, irreplaceable joke. Delivered in the voice of a woman who is no longer alive, at a concession speech, about raw milk legislation.

The room had no choice but to love him.

The Constitutional Lecture Nobody Asked For (But Everybody Needed)

Near the end, Massie went somewhere more serious. He’d been jousting all night — Tel Aviv, Vietnam, Amish cartels, Epstein files — but he closed with something that lands differently when you think about where the country is right now.

“If you always vote with the president, if the legislative branch always votes with the president, we do have a king. If the legislative branch votes whichever way the wind is blowing, then we have mob rule. But if the legislative branch and the representatives and the senators always follow the Constitution — we have a republic.”

This was the thesis under the whole speech.

This was why $35 million and nine months and the most expensive primary in American history was spent to remove one congressman from one rural Kentucky district. He voted his conscience. He voted the Constitution. He voted “No” when others voted “Yes,” and “Yes” when the room said “No.” He was, in his own accounting, a check — the kind that becomes more inconvenient the more power consolidates.

Whether you agree with his votes or not, the argument deserves engagement. He wasn’t wrong about the structure of what had been done to him. The price tag proved it.

“Transpartisan” — And a Diss on Political Science

In a brief tangent that drew one of the bigger laughs of the night, Massie reflected on his unusual position as someone who voted against his own party at least as much as against the other one:

“I’m not even sure I’m bipartisan. Bipartisan means you like both. I might be transpartisan — because I can’t identify with either some days. That’s the great thing about the polls being closed. I can’t run an ad where I claim to be trans. Transpartisan. Thank you very much. I don’t know which cloakroom to go in.”

Then, turning to an audience member who apparently studied political science, he delivered what might be the best throwaway line of the speech:

“Political science, by the way — that’s not a real science. I’m a political science denier.”

Elon Musk and the Impossible Problem

On DOGE, federal spending, and Musk’s brief foray into Washington cost-cutting, Massie offered an assessment that was both sympathetic and devastating:

“Elon Musk found out it was easier to land a rocket backwards. It was easier to get a car to drive itself. It was easier to put internet on Antarctica than it was to cut a hundred dollars of spending in Washington DC.”

He wasn’t mocking Musk. He was making a structural point he’s been making for years: that Washington’s spending machine isn’t a bug, it’s the feature — engineered to be unkillable by design, bipartisan in its bloat, defended by every lobbying interest it has ever spawned.

The point landed harder for being true.

The Closing: “We Won”

Massie closed — after teasing a 2028 run with the non-denial of a man who knows exactly what he’s doing — with a declaration that would have sounded delusional from anyone else:

“I decided before today that we were going to win or lose today and we would win either way... We won. We won because we started a movement. We showed people that if you’re under 50, you want to save this country.”

Then, on whether tonight’s result was God’s plan:

“What happened tonight was God’s will. It couldn’t happen if God didn’t want it to. So our job is to figure out what was the purpose of having the biggest fight ever — why did it converge on one of 435 congressional seats right here in Kentucky? What was God’s purpose? What is He showing us tonight?”

He didn’t answer the question. He left it open, the way a good speaker leaves the audience with the one thing they’ll still be thinking about at 2 a.m.

Then: “I need a medical margarita right now.”

“You know, I don’t drink recreationally. I have medical margaritas. I even have a medical margarita card.”

And with that, one of the strangest, funniest, sharpest concession speeches in recent American political memory was over.

What He Leaves Behind

Thomas Massie is 54 years old, holds an engineering degree from MIT, built his own house off the grid in rural Kentucky, and spent 14 years in Congress without accumulating a single ethics complaint. He voted “No” on things other people were afraid to vote “No” on. He introduced legislation others wouldn’t touch. He got primaried by $35 million because he was inconvenient.

He called the result God’s will and then toasted his late wife with black-market Amish raw milk traded for peaches.

Seven months left. He’s not done.

The lactose lobby remains, apparently, intolerant.

All quotations drawn directly from Massie’s primary night concession speech, Kentucky 4th Congressional District, May 2026.

Learn more about Massie: "Why Rep. Thomas Massie prefers living off the grid"

Share